<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7554600</article-id><article-id pub-id-type="pmcid-ver">PMC7554600.1</article-id><article-id pub-id-type="pmcaid">7554600</article-id><article-id pub-id-type="pmcaiid">7554600</article-id><article-id pub-id-type="pmid">33101309</article-id><article-id pub-id-type="doi">10.3389/fimmu.2020.583077</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Emerging Concepts and Technologies in Vaccine Development</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Brisse</surname><given-names initials="M">Morgan</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/668112"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vrba</surname><given-names initials="SM">Sophia M.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1031667"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kirk</surname><given-names initials="N">Natalie</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1095901"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liang</surname><given-names initials="Y">Yuying</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1096245"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ly</surname><given-names initials="H">Hinh</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/180042"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Biochemistry, Molecular Biology, and Biophysics Graduate Program, University of Minnesota Twin Cities</institution>, <addr-line>St. Paul, MN</addr-line>, <country>United States</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Department of Veterinary &amp; Biomedical Sciences, University of Minnesota Twin Cities</institution>, <addr-line>St. Paul, MN</addr-line>, <country>United States</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Comparative Molecular Biosciences Graduate Program, University of Minnesota Twin Cities</institution>, <addr-line>St. Paul, MN</addr-line>, <country>United States</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Katie Ewer, University of Oxford, United Kingdom</p></fn><fn fn-type="edited-by"><p>Reviewed by: Arun Kumar, Coalition for Epidemic Preparedness Innovations (CEPI), Norway; Hannah Sharpe, University of Oxford, United Kingdom</p></fn><corresp id="fn001">*Correspondence: Hinh Ly, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:hly@umn.edu">hly@umn.edu</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>30</day><month>9</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>11</volume><issue-id pub-id-type="pmc-issue-id">351098</issue-id><elocation-id>583077</elocation-id><history><date date-type="received"><day>14</day><month>7</month><year>2020</year></date><date date-type="accepted"><day>14</day><month>9</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>09</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>22</day><month>10</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-02-10 23:25:11.030"><day>10</day><month>02</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2020 Brisse, Vrba, Kirk, Liang and Ly</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Brisse, Vrba, Kirk, Liang and Ly</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-11-583077.pdf"/><abstract><p>Despite the success of vaccination to greatly mitigate or eliminate threat of diseases caused by pathogens, there are still known diseases and emerging pathogens for which the development of successful vaccines against them is inherently difficult. In addition, vaccine development for people with compromised immunity and other pre-existing medical conditions has remained a major challenge. Besides the traditional inactivated or live attenuated, virus-vectored and subunit vaccines, emerging non-viral vaccine technologies, such as viral-like particle and nanoparticle vaccines, DNA/RNA vaccines, and rational vaccine design, offer innovative approaches to address existing challenges of vaccine development. They have also significantly advanced our understanding of vaccine immunology and can guide future vaccine development for many diseases, including rapidly emerging infectious diseases, such as COVID-19, and diseases that have not traditionally been addressed by vaccination, such as cancers and substance abuse. This review provides an integrative discussion of new non-viral vaccine development technologies and their use to address the most fundamental and ongoing challenges of vaccine development.</p></abstract><kwd-group><kwd>non-viral DNA-RNA vaccines</kwd><kwd>nanoparticle vaccines</kwd><kwd>virus-like particle vaccines</kwd><kwd>cancer vaccines</kwd><kwd>substance abuse</kwd><kwd>noncommunicable disease</kwd><kwd>infectious disease</kwd><kwd>COVID19</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">National Institutes of Health<named-content content-type="fundref-id">10.13039/100000002</named-content></funding-source></award-group><award-group><funding-source id="cn002">U.S. Department of Agriculture<named-content content-type="fundref-id">10.13039/100000199</named-content></funding-source></award-group><award-group><funding-source id="cn003">National Institutes of Health<named-content content-type="fundref-id">10.13039/100000002</named-content></funding-source></award-group></funding-group><counts><fig-count count="5"/><table-count count="2"/><equation-count count="0"/><ref-count count="308"/><page-count count="22"/><word-count count="9521"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Beginning with the discovery of cowpox inoculation that can protect humans against smallpox infection by Edward Jenner in the late 18<sup>th</sup> century, vaccination has become an important means to prevent disease. Despite the success of vaccination in the eradication or control of some major pathogens, several challenges remain in vaccine development and administration. Several widespread infectious diseases such as HIV, tuberculosis, and influenza continue to pose great challenges for fully protective vaccination. Emerging and reemerging pathogens present a pressing need for expediting vaccine development and approval as a rapid response to epidemics, such as the current COVID-19 global pandemic caused by the SARS-CoV-2 virus. The advantages and disadvantages of the various vaccine platforms can make the choice for preferred platform(s) to use for vaccine development during a pandemic complicated. The traditional methods to produce a vaccine, such as live attenuated and inactivated vaccines or protein subunit vaccines have their advantages and disadvantages, which have been extensively reviewed elsewhere (<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B3" ref-type="bibr">3</xref>). Briefly, live attenuated vaccines present the risk of reversion to a highly pathogenic form while inactivated vaccines may not be sufficiently immunogenic or in some cases can lead to an enhanced disease pathology (<xref rid="B3" ref-type="bibr">3</xref>). Additionally, most pandemic vaccines have to be clinically tested during an active outbreak in order to obtain sufficient safety and efficacy data, thereby limiting the number of vaccine candidates that can be deployed to save life during an emergency situation.</p><p>Less conventional approaches to vaccinology include the non-viral vaccine technologies that are the topic of this review, as well as viral vector platforms. Viral vector vaccines rely on antigen delivered on an unrelated, non-pathogenic viral backbone. This technology was developed almost forty years ago using a vaccinia virus vector expressing the hepatitis B surface antigen (HBsAg), which provided protective immunity to chimpanzees exposed to hepatitis B (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). Since then, viral vectors have been used successfully in many veterinary species (<xref rid="B6" ref-type="bibr">6</xref>&#8211;<xref rid="B12" ref-type="bibr">12</xref>), although only a single viral vector has been licensed for human vaccination (rVSV-ZEBOV for Ebola virus) (<xref rid="B13" ref-type="bibr">13</xref>). A number of viruses have been developed as vectors for vaccine development, including poxviruses, adenoviruses, herpesviruses, arenaviruses, retroviruses, paramyxoviruses, and flaviviruses, among others (<xref rid="B14" ref-type="bibr">14</xref>&#8211;<xref rid="B16" ref-type="bibr">16</xref>). The main advantage of viral vectors over traditional vaccines is their ability to evoke a robust adaptive immune response in the absence of an adjuvant (<xref rid="B17" ref-type="bibr">17</xref>). However, the tradeoff for enhanced immunogenicity is the concern for potential reversion of the attenuated viral vector to virulence, especially when using a replication-competent vector (<xref rid="B18" ref-type="bibr">18</xref>). Replication-defective and single-cycle viral vectors are attractive alternatives that have an increased safety profile and, in some cases, are still able to elicit a strong immune response (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>). More details about the known viral vectors and their recent advances in vaccine development will be discussed in our forthcoming review article (Vrba, S.M., et&#160;al., in preparation).</p><p>Other fundamental challenges toward successful vaccination include the ever-changing and highly divergent nature of some viruses that allow for the potential to escape vaccine coverage, pre-existing immunity of the vaccinated populations, and pre-existing medical conditions that can prevent vaccines from being fully effective and safe. Vaccination could also provide an enticing alternative therapy against diseases such as cancers and substance abuse. However, the efficacy of these vaccines is limited by the disease complexity and the lack of a more complete understanding of protective immunity in these medical conditions. The relative contribution and balance of the different arms of host immunity, i.e., antibodies and cell-mediated responses, toward protection without adverse effects remains a challenging issue that needs to be addressed for individual disease (<xref rid="B21" ref-type="bibr">21</xref>). Furthermore, the immune response to vaccination can be influenced by numerous factors such as gender, age, co-existing medical conditions, genetic variations, and lifestyle (<xref rid="B22" ref-type="bibr">22</xref>). While vaccines have traditionally been delivered as inactivated or attenuated preparations, recent developments of non-viral vaccine systems offer potential additional solutions to meet the new challenges of vaccine development, especially during epidemic or pandemic situations. This article focuses on new non-viral vaccine development technologies and their implications for combating on-going and emerging communicable and non-communicable diseases.</p></sec><sec id="s2"><title>Emerging Technologies in Non-Viral Vaccine Development</title><sec id="s2_1"><title>Virus-Like Particle and Nanoparticle Subunit Vaccines</title><p>Subunit vaccines deliver antigens as purified proteins, which confer the advantage of enhanced safety and scalability compared to whole-pathogen vaccines due to the lack of the requirement for the expression of all viral components and the ability to express and purify any particular antigens of interest in large quantity. A disadvantage of subunit vaccines is that they are generally less immunogenic in nature and therefore require adjuvants and repeated vaccination doses (<xref rid="B2" ref-type="bibr">2</xref>). Several approaches have been used to increase the immunogenicity and stability of subunit vaccines, such as virus-like particle (VLP) vaccines and nanoparticle (NP) vaccines.</p><p>VLP vaccines use platforms capable of producing particles that mimic the structure of authentic viruses. VLP vaccines can be produced by expressing antigenic proteins in a eukaryotic or prokaryotic system, resulting in the formation of particles with an inherent ability of the antigenic proteins to self-assemble (<xref rid="B23" ref-type="bibr">23</xref>) <bold>(</bold>
<xref ref-type="fig" rid="f1">
<bold>Figure 1</bold>
</xref>
<bold>)</bold>. Alternatively, VLP vaccines can also be made by producing blank VLP templates and then chemically linking antigenic peptides onto the pre-formed particles (<xref rid="B23" ref-type="bibr">23</xref>). Because these VLPs do not contain a viral genome, they are unable to replicate in cells and therefore have an improved safety profile compared to live viral vaccines (<xref rid="B24" ref-type="bibr">24</xref>). Yet, VLP vaccines can often fully activate immune systems of the vaccinated individual. VLPs are taken up by dendritic cells, where they are processed and presented on MHC class I and II molecules to activate the adaptive immune response. Subsequent stimulation of CD8<sup>+</sup> T cells and CD4<sup>+</sup> T helper cells leads to activation of cell mediated responses and B cells (and antibody production), respectively (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B25" ref-type="bibr">25</xref>&#8211;<xref rid="B29" ref-type="bibr">29</xref>). As a result, VLP vaccines are considered highly immunogenic and can stimulate robust cellular and humoral immune responses due to their highly repetitive display of antigenic epitopes (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>). A number of VLP vaccine candidates are now clinically applicable with some notable examples including the hepatitis B vaccine (HBV) Engerix (<xref rid="B32" ref-type="bibr">32</xref>), the human papillomavirus vaccine (HPV) Cervarix (<xref rid="B33" ref-type="bibr">33</xref>) from GlaxoSmithKline (GSK), the HBV vaccine Recombivax<sup>&#174;</sup> (<xref rid="B34" ref-type="bibr">34</xref>), and the human papillomavirus (HPV) vaccine Gardasil<sup>&#174;</sup> (<xref rid="B35" ref-type="bibr">35</xref>) from Merck &amp; Co, Inc. VLP vaccines that are currently in clinical trials include vaccines for malaria (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>), influenza (<xref rid="B38" ref-type="bibr">38</xref>), rotavirus (<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>), tuberculosis (<xref rid="B41" ref-type="bibr">41</xref>), Zika virus (<xref rid="B42" ref-type="bibr">42</xref>), and HIV (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>). Efforts to further increase the immunogenicity of VLP vaccines include optimizing antigen design and production platforms (of primarily bacterial origin) (<xref rid="B45" ref-type="bibr">45</xref>).</p><fig id="f1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Schematic of VLP vaccine production. The methodology to produce VLP vaccines is summarized in this cartoon. In brief, VLP vaccines are produced by transfecting eukaryotic cells or transforming bacterial cells with a DNA plasmid encoding an antigenic peptide attached to a viral capsid and/or other protein that is sufficient to form VLPs. The antigenic peptide is present on the outside of the VLP which becomes available for interaction with the immune system. Antigens conjugated with a chemical crosslinker can also be attached to VLPs containing external proteins conjugated to a complementary chemical crosslinker, which will result in antigens being linked to the VLP and being presented on the outside edges. Figure created using BioRender software.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-11-583077-g001.jpg"/></fig><p>NP vaccines are produced by chemically crosslinking protein antigens and carrier molecules to increase immunogenicity and decrease degradation of the antigens (<xref rid="B45" ref-type="bibr">45</xref>). These carriers can be organic (primarily lipid-based) or in-organic (primarily polymeric or metal based) (<xref ref-type="fig" rid="f2">
<bold>Figure 2</bold>
</xref>) (<xref rid="B46" ref-type="bibr">46</xref>&#8211;<xref rid="B49" ref-type="bibr">49</xref>). More recently, self-assembling protein NPs, which consist of oligomers of monomeric protein, have been found in some cases to also provide the benefit normally afforded by a carrier (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B50" ref-type="bibr">50</xref>). NPs have similarly high rates of stability as VLPs, but they do not stimulate the innate immune response to the same extent as VLPs. However, NPs are simpler in design than VLPs by lacking the multiple protein components of VLPs, which further decrease their cost of production and increase their reproducibility and safety. The challenges associated with decreased immunogenicity of NP vaccines as compared to VLP vaccines can be partly addressed by adjusting the carrier to the desired antigen, based on factors such as size, surface charge, shape and hydrophobicity (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B50" ref-type="bibr">50</xref>). Additionally, carriers can be used to directly target NPs to immune cells and to increase cross-presentation by antigen-presenting cells (APCs) (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>).</p><fig id="f2" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Schematic of NP vaccine production. The methodology to produce NP vaccines is summarized in this cartoon. In brief, NP vaccines are produced by assembling a complex of antigens, a linker molecule, and a carrier molecule by chemical conjugation. Figure created using BioRender software.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-11-583077-g002.jpg"/></fig></sec><sec id="s2_2"><title>DNA and RNA Vaccines</title><p>Another promising area of vaccine development includes vaccines that are based on nucleic acids: DNA or RNA vaccines. These vaccines have gained popularity due to their cost-effectiveness, ease of design and production, attractive biosafety profile, and, in the case of DNA, stability. Nucleic acid vaccines have gained particular attention for their potential to rapidly produce vaccines against emerging infectious diseases such as those currently being tested against SARS-CoV-2, the causative agent of COVID-19, which will be discussed in some detail below.</p><p>The immunogenic and protective efficacy of DNA vaccines have been demonstrated repeatedly <italic toggle="yes">in vitro</italic> and in small animal models, and a limited number of DNA vaccines have been approved for veterinary use (<xref rid="B51" ref-type="bibr">51</xref>). However, DNA vaccines tend to induce poor immune responses in humans and other large animal models (<xref rid="B52" ref-type="bibr">52</xref>). One possible explanation may be that intramuscular injection, which has been the most studied route of DNA vaccine administration in humans, tends to elicit mostly cell-mediated immune responses (<xref rid="B53" ref-type="bibr">53</xref>), which is likely due to significantly lower APC populations residing in muscles and antigen presentation dominated by MHC I (<xref rid="B51" ref-type="bibr">51</xref>). Alternatively, DNA vaccines can be coated with gold NPs and administered intradermally by a gene gun (<xref ref-type="fig" rid="f3">
<bold>Figure 3</bold>
</xref>). While preliminary data suggest that this method may increase humoral responses to DNA-based vaccines (<xref rid="B51" ref-type="bibr">51</xref>), it is limited by its low dose per administration (<xref rid="B54" ref-type="bibr">54</xref>). In vivo electroporation (permeabilization of the skin by an electric current to allow plasmid DNA uptake) has thus far been shown to have the highest immunogenicity in multiple small animal models (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B54" ref-type="bibr">54</xref>) and has been tested in two phase I clinical trials for HIV vaccination with some promising results. In the first clinical trial, the immune system was primed with a DNA vaccine encoding the IL12 gene followed by a boost dose with the recombinant VSV-based HIV vaccine (<xref rid="B55" ref-type="bibr">55</xref>). The second trial evaluated the cellular immunity induced by HIV DNA vaccines through intramuscular injection administered by electroporation (<xref rid="B56" ref-type="bibr">56</xref>). Other efforts are being undertaken to increase the immunogenicity of DNA vaccines such as codon optimization, optimal promoter usage and epigenetic design, generating nanocarrier plasmids to increase stability and plasmids fused to proteins that specifically target APCs, adjuvant use (which will be discussed in some detail below) and short hairpin RNA (shRNA) targeting of host cells that decrease immunogenicity to DNA vaccines. These approaches have been extensively reviewed elsewhere (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B54" ref-type="bibr">54</xref>).</p><fig id="f3" position="float" orientation="portrait"><label>Figure 3</label><caption><p>Methods of improving DNA vaccines. The various methods that have been developed to improve the stability and immunogenicity of DNA vaccines are summarized in this chart. A number of design and delivery mechanisms have contributed to improving the performance of nucleic acid vaccines, such as methods of clinical delivery, genetic engineering, and linking nucleic acid vaccines to cells or biomolecules. Figure created using BioRender software.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-11-583077-g003.jpg"/></fig><p>A recent development involves the successful use of mRNA as a protective vaccine. While mRNA was originally found to be viable for <italic toggle="yes">in vivo</italic> gene transfer in the early 1990&#8217;s, the development of mRNA vaccines was initiated much later due to the inherent instability of mRNA compared to DNA (<xref rid="B57" ref-type="bibr">57</xref>). The efficacy of mRNA vaccines can be increased by several factors, such as ensuring mRNA purity, adding 5&#8217; Kozak and cap sequences, 3&#8217; poly-A sequences and modified nucleosides to increase mRNA stability and decrease detection by the receptors of innate immune cells, codon optimization, introduction by intramuscular, and intradermal injection to reduce RNA degradation, and by generating thermostable mRNA (<xref rid="B57" ref-type="bibr">57</xref>&#8211;<xref rid="B59" ref-type="bibr">59</xref>) (<xref ref-type="fig" rid="f4">
<bold>Figures 4</bold>
</xref>, <xref ref-type="fig" rid="f5">
<bold>5</bold>
</xref>). Methods to encapsulate RNA have also been explored to increase the stability and immunogenicity of RNA vaccines, as has been used with exosome encapsulated RNA (<xref rid="B60" ref-type="bibr">60</xref>) and RNA-transfected dendritic cells (<xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B62" ref-type="bibr">62</xref>). When fully optimized, RNA vaccines may have an immunogenic advantage over DNA vaccines due to the presence of multiple cellular pathways that activate innate immunity in response to foreign RNA such as the toll-like receptors (TLRs) and RIG-I-like receptors (RLRs) (<xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B64" ref-type="bibr">64</xref>).</p><fig id="f4" position="float" orientation="portrait"><label>Figure 4</label><caption><p>Methods of improving RNA vaccines. The various methods that have been developed to improve the stability and immunogenicity of RNA vaccines are summarized in this chart. A number of design and delivery mechanisms have contributed to improving the performance of nucleic acid vaccines, such as methods of clinical delivery, genetic engineering, and linking nucleic acid vaccines to cells or biomolecules. Figure created using BioRender software.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-11-583077-g004.jpg"/></fig><fig id="f5" position="float" orientation="portrait"><label>Figure 5</label><caption><p>Methods of improving DNA and RNA vaccines. The various methods that have been developed to improve the stability and immunogenicity of both DNA and RNA vaccines are summarized in this chart. A number of design and delivery mechanisms have contributed to improving the performance of nucleic acid vaccines, such as methods of clinical delivery, genetic engineering, and linking nucleic acid vaccines to cells or biomolecules. Figure created using BioRender&#160;software.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-11-583077-g005.jpg"/></fig><p>In addition to the aforementioned non-replicating RNA, RNA&#160;vaccines can include self-replicating or self-amplifying RNA molecules that are normally based on positive-strand RNA viruses of which the structural genes are replaced by antigens (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B58" ref-type="bibr">58</xref>) (<xref ref-type="fig" rid="f4">
<bold>Figure 4</bold>
</xref>). One study comparing the efficacy of conventional mRNA versus self-amplifying RNA found that both were effective in protecting mice against influenza infection, but that self-amplifying RNA elicited protection at a much lower RNA dose and induced a delayed yet longer-lasting antigen expression (<xref rid="B65" ref-type="bibr">65</xref>). Self-replicating RNA transfected into dendritic cells (<xref rid="B66" ref-type="bibr">66</xref>) has been shown to induce an immune response <italic toggle="yes">in vivo</italic> (<xref rid="B67" ref-type="bibr">67</xref>). RNA vaccines have been used in a number of studies in animal models (<xref rid="B68" ref-type="bibr">68</xref>) and have recently completed phase 1 clinical trials for rabies (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B69" ref-type="bibr">69</xref>) and influenza (<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B70" ref-type="bibr">70</xref>). Both trials had similar safety profiles with most patients experiencing mild to moderate reactions to administration and a few patients experiencing more severe reactions. Both vaccines also demonstrated immunogenicity through neutralizing antibody levels, though antibody levels with the rabies vaccine were more highly dependent on dose and route, with needle-free intradermal dose able to sustain neutralizing antibody levels in half of the number of vaccinated individuals one year after injection but not with those receiving intramuscular or intradermal injections (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B69" ref-type="bibr">69</xref>). Additionally, phase 1 clinical trials are currently underway to test the self-replicating RNA vaccines for HIV and Zika virus (<xref rid="B68" ref-type="bibr">68</xref>).</p><p>Several challenges face the development of DNA/RNA vaccines. First, while DNA and RNA vaccines may avoid the safety concerns due to microorganism-based vaccine formulations, they have safety concerns of their own. While an early study suggested that DNA vaccination might result in some instances of random chromosomal integration, it was determined that this occurred with a significantly lower frequency than random genetic mutations (<xref rid="B71" ref-type="bibr">71</xref>). However, a subsequent study did not observe chromosomal integration to occur following DNA vaccination (<xref rid="B51" ref-type="bibr">51</xref>). The possibility of introducing unwanted bacterial DNA elements (such as antibiotic resistance genes to the gut microbiome) has been raised as a safety concern for DNA vaccination, but as of yet it has not been proven (<xref rid="B51" ref-type="bibr">51</xref>). As such, regulatory guidelines have been put in place for new DNA vaccine clinical trials in the United States and Europe (<xref rid="B72" ref-type="bibr">72</xref>). Vaccine formulation based on mRNA has the advantage of being produced in cell-free systems that can eliminate the concern of bacterial contamination and also lack the potential for chromosomal integration and long-lasting expression (<xref rid="B57" ref-type="bibr">57</xref>). While the World Health Organization (WHO) has recently classified mRNA vaccines as its own therapeutic class (<xref rid="B73" ref-type="bibr">73</xref>), similar regulations have not yet been developed due to the more limited testing of mRNA vaccines in humans.</p><p>It has been found that DNA vaccination primarily induces antigen expression at the site of administration with significantly lower levels being observed elsewhere (<xref rid="B51" ref-type="bibr">51</xref>), which may partly explain its poor immunogenicity. While less is known about the levels of on- and/or off-target expressions seen with RNA vaccination, they are presumed to be generally lower than DNA vaccine due to the decreased stability of RNA. However, off-target antigen expression may be relatively minor in shaping the immune response, as the route and mode of DNA/RNA vaccine delivery can markedly alter vaccine immunity, but the mechanism is yet to be fully understood. Generally, intramuscular or intradermal injection is used in animal models and human volunteers to elicit protection against infectious disease to maximize delivery to APCs, while intraperitoneal or intravenous injection has been used in selected animal models to induce systemic expression in therapeutic models, such as cancer vaccination (<xref rid="B57" ref-type="bibr">57</xref>). These findings implicating localized dosage routes as most effective for eliciting immunity from nucleic acid vaccines may help explain why gene gun and electroporation have been found to be the most effective routes for DNA vaccine administration. The most effective dosage routes may also be similar for RNA vaccines, as intradermal and intramuscular injection have repeatedly been found to be the most effective delivery routes for RNA vaccines, and needle-free delivery systems may also be more effective than injections (<xref rid="B57" ref-type="bibr">57</xref>). Interestingly, immunity can still result from injection of naked RNA in certain models, but it has been found in particular that IV administration of naked RNA results in rapid RNA degradation (<xref rid="B57" ref-type="bibr">57</xref>).</p></sec><sec id="s2_3"><title>Rationally Designed Vaccines</title><p>A key aspect of non-viral vaccine development involves the selection of antigens that can effectively elicit a protective immune response. Whereas traditional vaccines are generally developed through attenuation or inactivation of pathogens and through the incorporation of few selected antigens as vaccine components, new technologies have recently been applied toward antigen discovery and design. For example, &#8220;reverse vaccinology&#8221; refers to the ability to screen the complete antigen sets based on whole-genome sequencing of pathogens for the ability to induce protective antibody responses. Combinations of reverse vaccinology and traditional vaccine approaches allow for an efficient development of immunogenic vaccine candidates (<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B75" ref-type="bibr">75</xref>).</p><p>Bioinformatic tools have contributed greatly to vaccine design and evaluation in recent years. Computational approaches are continually improving in their ability to predict T and B-cell epitopes from the complete antigen pools and to rationally design antigens with potential long-lasting protective immunity. Such algorithms calculate antigen-antibody interaction energies and structures (<xref rid="B76" ref-type="bibr">76</xref>) that increasingly bridge modeling based on existing templates and free-modeling based on heterologous structures and database consensus design (<xref rid="B77" ref-type="bibr">77</xref>). Deep sequencing combined with computational analysis allows for thoroughly characterizing the B cell repertoire in survivors of disease to identify the protective immunity (<xref rid="B78" ref-type="bibr">78</xref>).</p><p>A computationally designed antigen found to be protective in animal models was first reported for the respiratory syncytial virus (RSV) F antigen in 2013 (<xref rid="B79" ref-type="bibr">79</xref>). Many challenging vaccine targets have since been developed rationally for HIV (<xref rid="B80" ref-type="bibr">80</xref>&#8211;<xref rid="B82" ref-type="bibr">82</xref>), hepatitis C (<xref rid="B83" ref-type="bibr">83</xref>, <xref rid="B84" ref-type="bibr">84</xref>), herpes (<xref rid="B85" ref-type="bibr">85</xref>), Zika (<xref rid="B86" ref-type="bibr">86</xref>, <xref rid="B87" ref-type="bibr">87</xref>), RSV (<xref rid="B82" ref-type="bibr">82</xref>), HPV (<xref rid="B88" ref-type="bibr">88</xref>), as well as for bacteria (<xref rid="B82" ref-type="bibr">82</xref>, <xref rid="B89" ref-type="bibr">89</xref>), fungi (<xref rid="B90" ref-type="bibr">90</xref>), and cancers (<xref rid="B91" ref-type="bibr">91</xref>). Rational vaccine design has also been utilized to improve VLP and NP vaccines by selecting a repetitive and predictive protein backbone structure for enhanced antigen presentation (<xref rid="B92" ref-type="bibr">92</xref>). Finally, rational antigen design is being explored for activation of dendritic cells (<xref rid="B93" ref-type="bibr">93</xref>) such as targeting C-type lectin receptors to activate antigen presentation in the context of the pathogens (e.g., Ebola and HIV) (<xref rid="B94" ref-type="bibr">94</xref>). The first rationally-designed vaccine to undergo human clinical trials is the anti-malarial vaccine Mosquirix, which was approved for use by the European Medicines Agency in 2015 (<xref rid="B95" ref-type="bibr">95</xref>). Human clinical trials have not yet begun for other rationally designed vaccines, however. A key point to note is that rationally designed vaccines require a comprehensive knowledge of the biology and immune response to a pathogen (<xref rid="B95" ref-type="bibr">95</xref>), and rational design is therefore more difficult to implement for rapidly emerging diseases.</p><p>A major challenge to rational vaccine antigen design is the lack of knowledge of T cell epitopes compared to B cell epitopes. Most successful antigens are expected to elicit both B and T cell responses. Quantitative databases have been developed more for predicting B cell receptor (BCR) epitopes than T cell receptor (TCR) epitopes. BCR epitopes can be predicted in part by the structural and chemical properties of the epitopes due to BCRs recognizing primary and tertiary antigen structures, while TCR epitopes have to be predicted based on known TCR epitopes because they only recognize the primary structures. Increasing capacity for identification of TCR epitopes by machine learning from known epitopes will likely help to mitigate this inequity (<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B96" ref-type="bibr">96</xref>).</p></sec></sec><sec id="s3"><title>Non-Viral Vaccine Systems to Address Ongoing Challenges of Vaccine Development</title><sec id="s3_1"><title>Vaccines for Immunosuppressed Individuals</title><p>A fundamental challenge to vaccination is the limited immunogenic response to vaccines seen in immunosuppressed individuals, namely, young children, the elderly, and those who are immunocompromised for medical reasons. The underlying causes of immunosuppression in each of these populations vary, and their underlying mechanisms should be taken into account when creating the best vaccine approach.</p><p>Young children, in particular infants and neonates, are considered to be immunosuppressed due to age-specific immune system developments that result in children being particularly susceptible to infection (<xref rid="B97" ref-type="bibr">97</xref>). The specific mechanisms for the immunosuppression in this population vary, but one prominent example is the decreased expression of Th17 supporting cytokines by TLR receptors and increased expression of anti-inflammatory cytokines in neonates and particularly in premature newborns (<xref rid="B98" ref-type="bibr">98</xref>). On the other hand, the immunosuppressive phenomenon observed in the elderly has been referred to as immunosenescence (<xref rid="B99" ref-type="bibr">99</xref>) and it is caused by a number of complex changes resulting in impaired innate and adaptive immune responses (<xref rid="B100" ref-type="bibr">100</xref>&#8211;<xref rid="B104" ref-type="bibr">104</xref>), degradation of lymphoid architecture (<xref rid="B105" ref-type="bibr">105</xref>), and increasing proinflammatory cytokines and chemokines (<xref rid="B106" ref-type="bibr">106</xref>, <xref rid="B107" ref-type="bibr">107</xref>). To highlight a few important changes, dendritic cells have reduced uptake of antigens (<xref rid="B108" ref-type="bibr">108</xref>, <xref rid="B109" ref-type="bibr">109</xref>), macrophages are unable to phagocytose apoptotic cells (<xref rid="B110" ref-type="bibr">110</xref>), the number of na&#239;ve T cells decreases (<xref rid="B111" ref-type="bibr">111</xref>, <xref rid="B112" ref-type="bibr">112</xref>), and B cell repertoire decreases (<xref rid="B113" ref-type="bibr">113</xref>). These age-related changes in the ability of the immune system to respond to infection differ from the challenges to vaccination presented by conditions or medications that result in immunosuppression. One such example of a medication that results in immunosuppression is steroids, which have been reviewed extensively elsewhere (<xref rid="B114" ref-type="bibr">114</xref>). Steroids exert many effects on immune cells, such as the reprogramming of dendritic cells to tolerogenic dendritic cells (<xref rid="B115" ref-type="bibr">115</xref>&#8211;<xref rid="B117" ref-type="bibr">117</xref>). These cells induce the formation of regulatory T cells (<xref rid="B118" ref-type="bibr">118</xref>).</p><p>The development of vaccines that can potently activate the innate immune response without using live attenuated vaccines is a central focus of vaccine development for immunocompromised individuals. This is particularly relevant for subunit vaccines, as they do not contain potential viral genomic elements that can act as pattern-associated molecular patterns (PAMPs) to activate innate immune responses. A major approach toward increasing the immunogenic response to a subunit vaccine is through the use of adjuvants. Originally discovered by including food products in equine vaccines and inducing sites of localized sterile inflammation and abscesses, the adjuvant repertoire has since been greatly expanded (<xref rid="B119" ref-type="bibr">119</xref>). The so-called &#8220;first generation adjuvants&#8221;, which remain the most common adjuvants in clinical use, include aluminum salts (alum) and mineral oil-in-water emulsions, which function by promoting the migration of APCs to the sites of intramuscular injection (<xref rid="B120" ref-type="bibr">120</xref>). However, the use of these adjuvants is limited greatly by the recruitment of only a comparatively small population of immune cells that are made up of APCs (<xref rid="B120" ref-type="bibr">120</xref>) and a markedly Th2 response with little to no cellular immune response (<xref rid="B120" ref-type="bibr">120</xref>). This has become the aim of current research to design new adjuvants that can increase the breadth of the innate immune responses to the vaccine.</p><p>Much effort has been focused on enhancing the usable adjuvant repertoire to further customize the immune response and to avoid the Th2-dominated immune response seen with some adjuvants (e.g., alum) and instead support a Th1 response in certain circumstances. Specifically, a response skewed toward Th2 response is desired for antibody production and antiparasitic immune response, while a Th1 response is desired for intracellular or viral pathogens. Skewing toward Th1 or Th2 is thought to occur after APCs stimulate certain cytokine gene expression profiles (<xref rid="B121" ref-type="bibr">121</xref>). For example, LPS-derivative&#8211;based AS04 is being used in hepatitis B and HPV vaccines (<xref rid="B122" ref-type="bibr">122</xref>) and has been found to increase cell-mediated immune responses in patients with end-stage renal disease (<xref rid="B123" ref-type="bibr">123</xref>). Other adjuvants that have been developed to induce a Th1 immune response include IC31<sup>&#174;</sup> (<xref rid="B124" ref-type="bibr">124</xref>, <xref rid="B125" ref-type="bibr">125</xref>), GLA-SE (<xref rid="B125" ref-type="bibr">125</xref>, <xref rid="B126" ref-type="bibr">126</xref>), and CAF01 (<xref rid="B125" ref-type="bibr">125</xref>, <xref rid="B127" ref-type="bibr">127</xref>). In addition to the Th1 skewed immune response that these adjuvants displayed, GLA-SE induced antibodies and CAF01 showed a Th1/Th17 response (<xref rid="B125" ref-type="bibr">125</xref>). Increasing the breadth of the immune response to vaccines thus can enhance the safety and effectiveness of vaccines for both immunosuppressed populations as well as the general population.</p><p>There has been an increasing effort toward developing new vaccines that may induce a safe and immunogenic response in immunocompromised individuals. As an example, DNA vaccines could be used to encode for antibodies that could be safely and temporarily expressed in immunocompromised patients, such as throughout the course of an influenza season. Recent studies that tested the efficacy of influenza neutralizing antibodies found that protection against lethal disease could be conferred by plasmids expressing antibodies given intramuscularly by electroporation (<xref rid="B128" ref-type="bibr">128</xref>). However, several major considerations need to be fully addressed before these techniques can be developed for human use. Specifically, the duration and the stability of plasmid vaccination have not yet been fully characterized in humans. Additionally, it has been shown that anti-dsDNA antibodies can be produced by primary B cells isolated from mice treated with plasmid DNA (<xref rid="B129" ref-type="bibr">129</xref>), which appear similar to anti-dsDNA antibodies that have been shown to be expressed during systemic lupus erythematosus (<xref rid="B130" ref-type="bibr">130</xref>, <xref rid="B131" ref-type="bibr">131</xref>). The anti-dsDNA antibodies may prefer to bind to certain CpG-rich sequences on bacterial DNA of the plasmid (<xref rid="B129" ref-type="bibr">129</xref>), which might serve as a means for DNA vaccine optimization. Finally, the purity of plasmid DNA stocks needs to be thoroughly confirmed in order to avoid possible stimulation of unwanted immune reactions.</p><p>Other novel adjuvant approaches include the surfactant and emulsifier-based AS03 that are currently being used in influenza-pandemic vaccines (<xref rid="B132" ref-type="bibr">132</xref>). LPS-derivative&#8211;based AS04 is being used in hepatitis B and HPV vaccines (<xref rid="B122" ref-type="bibr">122</xref>) and has been found to increase cell-mediated immune responses in patients with end-stage renal disease (<xref rid="B123" ref-type="bibr">123</xref>). Lipid products that form micelles in solution and act as solid particle carriers are another form of adjuvants that can activate innate immunity, as seen with CAF01 (<xref rid="B133" ref-type="bibr">133</xref>, <xref rid="B134" ref-type="bibr">134</xref>) and AS01B/E formulation from GlaxoSmithKline (<xref rid="B135" ref-type="bibr">135</xref>), which are used in the only currently available vaccine for malaria (<xref rid="B136" ref-type="bibr">136</xref>, <xref rid="B137" ref-type="bibr">137</xref>). Several other adjuvants currently in use primarily function as TLR agonists (<xref rid="B138" ref-type="bibr">138</xref>&#8211;<xref rid="B140" ref-type="bibr">140</xref>). TLR agonists have shown promise in aged and young mice (<xref rid="B141" ref-type="bibr">141</xref>) as various TLR agonists [e.g., CpG (TLR9), poly(I:C) (TLR3), and pam3CSK4 (TLR1 and TLR2)] can induce expression of co-stimulatory molecules on APCs (<xref rid="B141" ref-type="bibr">141</xref>). Another adjuvant approach taken to overcome the immune challenges presented by young children is the use of &#223;-glucan. These sugars, found in the cell walls of some pathogens, activate dendritic cells through the CLEC71-SYK-CARD9 pathway, and it was shown to provide protection against tuberculosis infection (<xref rid="B142" ref-type="bibr">142</xref>). Recently, defective-interfering (DI) viral particle vaccines have also been explored for use as adjuvants to increase the innate immune response (<xref rid="B143" ref-type="bibr">143</xref>&#8211;<xref rid="B152" ref-type="bibr">152</xref>). These are VLPs with aberrant and defective genomes, which have been found in some cases to increase the innate immune response when compared to the replicating virion. Taken together, several innovative strategies are currently being developed to increase the immunogenicity and safety of vaccines for immunocompromised populations.</p></sec><sec id="s3_2"><title>Vaccines With Non-Traditional Antigens</title><p>Because of their increased safety and versatility, such as the ability to deliver a diverse range of molecules as antigens, VLP and NP vaccines have the potential for use to provide immunity against non-protein antigens. A prime example is the development of NP vaccines to treat substance abuse disorders by attaching a drug molecule to a hapten carrier (<xref ref-type="fig" rid="f2">
<bold>Figure 2</bold>
</xref>
<bold>).</bold> Vaccines against drugs of abuse aim to elicit a humoral (antibody) response that can neutralize the drug target before it crosses the blood-brain barrier to induce psychotropic effects, thereby decreasing positive associations with and hopefully dependency on the addictive drug. Such vaccines have an advantage for long-term therapeutic use over pharmaceuticals targeting neural receptors by eliminating the medical complications and safety concerns of directly modulating neural signaling network. They also differ from other vaccines in that they are given to active users of drugs of abuse to prevent escalation of use or relapse and do not depend on herd immunity for effectiveness, so their efficacy is determined by individual responses to the vaccines (<xref rid="B153" ref-type="bibr">153</xref>).</p><p>A hapten carrier, which is a potent B cell antigen, is used to stimulate B cell responses and thereby also activates B cell responses to the attached drug. Therefore, hapten and linker design are of particular interest to ensure structural integrity and to maximize B cell responses (<xref rid="B153" ref-type="bibr">153</xref>&#8211;<xref rid="B170" ref-type="bibr">170</xref>). The vaccine can also be linked to a protein carrier designed to activate T cell responses (and particularly CD4 T cell response to then activate B cells) (<xref rid="B153" ref-type="bibr">153</xref>, <xref rid="B160" ref-type="bibr">160</xref>, <xref rid="B171" ref-type="bibr">171</xref>&#8211;<xref rid="B181" ref-type="bibr">181</xref>), though there has not been a clear determination of whether an increased CD4 Th2:Th1 ratio correlates with efficacy for vaccines against drugs of abuse (<xref rid="B153" ref-type="bibr">153</xref>). Finally, an additional consideration in designing vaccines against drugs of abuse is determining whether to target the drug itself or its possibly more psychotropic metabolites that can provide a greater level of protection. A prime example of this is heroin vaccines seemingly being most effective when they can structurally mimic the psychotropic heroin metabolite 6-acetylmorphine (6AM) (<xref rid="B166" ref-type="bibr">166</xref>, <xref rid="B172" ref-type="bibr">172</xref>, <xref rid="B182" ref-type="bibr">182</xref>). It should be noted that clinical trial results have only been reported for vaccines against nicotine and cocaine addictions, with the vaccines demonstrating efficacy only in a subset of patients that were able to achieve high neutralizing antibody titers (<xref rid="B153" ref-type="bibr">153</xref>, <xref rid="B183" ref-type="bibr">183</xref>&#8211;<xref rid="B186" ref-type="bibr">186</xref>). The recent vaccine developments to ameliorate drug abuse have been reviewed more extensively elsewhere (<xref rid="B153" ref-type="bibr">153</xref>, <xref rid="B160" ref-type="bibr">160</xref>, <xref rid="B187" ref-type="bibr">187</xref>).</p><p>Additionally, VLP and NP vaccines are being used in toxoid vaccine formulations, which provide quick neutralization against a cytotoxic molecule (primarily bacterial toxins) that cannot be expressed in its full and activated form. The most well-known example is the diphtheria, tetanus and pertussis (DTaP) inactivated subunit vaccine which has been in use for decades and can elicit effective immune responses against the toxin produced by any of these bacteria if/when the vaccinated individual happens to be exposed to them. The pertussis component of DTaP has a demonstrated high level of safety that it is one of only two known vaccines (besides influenza) that is given to pregnant women in several countries (<xref rid="B188" ref-type="bibr">188</xref>). Current clinical trials are focusing on testing potentially more effective toxoid vaccines for pertussis (<xref rid="B189" ref-type="bibr">189</xref>) as well as <italic toggle="yes">Haemophilius influenzae</italic> type b, polio virus, and hepatitis B virus (<xref rid="B190" ref-type="bibr">190</xref>). It has also been found that using bacterial membrane or red blood cell (RBC) membrane micelles as a carrier can significantly increase the immunogenicity of the vaccines, and pre-clinical testing is currently underway to use these carriers in vaccine development against the multi-drug resistant bacteria <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) (<xref rid="B191" ref-type="bibr">191</xref>).</p></sec><sec id="s3_3"><title>Therapeutic Vaccines for Noncommunicable Diseases</title><p>As our capabilities for vaccine development and production have expanded, a paradigm shift has recently taken place to use vaccines for disease treatment in addition to disease prevention. These therapeutic vaccine designs rely on the identification of protein markers unique to a disease phenotype which may evade the development of an immune response due to the markers not being recognized by the APCs. For example, cancer vaccines to elicit immune responses against cancer-specific antigens are one of the most widely studied therapeutic vaccines to date due to the inherent challenges of developing effective cancer therapeutics and a need for targeted treatment. The immunosuppressive environment present in cancers has made developing cancer vaccines a significant challenge, especially for vaccines that rely on viral vectors. Therefore, the improved safety profile of non-viral vaccines offers an attractive potential for cancer vaccine development. Non-viral vaccines also confer an additional advantage for developing cancer vaccines in that cancer vaccines may be most effective when an antigen specific to the mutational profile of the individual cancer is used (<xref rid="B192" ref-type="bibr">192</xref>&#8211;<xref rid="B194" ref-type="bibr">194</xref>), particularly in combination to overcome immune tolerance (<xref rid="B195" ref-type="bibr">195</xref>). The time needed to make a vaccine against an individual antigen or against a combination of individual antigens is greatly reduced with non-viral vaccines due to the ease of encoding an antigen on a nucleic acid vaccine or purifying protein for a subunit vaccine in comparison to incorporating a personalized antigen into a viral vaccine, growing viral stocks and verifying its expression (<xref rid="B196" ref-type="bibr">196</xref>).</p><p>Nucleic acid vaccines have been a key area in recent developments for cancer treatment. While a number of DNA cancer vaccine candidates have entered into early phase clinical trials (<xref rid="B197" ref-type="bibr">197</xref>), RNA vaccines are thought to have particularly encouraging potential due to their increased immunogenicity compared to DNA vaccines (<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B198" ref-type="bibr">198</xref>). Preliminary results indicate that intranodal injection of naked tumor antigen-encoding mRNA can control tumor growth in mouse cancer models (<xref rid="B199" ref-type="bibr">199</xref>&#8211;<xref rid="B202" ref-type="bibr">202</xref>). Additionally, naked mRNA was found to be immunogenic <italic toggle="yes">via</italic> intradermal injection in a phase I/II clinical trial for prostate cancer (<xref rid="B203" ref-type="bibr">203</xref>). However, a key challenge in developing RNA cancer vaccines has been the need to further ensure the stability of the RNA and to increase its targeting to APCs (<xref rid="B204" ref-type="bibr">204</xref>, <xref rid="B205" ref-type="bibr">205</xref>) in order to overcome the immunosuppressive environment of cancers. Developing a delivery vehicle for RNA cancer vaccines has therefore been a central focus of research and development in this area.</p><p>Loading RNA into liposomes is one method that has shown some success in controlling cancer growth in mouse models (<xref rid="B206" ref-type="bibr">206</xref>&#8211;<xref rid="B208" ref-type="bibr">208</xref>) and has demonstrated some preliminary efficacy in early stage clinical trials for use as a delivery system for anti-cancer genes (<xref rid="B209" ref-type="bibr">209</xref>, <xref rid="B210" ref-type="bibr">210</xref>) and siRNAs (<xref rid="B211" ref-type="bibr">211</xref>), with different liposome constructs targeting RNA localization to the spleen. RNA-loaded liposomes can also be targeted directly to T cells by using RNA that encodes for anti-CD3 along with the cancer antigens, bypassing the need for recognition by APCs. This concept has notably been tested in conjunction with chimeric antigen receptor (CAR) T cell therapy (<xref rid="B198" ref-type="bibr">198</xref>, <xref rid="B212" ref-type="bibr">212</xref>, <xref rid="B213" ref-type="bibr">213</xref>). Another method bypasses targeting RNA to APCs by directly transfecting dendritic cells (DCs) with RNA extracted from tumors or RNA encoding tumor antigens (<xref rid="B214" ref-type="bibr">214</xref>&#8211;<xref rid="B217" ref-type="bibr">217</xref>) <bold>(</bold>
<xref ref-type="fig" rid="f4">
<bold>Figure 4</bold>
</xref>
<bold>)</bold> and then introducing the engineered DCs into patients with a combination of cytokines and/or checkpoint blockades (<xref rid="B218" ref-type="bibr">218</xref>, <xref rid="B219" ref-type="bibr">219</xref>). However, DC-directed RNA vaccines are currently limited by the restrained immune environment present in cancers, which can limit the activity of DCs and increases the activity of regulatory T cells (<xref rid="B216" ref-type="bibr">216</xref>, <xref rid="B220" ref-type="bibr">220</xref>, <xref rid="B221" ref-type="bibr">221</xref>). It is thought that these challenges could be mitigated by optimizing the use of cytokines and other factors that would act as adjuvants in combination with cancer RNA vaccines (<xref rid="B195" ref-type="bibr">195</xref>, <xref rid="B222" ref-type="bibr">222</xref>&#8211;<xref rid="B225" ref-type="bibr">225</xref>) and by optimizing DC isolation and culturing conditions (<xref rid="B226" ref-type="bibr">226</xref>). A few DC-directed RNA vaccine candidates are currently in clinical trials, including those in phase III (<xref rid="B196" ref-type="bibr">196</xref>, <xref rid="B221" ref-type="bibr">221</xref>).</p><p>Subunit vaccines have also been developed for use as cancer vaccines (<xref rid="B227" ref-type="bibr">227</xref>), which are being tested with many of the same delivery systems as nucleic acid-based cancer vaccines to maximize vaccine targeting to immune cells (<xref rid="B228" ref-type="bibr">228</xref>). NP-based vaccines in particular have been developed and tested for use as cancer treatments (<xref rid="B228" ref-type="bibr">228</xref>&#8211;<xref rid="B235" ref-type="bibr">235</xref>), the most notable of which are several HPV vaccines for prevention of cervical cancer (<xref rid="B236" ref-type="bibr">236</xref>). While less development has been done on VLP-based cancer vaccines, one notable target that has been used is the widely expressed cancer antigen human epidermal growth factor receptor-2/neu (HER2), which has shown to be immunogenic in mouse models (<xref rid="B237" ref-type="bibr">237</xref>&#8211;<xref rid="B244" ref-type="bibr">244</xref>) and in early clinical testing in humans (<xref rid="B245" ref-type="bibr">245</xref>) and dogs (<xref rid="B246" ref-type="bibr">246</xref>), but as a whole these vaccines have had to undergo additional design in order to overcome B cell tolerance (<xref rid="B227" ref-type="bibr">227</xref>, <xref rid="B247" ref-type="bibr">247</xref>) and to fully characterize their anti-tumor activity.</p><p>Because subunit vaccines require antigen presentation in order to elicit an immune response, a primary challenge in VLP- and NP-based cancer vaccine developments has been optimizing their uptake by APCs (<xref rid="B228" ref-type="bibr">228</xref>). Vaccine uptake by APCs can be optimized by engineering VLP- and NP-based cancer vaccines to resemble the structure of viral particles as closely as possible, such as by using certain types of carriers (liposomes, polymers and ferritin cages), sizes (20&#8211;45 nm) and a spherical shape <bold>(</bold>
<xref ref-type="fig" rid="f4">
<bold>Figure 4</bold>
</xref>
<bold>).</bold> Subsequently, these vaccines may be most successful when combined with checkpoint blockade treatment by encouraging clonal expansion of lymphocytes (<xref rid="B248" ref-type="bibr">248</xref>). VLPs and NPs can also be used as immuno-enhancers, e.g., to deliver cytokines and TLR agonists to target sites, which has been found to boost localized immune responses while avoiding immunopathogenic and possibly systemic inflammation (<xref rid="B46" ref-type="bibr">46</xref>).</p></sec><sec id="s3_4"><title>Vaccines for Rapidly Emerging Viral Diseases</title><p>Emerging and reemerging pathogens, such as West Nile virus, pandemic influenza virus, Ebola virus, dengue virus, Zika virus, and the on-going global pandemic SARS-CoV-2 pose great challenges to the public health system. Rapid development and deployment of vaccines are critical to quickly build up resistance against these and other disease &#8220;X&#8221;, which is a term used by the WHO to refer to future unknown disease pandemics (<xref rid="B249" ref-type="bibr">249</xref>). The ideal vaccine platform in a pandemic situation must be cost-effective and can be rapidly developed and produced on a large scale to meet global demands. Temperature sensitivity is also a consideration, as cold chain storage can be particularly difficult to maintain in developing countries. Development of heat stable vaccines like the oral bovine rotavirus pentavalent vaccine (BRV-PV, Rotasil<sup>&#174;</sup> by the Serum Institute of India), which was prequalified by the WHO in 2018, can provide protection against serious diseases in regions where transportation and refrigeration are unreliable (<xref rid="B250" ref-type="bibr">250</xref>). In comparison, the only FDA approved Ebola virus vaccine (rVSV-ZEBOV, ERVEBO<sup>&#174;</sup> by Merck and Co., Inc.) must be stored at &#8722;80&#176;C or &#8722;60&#176;C (<xref rid="B251" ref-type="bibr">251</xref>), which presents a major obstacle for affected countries. Rapid production of low cost, scalable, and temperature stable vaccines is an ongoing challenge in the face of emerged and emerging global disease pandemics.</p><p>Currently, rapid development of vaccines is greatly limited by the resources and regulatory policies needed to bring a vaccine from its conceptualization stage to the clinic, which has been estimated to cost between $200 and $500 million dollars and to take 5&#8211;18 years (<xref rid="B252" ref-type="bibr">252</xref>). Vaccines also tend to be manufactured in countries with larger economic and technical prowess and more robust disease surveillance systems than developing countries and therefore can unfairly influence the equity of vaccine distribution and usage. This was seen in the 2009&#8211;2010 influenza pandemic, where 80% of the vaccines were manufactured and used in seven industrialized regions (United States, Canada, Australia, western Europe, Russia, China, and Japan), while the majority of developing regions in the world did not receive any pandemic influenza vaccines until January 2010, 9 months after the WHO declared the influenza pandemic (<xref rid="B253" ref-type="bibr">253</xref>). In addition, as mentioned previously, most pandemic vaccines have to be clinically tested during an active outbreak in order to obtain sufficient safety and efficacy data, thereby limiting the number of vaccine candidates that can be deployed to save lives.&#160;This was seen during the Ebola outbreak of 2013&#8211;2015, when two vaccines were fully developed in advance of clinical trials but only one (the simian adenovirus-based Ebola vaccine ChAd3-EBO-Z) was tested early enough in the outbreak to obtain sufficient clinical data (<xref rid="B254" ref-type="bibr">254</xref>). Similar challenges are also seen in selecting vaccine candidates for the large sample sizes needed for phase III clinical trials for HIV vaccine candidates. Statistical ranking systems to prioritize candidates are being developed to aid in this selection process (<xref rid="B255" ref-type="bibr">255</xref>). Zoonotic diseases present additional considerations, as it is economical to vaccinate the multiple species that may act as reservoirs of the pathogen(s) in order to control the spread of the disease. The first vaccine to provide protection in multiple species is the simian adenovirus-based vaccine candidate ChAdOx1 RVF, which has been shown to provide effective protection against Rift Valley Fever virus in sheep, goats, and cattle and is currently undergoing testing in larger livestock field trials and in humans (<xref rid="B254" ref-type="bibr">254</xref>, <xref rid="B256" ref-type="bibr">256</xref>).</p><p>Other measures have been undertaken to expedite the process of vaccine development and reduce the cost of vaccine production. International institutions allow for collaborative groups to rapidly co-operate on vaccine development and shorten the vaccine manufacturing process. The Coalition for Epidemic Preparedness and Innovations (CEPI) provides funds for clinical trial and stockpiling of vaccines that would not have market incentive in a traditional funding mechanism of vaccine development and manufacturing (<xref rid="B257" ref-type="bibr">257</xref>). Such international collaborations will help to bridge the differing vaccine development policies and investitures across countries and use these combined resources to develop vaccines to primarily benefit those living in either underdeveloped or developing nations (<xref rid="B258" ref-type="bibr">258</xref>). In a recent example of this, CEPI, Gavi, and the WHO have come together to form COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, with the mission to expedite the production of a COVID-19 vaccine to be equitably distributed throughout the world (<xref rid="B259" ref-type="bibr">259</xref>).</p><p>Technical challenges in vaccine production process can be an impediment. For example, the use of fertilized chicken eggs in vaccine production can pose challenges such as the restricted capacity of egg production, egg allergies, and the emergence of viruses with egg-culture-adapted mutations that can reduce vaccine efficacy (<xref rid="B260" ref-type="bibr">260</xref>). The use of animal cells for certain vaccines can also present significant challenges of cost, slow production rates, and potential high risk of contaminations. Other vaccine production systems, such as VLP vaccines produced in yeasts, insect cells and bacterial systems, as well as DNA/RNA vaccines, can benefit from increased robustness of antigen production, decreased risk of contaminations, and quicker time of response (<xref rid="B252" ref-type="bibr">252</xref>). This may especially be the case for DNA vaccines, where the increasing capacity of next-generation DNA sequencing, for example, has lowered the time for development of a DNA vaccine from 20 months following the 2003 SARS outbreak to 3.25 months following the 2016 Zika outbreak (<xref rid="B261" ref-type="bibr">261</xref>).</p></sec><sec id="s3_5"><title>COVID-19 Pandemic as a Case Study to Rapidly Develop Non-Viral Vaccines</title><p>The ongoing COVID-19 pandemic has presented unique opportunities as well as challenges for vaccine development. Unlike the influenza vaccines, no coronavirus vaccines existed prior to the COVID-19 pandemic. Such a rapid and widespread need for a completely novel vaccine for COVID-19 has resulted in a drive to significantly reduce the length of time required to produce a new vaccine. It has also highlighted the necessity to use non-viral vaccine platforms with overlapping stages of vaccine development, including preclinical and clinical testing and manufacturing that would otherwise be required to happen in a stepwise process for a traditional vaccine development effort (<xref rid="B262" ref-type="bibr">262</xref>&#8211;<xref rid="B264" ref-type="bibr">264</xref>). However, a rapid progression of clinical testing will need to be balanced by the need for obtaining quality data on vaccine safety and efficacy (<xref rid="B265" ref-type="bibr">265</xref>), especially considering previous reports of pathological antibody-dependent enhancement responses in some patients immunized with the 2003 SARS vaccine candidates (<xref rid="B266" ref-type="bibr">266</xref>, <xref rid="B267" ref-type="bibr">267</xref>). As with previous pandemics, widespread global availability and resource management will be another key consideration for vaccine selection, especially considering the near ubiquitous presence of COVID-19 around the globe and its disproportionate impact on populations of low socio-economic status (<xref rid="B268" ref-type="bibr">268</xref>, <xref rid="B269" ref-type="bibr">269</xref>). It is also likely that the approval of multiple vaccine candidates will be most optimal to controlling and ending the pandemic should more than one vaccine prove to be effective in preventing COVID-19 disease. Multiple COVID-19 vaccines would allow for more clinical and regulatory choices to accommodate differences in patient responses (particularly in more vulnerable patient populations) and manufacturing and distribution capabilities (<xref rid="B270" ref-type="bibr">270</xref>, <xref rid="B271" ref-type="bibr">271</xref>). Perhaps, with these considerations in mind, non-viral COVID-19 vaccine platforms (e.g., DNA and mRNA) have been selected among the first candidates to enter clinical testing, partly for their aforementioned reasons of safety profiles and relative ease of manufacturing <bold>(</bold>
<xref rid="T1" ref-type="table">
<bold>Table 1</bold>
</xref>
<bold>).</bold> Some of the RNA-based COVID-19 vaccines (all of which are currently in various stages of clinical trials) include but are not necessarily limited to:</p><list list-type="order"><list-item><p>The mRNA-1273 vaccine developed by the U.S. biotech company Moderna (<xref rid="B272" ref-type="bibr">272</xref>).</p></list-item><list-item><p>The mRNA CVnCoV vaccine developed by the German company CureVac (<xref rid="B273" ref-type="bibr">273</xref>).</p></list-item><list-item><p>A group of 4 RNA vaccines under the name BNT162 developed by the German company Biontech that consists of two nucleoside-modified mRNAs, a uridine-containing mRNA and a self-amplifying mRNA (<xref rid="B274" ref-type="bibr">274</xref>), which in an early phase I/II trial, the nucleoside-modified mRNA BNT1621b has been shown to elicit neutralizing antibodies (<xref rid="B275" ref-type="bibr">275</xref>) and is better tolerated particularly in older adults than BNT1621a (<xref rid="B276" ref-type="bibr">276</xref>, <xref rid="B277" ref-type="bibr">277</xref>).</p></list-item><list-item><p>The self-amplifying mRNA LNP-nCoVsaRNA (COVAC1) vaccine from the Imperial College London (<xref rid="B278" ref-type="bibr">278</xref>).</p></list-item><list-item><p>The mRNA vaccine LUNAR-COV19 (ARCT-021) from US company Arcturus Therapeutics (<xref rid="B279" ref-type="bibr">279</xref>).</p></list-item><list-item><p>An unnamed mRNA vaccine candidate from Chinese company Yunnan Walvax Biotechnology (<xref rid="B280" ref-type="bibr">280</xref>).</p></list-item></list><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Non-viral vaccines currently in development for SARS-CoV-2*.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Vaccine Name</th><th valign="top" align="center" rowspan="1" colspan="1">Vaccine type</th><th valign="top" align="center" rowspan="1" colspan="1">Company and Country </th><th valign="top" align="center" rowspan="1" colspan="1">Preliminary results</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">mRNA-1273</td><td valign="top" align="left" rowspan="1" colspan="1">mRNA</td><td valign="top" align="left" rowspan="1" colspan="1">Moderna, USA</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Self-reported preliminary data indicating all patients developed neutralizing antibody response. Patients developed moderate side effects with highest dose (250 ug) were eliminated from future study.</p></list-item><list-item><p>Entered phase III clinical trials in July 2020 with targeted enrollment of 30,000 people</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CVnCoV</td><td valign="top" align="left" rowspan="1" colspan="1">mRNA</td><td valign="top" align="left" rowspan="1" colspan="1">CureVac, Germany</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Entered phase II clinical trials in August 2020</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BNT162</td><td valign="top" align="left" rowspan="1" colspan="1">mRNA (4 candidates)</td><td valign="top" align="left" rowspan="1" colspan="1">Biontech, Germany</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Early phase I/II trial data showed that patients who received nucleoside-modified mRNA BNT1621b produced neutralizing antibodies.</p></list-item><list-item><p>Further phase I/II clinical trial data showed that BNT1621a and BNT1621b produced similar neutralizing antibody titers but that BNT1621b was associated with less systemic responses particularly in older adults.</p></list-item><list-item><p>BNT162b was selected to continue in phase II/III clinical trials.</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LNP-nCoVsaRNA (COVAC1)</td><td valign="top" align="left" rowspan="1" colspan="1">mRNA (self-amplifying)</td><td valign="top" align="left" rowspan="1" colspan="1">Imperial College London, UK</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Entered phase I/II clinical trials in June 2020</p></list-item><list-item><p>Transitioned to phase II clinical trials in July 2020</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LUNAR-COV19 (ARCT-021)</td><td valign="top" align="left" rowspan="1" colspan="1">mRNA</td><td valign="top" align="left" rowspan="1" colspan="1">Arcturus Therapeutics, USA</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Entered phase I/II clinical trials in July 2020</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Unnamed mRNA vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">mRNA</td><td valign="top" align="left" rowspan="1" colspan="1">Yunnan Walvax Biotechnology co, China</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">INO-4800</td><td valign="top" align="left" rowspan="1" colspan="1">DNA</td><td valign="top" align="left" rowspan="1" colspan="1">Inovio, USA</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Preliminary phase I data suggest that 94% of participants developed an immune response against the vaccine.</p></list-item><list-item><p>Preprint suggests that a single dose seroconverted vaccinated rhesus macaques. Neutralizing antibodies were produced against the D614 and G614 strains and memory responses lasted at least 4 months after vaccination.</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GX-19</td><td valign="top" align="left" rowspan="1" colspan="1">DNA</td><td valign="top" align="left" rowspan="1" colspan="1">Genexine, South Korea</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Entered phase I/II clinical trials in June 2020</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AG0301-COVID19</td><td valign="top" align="left" rowspan="1" colspan="1">DNA</td><td valign="top" align="left" rowspan="1" colspan="1">AnGes Inc, Japan</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Entered phase I/II clinical trials in July 2020</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ZyCoV-D</td><td valign="top" align="left" rowspan="1" colspan="1">DNA</td><td valign="top" align="left" rowspan="1" colspan="1">Cadila Healthcare Ltd, India</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Entered phase I/II clinical trials in July 2020</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">bacTRL-Spike</td><td valign="top" align="left" rowspan="1" colspan="1">DNA (live bacteria delivery)</td><td valign="top" align="left" rowspan="1" colspan="1">Symvivo, Canada</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LV-SMENP-DC</td><td valign="top" align="left" rowspan="1" colspan="1">APC (lentiviral)</td><td valign="top" align="left" rowspan="1" colspan="1">Shenzhen Geno-Immune Medical Institute, China</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Covid-19/aAPC</td><td valign="top" align="left" rowspan="1" colspan="1">APC (lentiviral)</td><td valign="top" align="left" rowspan="1" colspan="1">Shenzhen Geno-Immune Medical Institute, China</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AV-COVID-19</td><td valign="top" align="left" rowspan="1" colspan="1">APC (antigen-loaded)</td><td valign="top" align="left" rowspan="1" colspan="1">Aivita Biomedical, USA</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Entered phase I/II clinical trials in May 2020</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NVX-CoV2373</td><td valign="top" align="left" rowspan="1" colspan="1">NP</td><td valign="top" align="left" rowspan="1" colspan="1">Novavax, USA</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Entered phase I/II clinical trials in May 2020</p></list-item><list-item><p>Self-reported data from phase I indicate that the vaccine was well tolerated and induced neutralizing antibody responses in all patients after two doses.</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SCB-2019</td><td valign="top" align="left" rowspan="1" colspan="1">NP</td><td valign="top" align="left" rowspan="1" colspan="1">Clover Biopharmaceuticals, China</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Entered phase I/II clinical trials in May 2020</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">COVAX-19</td><td valign="top" align="left" rowspan="1" colspan="1">NP</td><td valign="top" align="left" rowspan="1" colspan="1">GeneCure Biotechnologies, USA</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Entered phase I clinical trials in June 2020</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MVC-COV1901</td><td valign="top" align="left" rowspan="1" colspan="1">NP</td><td valign="top" align="left" rowspan="1" colspan="1">Medigen Vaccine Biologics corp, Taiwan</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Entered phase I clinical trials in July 2020</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AdmirSC-2f</td><td valign="top" align="left" rowspan="1" colspan="1">NP</td><td valign="top" align="left" rowspan="1" colspan="1">Adimmune corp, Taiwan</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Entered phase I clinical trials in August 2020</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Unnamed spike protein vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">NP</td><td valign="top" align="left" rowspan="1" colspan="1">University of Queensland, Australia</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Entered phase I clinical trials in June 2020</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Unnamed VLP vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">VLP</td><td valign="top" align="left" rowspan="1" colspan="1">Medicago, Canada</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Entered phase I clinical trials in June 2020</p></list-item></list>
</td></tr></tbody></table><table-wrap-foot><p>*COVID19 vaccine data compiled with the aid of the BioRender COVID-19 Vaccine and Drug tracker: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://biorender.com/covid-vaccine-tracker">https://biorender.com/covid-vaccine-tracker</uri>.</p><p>This chart summarizes the name, type of vaccine, company and country of origin and preliminary data on existing non-viral vaccines for SARS-CoV-2 that are currently undergoing clinical testing.</p></table-wrap-foot></table-wrap><p>Some of the COVID-19 DNA vaccines (all of which are also in various stages of clinical trials) include but are not necessarily limited to:</p><list list-type="order"><list-item><p>The INO-4800 vaccine developed by the U.S. pharmaceutical company Inovio (<xref rid="B281" ref-type="bibr">281</xref>) with preliminary phase I data suggesting that 94% of participants might have developed an immune response against it following vaccine administration by electroporation (<xref rid="B282" ref-type="bibr">282</xref>) and that vaccination in rhesus macaques elicited neutralizing antibodies against both the D614 and G614 SARS-CoV-2 strains (<xref rid="B283" ref-type="bibr">283</xref>).</p></list-item><list-item><p>The GX-19 vaccine developed by the South Korean company Genexine (<xref rid="B284" ref-type="bibr">284</xref>).</p></list-item><list-item><p>The AG0301-COVID19 vaccine developed by the Japanese company AnGes, Inc. (<xref rid="B285" ref-type="bibr">285</xref>, <xref rid="B286" ref-type="bibr">286</xref>).</p></list-item><list-item><p>The ZyCoV-D vaccine developed by the Indian company Cadila Healthcare Ltd (<xref rid="B287" ref-type="bibr">287</xref>).</p></list-item><list-item><p>The live bacteria-mediated plasmid delivery system bacTRL-Spike developed by the Canadian company Symvivo (<xref rid="B288" ref-type="bibr">288</xref>).</p></list-item></list><p>Genetically engineered APCs are also being pursued as potential COVID-19 vaccine candidates, with DCs transfected with lentiviral vectors expressing COVID-19 antigens currently being tested in China (<xref rid="B289" ref-type="bibr">289</xref>, <xref rid="B290" ref-type="bibr">290</xref>) and in the United States (<xref rid="B291" ref-type="bibr">291</xref>). Meanwhile, COVID-19 VLP- and NP-based vaccines have also advanced into clinical trials, including the NP NVX-CoV2373 vaccine from the U.S. company Novavax (<xref rid="B292" ref-type="bibr">292</xref>), the NP SCB-2019 vaccine from the Chinese company Clover Biopharmaceuticals (<xref rid="B293" ref-type="bibr">293</xref>), the NP COVAX-19 vaccine from the U.S. company GeneCure Biotechnologies (<xref rid="B294" ref-type="bibr">294</xref>), the NP vaccine from the Taiwanese company Medigen Vaccine Biologics (<xref rid="B295" ref-type="bibr">295</xref>), the NP vaccine AdmirSC-2f from Taiwanese company Adimmune corp (<xref rid="B296" ref-type="bibr">296</xref>), an unnamed NP vaccine from the University of Queensland (<xref rid="B297" ref-type="bibr">297</xref>, <xref rid="B298" ref-type="bibr">298</xref>) and an unnamed VLP vaccine from the Canadian company Medicago (<xref rid="B299" ref-type="bibr">299</xref>). CEPI has collaborated in the development and testing of a selected number of these vaccine candidates (<xref rid="B273" ref-type="bibr">273</xref>, <xref rid="B281" ref-type="bibr">281</xref>, <xref rid="B298" ref-type="bibr">298</xref>).</p><p>It should also be noted that several viral vectored vaccine candidates for COVID-19 have also entered in clinical testing <bold>(</bold>
<xref rid="T2" ref-type="table">
<bold>Table 2</bold>
</xref>
<bold>).</bold> Several adenovirus vectored vaccines are currently the furthest along in clinical testing. One example is the vaccine candidate AZD1222 (formerly known as ChAdOx1 nCov-19), a replication-defective chimpanzee adenovirus developed by Oxford University which entered phase III clinical trials in August 2020. This viral vector was chosen due to its previous application as a vaccine vector for Middle East respiratory syndrome coronavirus (MERS-CoV). The ChAdOx1 vector encoding the spike (S) protein provided protection against six different strains of MERS-CoV in rhesus macaques (<xref rid="B25" ref-type="bibr">25</xref>), demonstrating its ability to be an effective vaccine for coronaviruses. Specific to COVID-19, AZ1222 was found to induce humoral and cell mediated immune repsonses in phase I/II cliical trial and did not result in any instances of severe side effects (<xref rid="B300" ref-type="bibr">300</xref>). It has recently found that AZD1222 could induce a robust humoral, CD8 and Th1 dominant CD4 response in mice and rhesus macaques and that both a prime and a prime-boost regimen protected rhesus macaques against COVID-19 related pneumonia. However, it should be noted that there was no difference in the amount of nasal virus shedding in vaccinated vs unvaccinated animals challenged with SARS-CoV-2 (<xref rid="B301" ref-type="bibr">301</xref>).</p><table-wrap id="T2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Viral vaccines currently in development for SARS-CoV-2*.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Vaccine Name</th><th valign="top" align="center" rowspan="1" colspan="1">Vaccine vector</th><th valign="top" align="center" rowspan="1" colspan="1">Company and Country </th><th valign="top" align="center" rowspan="1" colspan="1">Preliminary results</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">AZD1222 (ChAdOx1 nCoV-19)</td><td valign="top" align="left" rowspan="1" colspan="1">Adenovirus</td><td valign="top" align="left" rowspan="1" colspan="1">Oxford University, UK</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Vector was shown to protect rhesus macaques against six strains of MERS-CoV.</p></list-item><list-item><p>Early phase I/II clinical trial data show that vaccine was well tolerated and induced humoral and cell-mediated responses.</p></list-item><list-item><p>Vaccine was found to induce robust humoral, CD8 and Th1 dominated CD4 responses in mice and rhesus macaques, and that both a prime and prime-boost regimen protected rhesus macaques against COVID-19 related pneumonia.</p></list-item><list-item><p>Entered phase III clinical trials in August 2020</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ad5-nCoV</td><td valign="top" align="left" rowspan="1" colspan="1">Adenovirus</td><td valign="top" align="left" rowspan="1" colspan="1">CanSino biologics, China</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Early phase I/II clinical trial data show that vaccine induced antibody and cell-mediated responses after a single dose and was well tolerated.</p></list-item><list-item><p>Entered phase III clinical trials in August 2020</p></list-item><list-item><p>Approved by the Chinese government for use by its members of the armed forces</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ad26.COV2.S</td><td valign="top" align="left" rowspan="1" colspan="1">Adenovirus</td><td valign="top" align="left" rowspan="1" colspan="1">Johnson and Johnson, USA</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Vaccine was found to induce antibody and T cell responses in rhesus macaques after a single dose, and antibody titers negatively correlated with viral titers during viral challenge.</p></list-item><list-item><p>Entered phase III clinical trials in August 2020</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gam-COVID-Vac</td><td valign="top" align="left" rowspan="1" colspan="1">Adenovirus</td><td valign="top" align="left" rowspan="1" colspan="1">Gamaleya Research Institute of Epidemiology and Microbiology, Russia</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Approved for widespread use by the Russian government before the release of clinical trial data</p></list-item><list-item><p>Entered phase III clinical trials in August 2020</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TMV-083</td><td valign="top" align="left" rowspan="1" colspan="1">Measles</td><td valign="top" align="left" rowspan="1" colspan="1">Institut Pasteur, France</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Entered phase I clinical trials in August 2020</p></list-item></list>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">V591</td><td valign="top" align="left" rowspan="1" colspan="1">Measles</td><td valign="top" align="left" rowspan="1" colspan="1">Merck, USA</td><td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Entered phase I clinical trials in August 2020</p></list-item></list>
</td></tr></tbody></table><table-wrap-foot><p>*COVID19 vaccine data compiled with the aid of the BioRender COVID-19 Vaccine and Drug tracker: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://biorender.com/covid-vaccine-tracker">https://biorender.com/covid-vaccine-tracker</uri>.</p><p>This chart summarizes the name, viral vector used, company and country of origin, and preliminary data on existing viral vaccines for SARS-CoV-2 that are currently undergoing clinical testing.</p></table-wrap-foot></table-wrap><p>Two other replication-incompetent adenoviral vectored vaccines for COVID-19 have also entered clinical trials. The Ad5-nCoV candidate from Chinese company CanSino biologics was shown in early clinical trial data to induce significant antibody and T cell responses after a single dose and to have only rare instances of severe side effects that were more prevalent among the higher dose groups (<xref rid="B302" ref-type="bibr">302</xref>, <xref rid="B303" ref-type="bibr">303</xref>). The Chinese government has recently approved the vaccine for use among its members of the armed forces (<xref rid="B304" ref-type="bibr">304</xref>). Additionally, the Ad26.COV2.S from Johnson &amp; Johnson induced antibody and T cell responses in rhesus macaques after a single dose, and antibody titers negatively correlated with viral titers during viral challenge (<xref rid="B305" ref-type="bibr">305</xref>). Finally, the Gam-COVID-Vac candidate from the Gamaleya Research Institute of Epidemiology and Microbiology in Russia is another adenovirus-based vaccine that is the first COVID-19 vaccine to gain government approval for widespread use after a phase I trial. Phase III trials for this vaccine began in August 2020 (<xref rid="B306" ref-type="bibr">306</xref>).</p><p>Finally, two COVID-19 vaccine candidates based on live-attenuated measles platforms have also entered into early clinical trials. The TMV-083 candidate from the Institut Pasteur and with collaboration with CEPI is a measles vectored vaccine expressing a modified SARS-CoV-2 surface glycoprotein that entered phase I clinical trials in August 2020 (<xref rid="B307" ref-type="bibr">307</xref>), while the V591 candidate from Merck also entered phase I clinical trials in August 2020 (<xref rid="B308" ref-type="bibr">308</xref>). Many other viral vectored vaccine candidates for COVID-19 are also in preclinical stages of development.</p></sec></sec><sec id="s4"><title>Summary</title><p>The emergence of new non-viral vaccine technologies has significantly advanced the scope and efficacy of traditional vaccine formulations that are generally based on single protein subunit vaccines or attenuated or killed vaccines. Non-viral vaccine technologies have allowed for new applications to address ongoing challenges of vaccination with customization in the areas of safety, immunogenicity, breadth of protection, scalability, and ease of production. These new technologies have also expanded the notion of what is possible with vaccination by extending their reach to once untenable areas, such as cancer treatment and neutralization of drugs of abuse. It is clear that continued development and optimization of vaccines will require&#160;multi-faceted approaches that can only be implemented with extensive cross-field collaboration and periodic review of the current state of vaccinology. These challenges as well as opportunities ensure that vaccine development will remain on the cutting edge of science for decades to come to combat new and&#160;emerging pathogens as well as other noncommunicable diseases.</p></sec><sec id="s5"><title>Author Contributions</title><p>MB, SV, NK, and HL contributed to the literature review and writing of the manuscript. MB prepared all figures and tables. All authors contributed to the article and approved the submitted version.</p></sec><sec id="s6"><title>Funding</title><p>This work was supported in parts by NIH NIAID grant R01 AI131586,&#160;USDA-NIFA-Capacity Funds (Hatch and Animal Health), and the University of Minnesota School of Medicine Academic Investment Research Program (AIRP) and COVID-19 Rapid Response Funds to HL and YL, USDA-NIFA AFRI grant #2019-05384&#160;and Minnesota Agricultural Experiment Station Rapid Agricultural Response Fund to HL, and by a pre-doctoral NIH fellowship T32 DA007097 to MB. NIH T32 training grant in Comparative Medicine and Pathology (5T32 OD010993-17) for NK.</p></sec><sec id="s7"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>MA</given-names></name></person-group><article-title>Immunologic basis of vaccine vectors</article-title>. <source>Immunity</source> (<year>2010</year>) <volume>33</volume>:<page-range>504&#8211;15</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.004</pub-id><pub-id pub-id-type="pmid">21029961</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plotkin</surname><given-names>S</given-names></name></person-group><article-title>History of vaccination</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2014</year>) <volume>111</volume>:<page-range>12283&#8211;7</page-range>. &#160;<pub-id pub-id-type="doi">10.1073/pnas.1400472111</pub-id><pub-id pub-id-type="pmcid">PMC4151719</pub-id><pub-id pub-id-type="pmid">25136134</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rauch</surname><given-names>S</given-names></name><name name-style="western"><surname>Jasny</surname><given-names>E</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>KE</given-names></name><name name-style="western"><surname>Petsch</surname><given-names>B</given-names></name></person-group><article-title>New vaccine technologies to combat outbreaksituations</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>(<issue>1963</issue>):<fpage>1</fpage>&#8211;<lpage>24</lpage>. &#160;<pub-id pub-id-type="doi">10.3389/fimmu.2018.01963</pub-id><pub-id pub-id-type="pmid">30283434</pub-id><pub-id pub-id-type="pmcid">PMC6156540</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>GL</given-names></name><name name-style="western"><surname>MacKett</surname><given-names>M</given-names></name><name name-style="western"><surname>Moss</surname><given-names>B</given-names></name></person-group><article-title>Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen</article-title>. <source>Nature</source> (<year>1983</year>) <volume>302</volume>:<page-range>490&#8211;5</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/302490a0</pub-id><pub-id pub-id-type="pmid">6835382</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moss</surname><given-names>B</given-names></name><name name-style="western"><surname>Smith</surname><given-names>GL</given-names></name><name name-style="western"><surname>Gerin</surname><given-names>JL</given-names></name><name name-style="western"><surname>Purcell</surname><given-names>RH</given-names></name></person-group><article-title>Live recombinant vaccinia virus protects chimpanzees against hepatitis B</article-title>. <source>Nature</source> (<year>1984</year>) <volume>311</volume>:<page-range>67&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/311067a0</pub-id><pub-id pub-id-type="pmid">6472464</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tartaglia</surname><given-names>J</given-names></name><name name-style="western"><surname>Jarrett</surname><given-names>O</given-names></name><name name-style="western"><surname>Neil</surname><given-names>JC</given-names></name><name name-style="western"><surname>Desmettre</surname><given-names>P</given-names></name><name name-style="western"><surname>Paoletti</surname><given-names>E</given-names></name></person-group><article-title>Protection of cats against feline leukemia virus by vaccination witha canarypox virus recombinant, ALVAC-FL</article-title>. <source>J Virol</source>(<year>1993</year>) <volume>67</volume>:<page-range>2370&#8211;5</page-range>. <pub-id pub-id-type="doi">10.1128/JVI.67.4.2370-2375.1993</pub-id><pub-id pub-id-type="pmcid">PMC240401</pub-id><pub-id pub-id-type="pmid">8383248</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darteil</surname><given-names>R</given-names></name><name name-style="western"><surname>Bublot</surname><given-names>M</given-names></name><name name-style="western"><surname>Laplace</surname><given-names>E</given-names></name><name name-style="western"><surname>Bouquet</surname><given-names>JF</given-names></name><name name-style="western"><surname>Audonnet</surname><given-names>JC</given-names></name><name name-style="western"><surname>Rivi&#232;</surname><given-names>M</given-names></name></person-group><article-title>Herpesvirus of turkey recombinant viruses expressing infectious bursal disease virus (IBDV) VP2 immunogen induce protection against an IBDV virulent challenge in chickens</article-title>. <source>Virology</source> (<year>1995</year>) <volume>211</volume>:<page-range>481&#8211;90</page-range>. &#160;<pub-id pub-id-type="doi">10.1006/viro.1995.1430</pub-id><pub-id pub-id-type="pmid">7645252</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pastoret</surname><given-names>PP</given-names></name><name name-style="western"><surname>Brochier</surname><given-names>B</given-names></name></person-group><article-title>The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; A link between Jenner and Pasteur</article-title>. <source>Epidemiol Infect</source> (<year>1996</year>) <volume>116</volume>:<page-range>235&#8211;40</page-range>. &#160;<pub-id pub-id-type="doi">10.1017/s0950268800052535</pub-id><pub-id pub-id-type="pmcid">PMC2271442</pub-id><pub-id pub-id-type="pmid">8666066</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welter</surname><given-names>J</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>J</given-names></name><name name-style="western"><surname>Tartaglia</surname><given-names>J</given-names></name><name name-style="western"><surname>Paoletti</surname><given-names>E</given-names></name><name name-style="western"><surname>Stephensen</surname><given-names>CB</given-names></name></person-group><article-title>Vaccination against Canine Distemper Virus Infection in Infant Ferrets with and without Maternal Antibody Protection, Using Recombinant Attenuated Poxvirus Vaccines</article-title>. <source>J Virol</source> (<year>2000</year>) <volume>74</volume>:<page-range>6358&#8211;67</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/jvi.74.14.6358-6367.2000</pub-id><pub-id pub-id-type="pmcid">PMC112142</pub-id><pub-id pub-id-type="pmid">10864646</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardo</surname><given-names>MC</given-names></name><name name-style="western"><surname>Tanner</surname><given-names>P</given-names></name><name name-style="western"><surname>Bauman</surname><given-names>J</given-names></name><name name-style="western"><surname>Silver</surname><given-names>K</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>L</given-names></name></person-group><article-title>Immunization of Puppies in the Presence of Maternally Derived Antibodies Against Canine Distemper Virus</article-title>. <source>J Comp Pathol</source> (<year>2007</year>) <volume>137</volume>:<fpage>S72</fpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.jcpa.2007.04.015</pub-id><pub-id pub-id-type="pmid">17560592</pub-id><pub-id pub-id-type="pmcid">PMC7094307</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jas</surname><given-names>D</given-names></name><name name-style="western"><surname>Coupier</surname><given-names>C</given-names></name><name name-style="western"><surname>Toulemonde</surname><given-names>CE</given-names></name><name name-style="western"><surname>Guigal</surname><given-names>PM</given-names></name><name name-style="western"><surname>Poulet</surname><given-names>H</given-names></name></person-group><article-title>Three-year duration of immunity in cats vaccinated with a canarypox-vectored recombinant rabies virus vaccine</article-title>. <source>Vaccine</source> (<year>2012</year>) <volume>30</volume>:<page-range>6991&#8211;6</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2012.09.068</pub-id><pub-id pub-id-type="pmid">23059358</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Godoy</surname><given-names>A</given-names></name><name name-style="western"><surname>Rosenberger</surname><given-names>JK</given-names></name><name name-style="western"><surname>Rosenberger</surname><given-names>SC</given-names></name><name name-style="western"><surname>Gardin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yasuda</surname><given-names>A</given-names></name><etal/></person-group><article-title>Protection and antibody response caused by turkey herpesvirus vector newcastle disease vaccine</article-title>. <source>Avian Dis</source> (<year>2013</year>) <volume>57</volume>:<page-range>750&#8211;5</page-range>. &#160;<pub-id pub-id-type="doi">10.1637/10540-032613-Reg.1</pub-id><pub-id pub-id-type="pmid">24597117</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="webpage"><source>First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response | FDA</source> . Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health">https://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health</uri> (Accessed <date-in-citation>September 1, 2020</date-in-citation>).</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Draper</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Heeney</surname><given-names>JL</given-names></name></person-group><article-title>Viruses as vaccine vectors for infectious diseases and cancer</article-title>. <source>Nat Rev Microbiol</source> (<year>2010</year>) <volume>8</volume>:<fpage>62</fpage>&#8211;<lpage>73</lpage>. &#160;<pub-id pub-id-type="doi">10.1038/nrmicro2240</pub-id><pub-id pub-id-type="pmid">19966816</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhanwani</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Verma</surname><given-names>V</given-names></name><name name-style="western"><surname>Dileepan</surname><given-names>M</given-names></name><name name-style="western"><surname>Ly</surname><given-names>H</given-names></name><etal/></person-group><article-title>A Novel Live Pichinde Virus-Based Vaccine Vector Induces Enhanced Humoral and Cellular Immunity after a Booster Dose</article-title>. <source>J Virol</source> (<year>2015</year>) <volume>90</volume>:<page-range>2551&#8211;60</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/JVI.02705-15</pub-id><pub-id pub-id-type="pmcid">PMC4810697</pub-id><pub-id pub-id-type="pmid">26676795</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Dhanwani</surname><given-names>R</given-names></name><name name-style="western"><surname>Ly</surname><given-names>H</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name></person-group><article-title>Recombinant Tri-Segmented Pichinde Virus as a Novel Live Viral Vaccine Platform</article-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>Clifton</surname><given-names>NJ</given-names></name></person-group>, editor. <source>Methods in molecular biology</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Humana Press</publisher-name> (<year>2017</year>). p. <page-range>169&#8211;79</page-range>. &#160;<pub-id pub-id-type="doi">10.1007/978-1-4939-6869-5_10</pub-id><pub-id pub-id-type="pmcid">PMC6340294</pub-id><pub-id pub-id-type="pmid">28374249</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>LR</given-names></name><name name-style="western"><surname>Gomez-Roman</surname><given-names>VR</given-names></name><name name-style="western"><surname>Davis-Warren</surname><given-names>A</given-names></name><name name-style="western"><surname>Montefiori</surname><given-names>DC</given-names></name><name name-style="western"><surname>Kalyanaraman</surname><given-names>VS</given-names></name><etal/></person-group><article-title>Replicating Rather than Nonreplicating Adenovirus-HumanImmunodeficiency Virus Recombinant Vaccines Are Better at Eliciting Potent Cellular Immunity andPriming High-Titer Antibodies</article-title>. <source>J Virol</source> (<year>2017</year>) <volume>79</volume>:<page-range>10200&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/jvi.79.16.10200-10209.2005</pub-id><pub-id pub-id-type="pmcid">PMC1182659</pub-id><pub-id pub-id-type="pmid">16051813</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Condit</surname><given-names>RC</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>AL</given-names></name><name name-style="western"><surname>Sheets</surname><given-names>R</given-names></name><name name-style="western"><surname>Seligman</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Monath</surname><given-names>TP</given-names></name><name name-style="western"><surname>Excler</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains</article-title>. <source>Vaccine</source> (<year>2016</year>) <volume>34</volume>:<page-range>6610&#8211;6</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.04.060</pub-id><pub-id pub-id-type="pmcid">PMC5204448</pub-id><pub-id pub-id-type="pmid">27346303</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dudek</surname><given-names>T</given-names></name><name name-style="western"><surname>Knipe</surname><given-names>DM</given-names></name></person-group><article-title>Replication-defective viruses as vaccines and vaccine vectors</article-title>. <source>Virology</source> (<year>2006</year>) <volume>344</volume>:<page-range>230&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.virol.2005.09.020</pub-id><pub-id pub-id-type="pmid">16364753</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barry</surname><given-names>M</given-names></name></person-group><article-title>Single-cycle adenovirus vectors in the current vaccine landscape</article-title>. <source>Expert Rev Vaccines</source> (<year>2018</year>) <volume>17</volume>:<page-range>163&#8211;73</page-range>. &#160;<pub-id pub-id-type="doi">10.1080/14760584.2018.1419067</pub-id><pub-id pub-id-type="pmcid">PMC6072458</pub-id><pub-id pub-id-type="pmid">29251011</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clem</surname><given-names>AS</given-names></name></person-group><article-title>Fundamentals of vaccine immunology</article-title>. <source>J GlobalInfect Dis</source> (<year>2011</year>) <volume>3</volume>:<page-range>373&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.4103/0974-777X.77299</pub-id><pub-id pub-id-type="pmcid">PMC3068582</pub-id><pub-id pub-id-type="pmid">21572612</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmermann</surname><given-names>P</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>N</given-names></name></person-group><article-title>Factors that influence the immune response tovaccination</article-title>. <source>Clin Microbiol Rev</source> (<year>2019</year>) <volume>32</volume>:<page-range>e00084&#8211;18</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/CMR.00084-18</pub-id><pub-id pub-id-type="pmcid">PMC6431125</pub-id><pub-id pub-id-type="pmid">30867162</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kushnir</surname><given-names>N</given-names></name><name name-style="western"><surname>Streatfield</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Yusibov</surname><given-names>V</given-names></name></person-group><article-title>Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development</article-title>. <source>Vaccine</source> (<year>2012</year>) <volume>31</volume>:<fpage>58</fpage>&#8211;<lpage>83</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2012.10.083</pub-id><pub-id pub-id-type="pmid">23142589</pub-id><pub-id pub-id-type="pmcid">PMC7115575</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohsen</surname><given-names>MO</given-names></name><name name-style="western"><surname>Zha</surname><given-names>L</given-names></name><name name-style="western"><surname>Cabral-Miranda</surname><given-names>G</given-names></name><name name-style="western"><surname>Bachmann</surname><given-names>MF</given-names></name></person-group><article-title>Major findings and recent advances in virus&#8211;like particle (VLP)-based vaccines</article-title>. <source>Semin Immunol</source> (<year>2017</year>) <volume>34</volume>:<page-range>123&#8211;32</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.smim.2017.08.014</pub-id><pub-id pub-id-type="pmid">28887001</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deml</surname><given-names>L</given-names></name><name name-style="western"><surname>Speth</surname><given-names>C</given-names></name><name name-style="western"><surname>Dierich</surname><given-names>MP</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>H</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>R</given-names></name></person-group><article-title>Recombinant HIV-1 Pr55gag virus-like particles: Potent stimulators of innate and acquired immune responses</article-title>. <source>Mol Immunol</source> (<year>2005</year>) <volume>42</volume>:<page-range>259&#8211;77</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.molimm.2004.06.028</pub-id><pub-id pub-id-type="pmid">15488613</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paliard</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>R</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>H</given-names></name><name name-style="western"><surname>Baenziger</surname><given-names>J</given-names></name><name name-style="western"><surname>Walker</surname><given-names>CM</given-names></name></person-group><article-title>Priming of strong, broad, and long-lived HIV type 1 p55(gag)-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques</article-title>. <source>AIDS Res Hum Retroviruses</source> (<year>2000</year>) <volume>16</volume>:<page-range>273&#8211;82</page-range>. &#160;<pub-id pub-id-type="doi">10.1089/088922200309368</pub-id><pub-id pub-id-type="pmid">10710215</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murata</surname><given-names>K</given-names></name><name name-style="western"><surname>Lechmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>M</given-names></name><name name-style="western"><surname>Gunji</surname><given-names>T</given-names></name><name name-style="western"><surname>Altert</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Liang</surname><given-names>TJ</given-names></name></person-group><article-title>Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection</article-title>. <source>Proc Natl Acad Sci U.S.A.</source> (<year>2003</year>) <volume>100</volume>:<page-range>6753&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.1073/pnas.1131929100</pub-id><pub-id pub-id-type="pmcid">PMC164519</pub-id><pub-id pub-id-type="pmid">12748380</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schirmbeck</surname><given-names>R</given-names></name><name name-style="western"><surname>B&#246;hm</surname><given-names>W</given-names></name><name name-style="western"><surname>Reimann</surname><given-names>J</given-names></name></person-group><article-title>Virus-like Particles Induce MHC Class I-Restricted T-Cell Responses: Lessons learned from the hepatitis B small surface antigen</article-title>. <source>Intervirology</source> (<year>1996</year>) <volume>39</volume>:<page-range>111&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1159/000150482</pub-id><pub-id pub-id-type="pmid">8957677</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Win</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Ward</surname><given-names>VK</given-names></name><name name-style="western"><surname>Dunbar</surname><given-names>PR</given-names></name><name name-style="western"><surname>Young</surname><given-names>SL</given-names></name><name name-style="western"><surname>Baird</surname><given-names>MA</given-names></name></person-group><article-title>Cross-presentation of epitopes on virus-like particles via the MHC i receptor recycling pathway</article-title>. <source>Immunol Cell Biol</source> (<year>2011</year>) <volume>89</volume>:<page-range>681&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/icb.2010.161</pub-id><pub-id pub-id-type="pmid">21221122</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grgacic</surname><given-names>EVL</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>DA</given-names></name></person-group><article-title>Virus-like particles: Passport to immune recognition</article-title>. <source>Methods</source> (<year>2006</year>) <volume>40</volume>:<page-range>60&#8211;5</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.ymeth.2006.07.018</pub-id><pub-id pub-id-type="pmcid">PMC7128828</pub-id><pub-id pub-id-type="pmid">16997714</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chackerian</surname><given-names>B</given-names></name></person-group><article-title>Virus-like particles: Flexible platforms for vaccine development</article-title>. <source>Expert Rev Vaccines</source> (<year>2007</year>) <volume>6</volume>:<page-range>381&#8211;90</page-range>. &#160;<pub-id pub-id-type="doi">10.1586/14760584.6.3.381</pub-id><pub-id pub-id-type="pmid">17542753</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>glaxosmithkline</collab></person-group><source>ENGERIX-B [Hepatitis B Vaccine (Recombinant)] injectable suspension, for intramuscular use</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.vaers.hhs.gov">www.vaers.hhs.gov</uri>.</mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>glaxosmithkline</collab></person-group><source>Cervarix, Suspension for Intramuscular Injection</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.vaers.hhs.gov">www.vaers.hhs.gov</uri>.</mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>RECOMBIVAX HB&#174;</collab></person-group><source>Hepatitis B Vaccine (Recombinant) Suspension for intramuscular injection</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.vaers.hhs.gov">www.vaers.hhs.gov</uri>.</mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Merck</collab></person-group><source>GARDASIL&#174; [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] Suspension for intramuscular injection</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.vaers.hhs.gov">www.vaers.hhs.gov</uri>.</mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agnandji</surname><given-names>ST</given-names></name><name name-style="western"><surname>Lell</surname><given-names>B</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>JF</given-names></name><name name-style="western"><surname>Abossolo</surname><given-names>BP</given-names></name><name name-style="western"><surname>Methogo</surname><given-names>BGNO</given-names></name><name name-style="western"><surname>Kabwende</surname><given-names>AL</given-names></name><etal/></person-group><article-title>A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants</article-title>. <source>N Engl J Med</source> (<year>2012</year>) <volume>367</volume>:<page-range>2284&#8211;95</page-range>. &#160;<pub-id pub-id-type="doi">10.1056/NEJMoa1208394</pub-id><pub-id pub-id-type="pmcid">PMC10915853</pub-id><pub-id pub-id-type="pmid">23136909</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agnandji</surname><given-names>ST</given-names></name><name name-style="western"><surname>Lell</surname><given-names>B</given-names></name><name name-style="western"><surname>Soulanoudjingar</surname><given-names>SS</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>JF</given-names></name><name name-style="western"><surname>Abossolo</surname><given-names>BP</given-names></name><name name-style="western"><surname>Conzelmann</surname><given-names>C</given-names></name><etal/></person-group><article-title>First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children</article-title>. <source>N Engl J Med</source> (<year>2011</year>) <volume>365</volume>:<page-range>1863&#8211;75</page-range>. &#160;<pub-id pub-id-type="doi">10.1056/NEJMoa1102287</pub-id><pub-id pub-id-type="pmid">22007715</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>JM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>BZ</given-names></name><name name-style="western"><surname>Park</surname><given-names>KM</given-names></name><name name-style="western"><surname>van Rooijen</surname><given-names>N</given-names></name><name name-style="western"><surname>Quan</surname><given-names>FS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Influenza virus-like particles containing M2 induce broadly crossprotective immunity</article-title>. <source>PloS One</source> (<year>2011</year>) <volume>6</volume>:<page-range>e14538</page-range>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0014538</pub-id><pub-id pub-id-type="pmcid">PMC3022578</pub-id><pub-id pub-id-type="pmid">21267073</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Attar</surname><given-names>L</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>SL</given-names></name><name name-style="western"><surname>Mackie</surname><given-names>A</given-names></name><name name-style="western"><surname>Charpilienne</surname><given-names>A</given-names></name><name name-style="western"><surname>Poncet</surname><given-names>D</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease</article-title>. <source>Vaccine</source> (<year>2009</year>) <volume>27</volume>:<page-range>3201&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2009.03.043</pub-id><pub-id pub-id-type="pmid">19446192</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Qu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prime immunization with rotavirus VLP 2/6 followed by boosting withan adenovirus expressing VP6 induces protective immunization against rotavirus inmice</article-title>. <source>Virol J</source> (<year>2011</year>) <volume>8</volume>(<issue>3</issue>):<fpage>1</fpage>&#8211;<lpage>8</lpage>. &#160;<pub-id pub-id-type="doi">10.1186/1743-422X-8-3</pub-id><pub-id pub-id-type="pmid">21205330</pub-id><pub-id pub-id-type="pmcid">PMC3024956</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Dhanasooraj</surname><given-names>D</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>RA</given-names></name><name name-style="western"><surname>Mundayoor</surname><given-names>S</given-names></name></person-group><article-title>Subunit protein vaccine delivery system for tuberculosis based on hepatitis B virus core VLP (HBc-VLP) particles</article-title>. In: <source>Methods in Molecular Biology</source>. <publisher-loc>Totowa, NJ</publisher-loc>: <publisher-name>Humana Press Inc</publisher-name> (<year>2016</year>). p. <page-range>377&#8211;92</page-range>. &#160;<pub-id pub-id-type="doi">10.1007/978-1-4939-3389-1_26</pub-id><pub-id pub-id-type="pmid">27076312</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boigard</surname><given-names>H</given-names></name><name name-style="western"><surname>Alimova</surname><given-names>A</given-names></name><name name-style="western"><surname>Martin</surname><given-names>GR</given-names></name><name name-style="western"><surname>Katz</surname><given-names>A</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>P</given-names></name><name name-style="western"><surname>Galarza</surname><given-names>JM</given-names></name></person-group><article-title>Zika virus-like particle (VLP) based vaccine</article-title>. <source>PloS Negl Trop Dis</source> (<year>2017</year>) <volume>11</volume>:<elocation-id>e0005608</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pntd.0005608</pub-id><pub-id pub-id-type="pmid">28481898</pub-id><pub-id pub-id-type="pmcid">PMC5436897</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franco</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Gardiner</surname><given-names>DF</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>BH</given-names></name><name name-style="western"><surname>Ho</surname><given-names>DD</given-names></name></person-group><article-title>CD40L-containing virus-like particle as a candidate HIV-1 vaccine targeting dendritic cells</article-title>. <source>J Acquir Immune Defic Syndr</source> (<year>2011</year>) <volume>56</volume>:<fpage>393</fpage>&#8211;<lpage>400</lpage>. &#160;<pub-id pub-id-type="doi">10.1097/QAI.0b013e31820b844e</pub-id><pub-id pub-id-type="pmid">21239998</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pillay</surname><given-names>S</given-names></name><name name-style="western"><surname>Shephard</surname><given-names>EG</given-names></name><name name-style="western"><surname>Meyers</surname><given-names>AE</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>AL</given-names></name><name name-style="western"><surname>Rybicki</surname><given-names>EP</given-names></name></person-group><article-title>HIV-1 sub-type C chimaeric VLPs boost cellular immune responses inmice</article-title>. <source>J Immune Based Ther Vaccines</source> (<year>2010</year>) <volume>8</volume>(<issue>7</issue>):<fpage>1</fpage>&#8211;<lpage>6</lpage>. &#160;<pub-id pub-id-type="doi">10.1186/1476-8518-8-7</pub-id><pub-id pub-id-type="pmid">21087527</pub-id><pub-id pub-id-type="pmcid">PMC2996383</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frietze</surname><given-names>KM</given-names></name><name name-style="western"><surname>Peabody</surname><given-names>DS</given-names></name><name name-style="western"><surname>Chackerian</surname><given-names>B</given-names></name></person-group><article-title>Engineering virus-like particles as vaccine platforms</article-title>. <source>Curr Opin Virol</source> (<year>2016</year>) <volume>18</volume>:<page-range>44&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.coviro.2016.03.001</pub-id><pub-id pub-id-type="pmcid">PMC4983494</pub-id><pub-id pub-id-type="pmid">27039982</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pati</surname><given-names>R</given-names></name><name name-style="western"><surname>Shevtsov</surname><given-names>M</given-names></name><name name-style="western"><surname>Sonawane</surname><given-names>A</given-names></name></person-group><article-title>Nanoparticle vaccines against infectious diseases</article-title>.<source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>(<issue>2224</issue>):<fpage>1</fpage>&#8211;<fpage>16</fpage>. &#160;<pub-id pub-id-type="doi">10.3389/fimmu.2018.02224</pub-id><pub-id pub-id-type="pmid">30337923</pub-id><pub-id pub-id-type="pmcid">PMC6180194</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Seth</surname><given-names>A</given-names></name><name name-style="western"><surname>Wibowo</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>CX</given-names></name><name name-style="western"><surname>Mitter</surname><given-names>N</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Nanoparticle vaccines</article-title>. <source>Vaccine</source> (<year>2014</year>) <volume>32</volume>:<page-range>327&#8211;37</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2013.11.069</pub-id><pub-id pub-id-type="pmid">24295808</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>K</given-names></name></person-group><article-title>Polymer-based nanomaterials and applications for vaccines anddrugs</article-title>. <source>Polym (Basel)</source> (<year>2018</year>) <volume>10</volume>(<issue>31</issue>):<fpage>1</fpage>&#8211;<lpage>14</lpage>. &#160;<pub-id pub-id-type="doi">10.3390/polym10010031</pub-id><pub-id pub-id-type="pmcid">PMC6415012</pub-id><pub-id pub-id-type="pmid">30966075</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hong</surname><given-names>X</given-names></name><name name-style="western"><surname>Gong</surname><given-names>T</given-names></name><etal/></person-group><article-title>Rational design of polymeric hybrid micelles to overcome lymphaticand intracellular delivery barriers in cancer immunotherapy</article-title>. <source>Theranostics</source> (<year>2017</year>) <volume>7</volume>:<page-range>4383&#8211;98</page-range>. &#160;<pub-id pub-id-type="doi">10.7150/thno.20745</pub-id><pub-id pub-id-type="pmcid">PMC5695138</pub-id><pub-id pub-id-type="pmid">29158834</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Halifa</surname><given-names>S</given-names></name><name name-style="western"><surname>Gauthier</surname><given-names>L</given-names></name><name name-style="western"><surname>Arpin</surname><given-names>D</given-names></name><name name-style="western"><surname>Bourgault</surname><given-names>S</given-names></name><name name-style="western"><surname>Archambault</surname><given-names>D</given-names></name></person-group><article-title>Nanoparticle-Based Vaccines Against RespiratoryViruses</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>22</elocation-id>. &#160;<pub-id pub-id-type="doi">10.3389/fimmu.2019.00022</pub-id><pub-id pub-id-type="pmid">30733717</pub-id><pub-id pub-id-type="pmcid">PMC6353795</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hobernik</surname><given-names>D</given-names></name><name name-style="western"><surname>Bros</surname><given-names>M</given-names></name></person-group><article-title>DNA vaccines&#8212;How far from clinical use</article-title>? <source>Int J Mol</source> (<year>2018</year>) <volume>19</volume>:<issue>3605</issue>. &#160;<pub-id pub-id-type="doi">10.3390/ijms19113605</pub-id><pub-id pub-id-type="pmcid">PMC6274812</pub-id><pub-id pub-id-type="pmid">30445702</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>KH</given-names></name></person-group><article-title>DNA vaccines: Roles against diseases</article-title>. <source>GERMS</source> (<year>2013</year>) <volume>3</volume>:<fpage>26</fpage>&#8211;<lpage>35</lpage>. &#160;<pub-id pub-id-type="doi">10.11599/germs.2013.1034</pub-id><pub-id pub-id-type="pmid">24432284</pub-id><pub-id pub-id-type="pmcid">PMC3882840</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kennedy</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Spithill</surname><given-names>TW</given-names></name><name name-style="western"><surname>Tennent</surname><given-names>J</given-names></name><name name-style="western"><surname>Wood</surname><given-names>PR</given-names></name><name name-style="western"><surname>Piedrafita</surname><given-names>D</given-names></name></person-group><article-title>DNA vaccines in sheep: CTLA-4 mediated targeting and CpG motifs enhance immunogenicity in a DNA prime/protein boost strategy</article-title>. <source>Vaccine</source> (<year>2006</year>) <volume>24</volume>:<page-range>970&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2005.08.076</pub-id><pub-id pub-id-type="pmid">16242220</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Saade</surname><given-names>F</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N</given-names></name></person-group><article-title>The future of human DNA vaccines</article-title>. <source>J Biotechnol</source> (<year>2012</year>) <volume>162</volume>:<page-range>171&#8211;82</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.jbiotec.2012.08.012</pub-id><pub-id pub-id-type="pmcid">PMC3511659</pub-id><pub-id pub-id-type="pmid">22981627</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>SS</given-names></name><name name-style="western"><surname>Kochar</surname><given-names>NK</given-names></name><name name-style="western"><surname>Elizaga</surname><given-names>M</given-names></name><name name-style="western"><surname>Hay</surname><given-names>CM</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>KW</given-names></name><etal/></person-group><article-title>DNA priming increases frequency of T-cell responses to a vesicularstomatitis virus HIV vaccine with specific enhancement of CD8 T-cell responses by interleukin-12plasmid DNA</article-title>. <source>Clin Vaccine Immunol</source> (<year>2017</year>) <volume>24</volume>:<fpage>1</fpage>&#8211;<lpage>14</lpage><elocation-id>e00263-17</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1128/CVI.00263-17</pub-id><pub-id pub-id-type="pmcid">PMC5674193</pub-id><pub-id pub-id-type="pmid">28931520</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haidari</surname><given-names>G</given-names></name><name name-style="western"><surname>Cope</surname><given-names>A</given-names></name><name name-style="western"><surname>Miller</surname><given-names>A</given-names></name><name name-style="western"><surname>Venables</surname><given-names>S</given-names></name><name name-style="western"><surname>Yan</surname><given-names>C</given-names></name><name name-style="western"><surname>Ridgers</surname><given-names>H</given-names></name><etal/></person-group><article-title>Combined skin and muscle vaccination differentially impact thequality of effector T cell functions: The CUTHIVAC-001 randomized trial</article-title>. <source>SciRep</source> (<year>2017</year>) <volume>7</volume>:<issue>13011</issue>. &#160;<pub-id pub-id-type="doi">10.1038/s41598-017-13331-1</pub-id><pub-id pub-id-type="pmcid">PMC5638927</pub-id><pub-id pub-id-type="pmid">29026141</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Maruggi</surname><given-names>G</given-names></name><name name-style="western"><surname>Shan</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>Advances in mRNA vaccines for infectious diseases</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>594</elocation-id>. &#160;<pub-id pub-id-type="doi">10.3389/fimmu.2019.00594</pub-id><pub-id pub-id-type="pmid">30972078</pub-id><pub-id pub-id-type="pmcid">PMC6446947</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lundstrom</surname><given-names>K</given-names></name></person-group><article-title>Latest development on RNA-based drugs and vaccines</article-title>.<source>Futur Sci OA</source> (<year>2018</year>) <volume>4</volume>(<issue>5</issue>):<fpage>FSO300</fpage>. &#160;<pub-id pub-id-type="doi">10.4155/fsoa-2017-0151</pub-id><pub-id pub-id-type="pmcid">PMC5961404</pub-id><pub-id pub-id-type="pmid">29796303</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uchida</surname><given-names>S</given-names></name><name name-style="western"><surname>Yoshinaga</surname><given-names>N</given-names></name><name name-style="western"><surname>Yanagihara</surname><given-names>K</given-names></name><name name-style="western"><surname>Yuba</surname><given-names>E</given-names></name><name name-style="western"><surname>Kataoka</surname><given-names>K</given-names></name><name name-style="western"><surname>Itaka</surname><given-names>K</given-names></name></person-group><article-title>Designing immunostimulatory double stranded messenger RNA with maintained translational activity through hybridization with poly A sequences for effective vaccination</article-title>. <source>Biomaterials</source> (<year>2018</year>) <volume>150</volume>:<page-range>162&#8211;70</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/J.BIOMATERIALS.2017.09.033</pub-id><pub-id pub-id-type="pmid">29031816</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hood</surname><given-names>JL</given-names></name></person-group><article-title>Post isolation modification of exosomes for nanomedicine applications</article-title>. <source>Nanomedicine</source> (<year>2016</year>) <volume>11</volume>:<page-range>1745&#8211;56</page-range>. &#160;<pub-id pub-id-type="doi">10.2217/nnm-2016-0102</pub-id><pub-id pub-id-type="pmcid">PMC4941124</pub-id><pub-id pub-id-type="pmid">27348448</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benteyn</surname><given-names>D</given-names></name><name name-style="western"><surname>Heirman</surname><given-names>C</given-names></name><name name-style="western"><surname>Bonehill</surname><given-names>A</given-names></name><name name-style="western"><surname>Thielemans</surname><given-names>K</given-names></name><name name-style="western"><surname>Breckpot</surname><given-names>K</given-names></name></person-group><article-title>mRNA-based dendritic cell vaccines</article-title>. <source>Expert Rev Vaccines</source> (<year>2014</year>) <volume>14</volume>:<page-range>161&#8211;76</page-range>. &#160;<pub-id pub-id-type="doi">10.1586/14760584.2014.957684</pub-id><pub-id pub-id-type="pmid">25196947</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diken</surname><given-names>M</given-names></name><name name-style="western"><surname>Kreiter</surname><given-names>S</given-names></name><name name-style="western"><surname>Selmi</surname><given-names>A</given-names></name><name name-style="western"><surname>Britten</surname><given-names>CM</given-names></name><name name-style="western"><surname>Huber</surname><given-names>C</given-names></name><name name-style="western"><surname>T&#252;reci</surname><given-names>&#214;</given-names></name><etal/></person-group><article-title>Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation</article-title>. <source>Gene Ther</source> (<year>2011</year>) <volume>18</volume>:<page-range>702&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/gt.2011.17</pub-id><pub-id pub-id-type="pmid">21368901</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van den Boorn</surname><given-names>JG</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>G</given-names></name></person-group><article-title>Turning Tumors into Vaccines: Co-opting the Innate Immune System</article-title>. <source>Immunity</source> (<year>2013</year>) <volume>39</volume>:<fpage>27</fpage>&#8211;<lpage>37</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2013.07.011</pub-id><pub-id pub-id-type="pmid">23890061</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elion</surname><given-names>DL</given-names></name><name name-style="western"><surname>Cook</surname><given-names>RS</given-names></name><name name-style="western"><surname>Elion</surname><given-names>DL</given-names></name><name name-style="western"><surname>Cook</surname><given-names>RS</given-names></name></person-group><article-title>Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment</article-title>. <source>Oncotarget</source> (<year>2018</year>) <volume>9</volume>:<page-range>29007&#8211;17</page-range>. &#160;<pub-id pub-id-type="doi">10.18632/oncotarget.25626</pub-id><pub-id pub-id-type="pmcid">PMC6034747</pub-id><pub-id pub-id-type="pmid">29989043</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vogel</surname><given-names>AB</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>L</given-names></name><name name-style="western"><surname>Kinnear</surname><given-names>E</given-names></name><name name-style="western"><surname>Busse</surname><given-names>D</given-names></name><name name-style="western"><surname>Erbar</surname><given-names>S</given-names></name><name name-style="western"><surname>Reuter</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses</article-title>. <source>Mol Ther</source> (<year>2018</year>) <volume>26</volume>:<page-range>446&#8211;55</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.ymthe.2017.11.017</pub-id><pub-id pub-id-type="pmcid">PMC5835025</pub-id><pub-id pub-id-type="pmid">29275847</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#233;moulins</surname><given-names>T</given-names></name><name name-style="western"><surname>Englezou</surname><given-names>PC</given-names></name><name name-style="western"><surname>Milona</surname><given-names>P</given-names></name><name name-style="western"><surname>Ruggli</surname><given-names>N</given-names></name><name name-style="western"><surname>Tirelli</surname><given-names>N</given-names></name><name name-style="western"><surname>Pichon</surname><given-names>C</given-names></name><etal/></person-group><article-title>Self-replicating RNA vaccine delivery to dendriticcells</article-title>. <source>Methods Mol Biol</source> (<year>2017</year>) <volume>1499</volume>:<fpage>37</fpage>&#8211;<lpage>75</lpage>. &#160;<pub-id pub-id-type="doi">10.1007/978-1-4939-6481-9_3</pub-id><pub-id pub-id-type="pmid">27987142</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Englezou</surname><given-names>PC</given-names></name><name name-style="western"><surname>Sapet</surname><given-names>C</given-names></name><name name-style="western"><surname>D&#233;moulins</surname><given-names>T</given-names></name><name name-style="western"><surname>Milona</surname><given-names>P</given-names></name><name name-style="western"><surname>Ebensen</surname><given-names>T</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>K</given-names></name><etal/></person-group><article-title>Self-Amplifying Replicon RNA Delivery to Dendritic Cells by Cationic Lipids</article-title>. <source>Mol Ther Nucleic Acids</source> (<year>2018</year>) <volume>12</volume>:<page-range>118&#8211;34</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.omtn.2018.04.019</pub-id><pub-id pub-id-type="pmcid">PMC6023837</pub-id><pub-id pub-id-type="pmid">30195751</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardi</surname><given-names>N</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Porter</surname><given-names>FW</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D</given-names></name></person-group><article-title>mRNA vaccines-a new era in vaccinology</article-title>. <source>Nat Rev Drug Discovery</source> (<year>2018</year>) <volume>17</volume>:<page-range>261&#8211;79</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/nrd.2017.243</pub-id><pub-id pub-id-type="pmcid">PMC5906799</pub-id><pub-id pub-id-type="pmid">29326426</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alberer</surname><given-names>M</given-names></name><name name-style="western"><surname>Gnad-Vogt</surname><given-names>U</given-names></name><name name-style="western"><surname>Hong</surname><given-names>HS</given-names></name><name name-style="western"><surname>Mehr</surname><given-names>KT</given-names></name><name name-style="western"><surname>Backert</surname><given-names>L</given-names></name><name name-style="western"><surname>Finak</surname><given-names>G</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial</article-title>. <source>Lancet</source> (<year>2017</year>) <volume>390</volume>:<page-range>1511&#8211;20</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(17)31665-3</pub-id><pub-id pub-id-type="pmid">28754494</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahl</surname><given-names>K</given-names></name><name name-style="western"><surname>Senn</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Yuzhakov</surname><given-names>O</given-names></name><name name-style="western"><surname>Bulychev</surname><given-names>A</given-names></name><name name-style="western"><surname>Brito</surname><given-names>LA</given-names></name><name name-style="western"><surname>Hassett</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses</article-title>. <source>Mol Ther</source> (<year>2017</year>) <volume>25</volume>:<page-range>1316&#8211;27</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.ymthe.2017.03.035</pub-id><pub-id pub-id-type="pmcid">PMC5475249</pub-id><pub-id pub-id-type="pmid">28457665</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Troilo</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>TG</given-names></name><name name-style="western"><surname>Pacchione</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Barnum</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation</article-title>. <source>Gene Ther</source> (<year>2004</year>) <volume>11</volume>:<page-range>711&#8211;21</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/sj.gt.3302213</pub-id><pub-id pub-id-type="pmid">14724672</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Myhr</surname><given-names>AI</given-names></name></person-group><article-title>DNA Vaccines: Regulatory Considerations and Safety Aspects</article-title>. <source>Curr Issues Mol Biol</source> (<year>2017</year>) <volume>22</volume>:<fpage>79</fpage>&#8211;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.21775/cimb.022.079</pub-id><pub-id pub-id-type="pmid">27705898</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kramps</surname><given-names>T</given-names></name><name name-style="western"><surname>Elbers</surname><given-names>K</given-names></name></person-group><article-title>Introduction to RNA vaccines</article-title>. <source>Methods MolBiol</source> (<year>2017</year>) <volume>1499</volume>:<fpage>1</fpage>&#8211;<lpage>11</lpage>. &#160;<pub-id pub-id-type="doi">10.1007/978-1-4939-6481-9_1</pub-id><pub-id pub-id-type="pmid">27987140</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rueckert</surname><given-names>C</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>CA</given-names></name></person-group><article-title>Vaccines: From Empirical Development to RationalDesign</article-title>. <source>PloS Pathog</source> (<year>2012</year>) <volume>8</volume>:<elocation-id>e1003001</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1371/journal.ppat.1003001</pub-id><pub-id pub-id-type="pmid">23144616</pub-id><pub-id pub-id-type="pmcid">PMC3493475</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peri</surname><given-names>C</given-names></name><name name-style="western"><surname>Gagni</surname><given-names>P</given-names></name><name name-style="western"><surname>Combi</surname><given-names>F</given-names></name><name name-style="western"><surname>Gori</surname><given-names>A</given-names></name><name name-style="western"><surname>Chiari</surname><given-names>M</given-names></name><name name-style="western"><surname>Longhi</surname><given-names>R</given-names></name><etal/></person-group><article-title>Rational epitope design for protein targeting</article-title>. <source>ACS Chem Biol</source> (<year>2013</year>) <volume>8</volume>:<fpage>397</fpage>&#8211;<lpage>404</lpage>. &#160;<pub-id pub-id-type="doi">10.1021/cb300487u</pub-id><pub-id pub-id-type="pmid">23138758</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamashita</surname><given-names>T</given-names></name></person-group><article-title>Toward rational antibody design: Recent advancements in molecular dynamics simulations</article-title>. <source>Int Immunol</source> (<year>2018</year>) <volume>30</volume>:<page-range>133&#8211;40</page-range>. &#160;<pub-id pub-id-type="doi">10.1093/intimm/dxx077</pub-id><pub-id pub-id-type="pmid">29346652</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name></person-group><article-title>Computational tools for epitope vaccine design and evaluation</article-title>. <source>Curr Opin Virol</source> (<year>2015</year>) <volume>11</volume>:<page-range>103&#8211;12</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/J.COVIRO.2015.03.013</pub-id><pub-id pub-id-type="pmcid">PMC4456225</pub-id><pub-id pub-id-type="pmid">25837467</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></name><name name-style="western"><surname>Bottomley</surname><given-names>MJ</given-names></name><name name-style="western"><surname>D&#8217;Oro</surname><given-names>U</given-names></name><name name-style="western"><surname>Finco</surname><given-names>O</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>E</given-names></name></person-group><article-title>Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design</article-title>. <source>J Exp Med</source> (<year>2016</year>) <volume>213</volume>:<page-range>469&#8211;81</page-range>. &#160;<pub-id pub-id-type="doi">10.1084/JEM.20151960</pub-id><pub-id pub-id-type="pmcid">PMC4821650</pub-id><pub-id pub-id-type="pmid">27022144</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McLellan</surname><given-names>JS</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>MG</given-names></name><name name-style="western"><surname>Sastry</surname><given-names>M</given-names></name><name name-style="western"><surname>Stewart-Jones</surname><given-names>GBE</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus</article-title>. <source>Sci (80 )</source> (<year>2013</year>) <volume>342</volume>:<page-range>592&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.1126/science.1243283</pub-id><pub-id pub-id-type="pmcid">PMC4461862</pub-id><pub-id pub-id-type="pmid">24179220</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>ZY</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hogerkorp</surname><given-names>CM</given-names></name><name name-style="western"><surname>Schief</surname><given-names>WR</given-names></name><name name-style="western"><surname>Seaman</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1</article-title>. <source>Sci (80)</source> (<year>2010</year>) <volume>329</volume>:<page-range>856&#8211;61</page-range>. &#160;<pub-id pub-id-type="doi">10.1126/science.1187659</pub-id><pub-id pub-id-type="pmcid">PMC2965066</pub-id><pub-id pub-id-type="pmid">20616233</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>T</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K</given-names></name></person-group><article-title>Structural features of broadly neutralizing antibodies and rational design of vaccine</article-title>. In: <source>Advances in Experimental Medicine and Biology</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer New York LLC</publisher-name> (<year>2018</year>). p. <fpage>73</fpage>&#8211;<lpage>95</lpage>. &#160;<pub-id pub-id-type="doi">10.1007/978-981-13-0484-2_4</pub-id><pub-id pub-id-type="pmid">30030790</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferlenghi</surname><given-names>I</given-names></name><name name-style="western"><surname>Cozzi</surname><given-names>R</given-names></name><name name-style="western"><surname>Scarselli</surname><given-names>M</given-names></name></person-group><article-title>Structural Vaccinology: A Three-dimensional View for Vaccine Development</article-title>. <source>Curr Top Med Chem</source> (<year>2013</year>) <volume>13</volume>:<page-range>2629&#8211;37</page-range>. &#160;<pub-id pub-id-type="doi">10.2174/15680266113136660187</pub-id><pub-id pub-id-type="pmid">24066888</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keck</surname><given-names>M-L</given-names></name><name name-style="western"><surname>Wrensch</surname><given-names>F</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>BG</given-names></name><name name-style="western"><surname>Baumert</surname><given-names>TF</given-names></name><name name-style="western"><surname>Foung</surname><given-names>SKH</given-names></name></person-group><article-title>Mapping Determinants of Virus Neutralization and Viral Escape forRational Design of a Hepatitis C Virus Vaccine</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>1194</elocation-id>. &#160;<pub-id pub-id-type="doi">10.3389/fimmu.2018.01194</pub-id><pub-id pub-id-type="pmid">29904384</pub-id><pub-id pub-id-type="pmcid">PMC5991293</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>L</given-names></name><name name-style="western"><surname>Tzarum</surname><given-names>N</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X</given-names></name><name name-style="western"><surname>Shapero</surname><given-names>B</given-names></name><name name-style="western"><surname>Sou</surname><given-names>C</given-names></name><name name-style="western"><surname>Mann</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines</article-title>. <source>Sci Adv</source> (<year>2020</year>) <volume>6</volume>:<fpage>eaaz6225</fpage>. &#160;<pub-id pub-id-type="doi">10.1126/sciadv.aaz6225</pub-id><pub-id pub-id-type="pmid">32494617</pub-id><pub-id pub-id-type="pmcid">PMC7159917</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufmann</surname><given-names>JK</given-names></name><name name-style="western"><surname>Flechtner</surname><given-names>JB</given-names></name></person-group><article-title>Evolution of rational vaccine designs for genital herpes immunotherapy</article-title>. <source>Curr Opin Virol</source> (<year>2016</year>) <volume>17</volume>:<page-range>80&#8211;6</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.coviro.2016.01.021</pub-id><pub-id pub-id-type="pmid">26896782</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#243;pez-Camacho</surname><given-names>C</given-names></name><name name-style="western"><surname>Abbink</surname><given-names>P</given-names></name><name name-style="western"><surname>Larocca</surname><given-names>RA</given-names></name><name name-style="western"><surname>Dejnirattisai</surname><given-names>W</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>M</given-names></name><name name-style="western"><surname>Badamchi-Zadeh</surname><given-names>A</given-names></name><etal/></person-group><article-title>Rational Zika vaccine design via the modulation of antigen membraneanchors in chimpanzee adenoviral vectors</article-title>. <source>Nat Commun</source> (<year>2018</year>) <volume>9</volume>(<issue>1</issue>):<page-range>2441</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/s41467-018-04859-5</pub-id><pub-id pub-id-type="pmcid">PMC6015009</pub-id><pub-id pub-id-type="pmid">29934593</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tai</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Geng</surname><given-names>Q</given-names></name><name name-style="western"><surname>He</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Rational Design of Zika Virus Subunit Vaccine with EnhancedEfficacy</article-title>. <source>J Virol</source> (<year>2019</year>) <volume>93</volume>(<issue>17</issue>):<elocation-id>e02187-18</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1128/jvi.02187-18</pub-id><pub-id pub-id-type="pmid">31189716</pub-id><pub-id pub-id-type="pmcid">PMC6694833</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Song</surname><given-names>S</given-names></name><name name-style="western"><surname>He</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Rational design of a triple-type human papillomavirus vaccine bycompromising viral-type specificity</article-title>. <source>Nat Commun</source> (<year>2018</year>) <volume>9</volume>(<issue>1</issue>):<page-range>5360</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/s41467-018-07199-6</pub-id><pub-id pub-id-type="pmcid">PMC6299097</pub-id><pub-id pub-id-type="pmid">30560935</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ong</surname><given-names>E</given-names></name><name name-style="western"><surname>Wong</surname><given-names>MU</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name></person-group><article-title>Identification of new features from known bacterial protectivevaccine antigens enhances rational vaccine design</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>8</volume>:<elocation-id>1382</elocation-id>. &#160;<pub-id pub-id-type="doi">10.3389/fimmu.2017.01382</pub-id><pub-id pub-id-type="pmid">29123525</pub-id><pub-id pub-id-type="pmcid">PMC5662880</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hurtgen</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Hung</surname><given-names>CY</given-names></name></person-group><article-title>Rational design to T lymphocyte epitope-based vaccines against Coccidioides infection</article-title>. <source>Methods Mol Biol</source> (<year>2017</year>) <volume>1625</volume>:<fpage>45</fpage>&#8211;<lpage>64</lpage>. &#160;<pub-id pub-id-type="doi">10.1007/978-1-4939-7104-6_4</pub-id><pub-id pub-id-type="pmid">28584982</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;nez-S&#225;ez</surname><given-names>N</given-names></name><name name-style="western"><surname>Peregrina</surname><given-names>JM</given-names></name><name name-style="western"><surname>Corzana</surname><given-names>F</given-names></name></person-group><article-title>Principles of mucin structure: Implications for the rational design of cancer vaccines derived from MUC1-glycopeptides</article-title>. <source>Chem Soc Rev</source> (<year>2017</year>) <volume>46</volume>:<page-range>7154&#8211;75</page-range>. &#160;<pub-id pub-id-type="doi">10.1039/c6cs00858e</pub-id><pub-id pub-id-type="pmid">29022615</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karch</surname><given-names>CP</given-names></name><name name-style="western"><surname>Burkhard</surname><given-names>P</given-names></name></person-group><article-title>Vaccine technologies: From whole organisms to rationally designed protein assemblies</article-title>. <source>Biochem Pharmacol</source> (<year>2016</year>) <volume>120</volume>:<fpage>1</fpage>&#8211;<lpage>14</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.bcp.2016.05.001</pub-id><pub-id pub-id-type="pmid">27157411</pub-id><pub-id pub-id-type="pmcid">PMC5079805</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zupan&#269;i&#269;</surname><given-names>E</given-names></name><name name-style="western"><surname>Curato</surname><given-names>C</given-names></name><name name-style="western"><surname>Paisana</surname><given-names>M</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>C</given-names></name><name name-style="western"><surname>Porat</surname><given-names>Z</given-names></name><name name-style="western"><surname>Viana</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming</article-title>. <source>J Control Release</source> (<year>2017</year>) <volume>258</volume>:<page-range>182&#8211;95</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.jconrel.2017.05.014</pub-id><pub-id pub-id-type="pmid">28511928</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porkolab</surname><given-names>V</given-names></name><name name-style="western"><surname>Chabrol</surname><given-names>E</given-names></name><name name-style="western"><surname>Varga</surname><given-names>N</given-names></name><name name-style="western"><surname>Ordanini</surname><given-names>S</given-names></name><name name-style="western"><surname>Sutkevi&#269;iute</surname><given-names>I</given-names></name><name name-style="western"><surname>Th&#233;paut</surname><given-names>M</given-names></name><etal/></person-group><article-title>Rational-Differential Design of Highly Specific Glycomimetic Ligands: Targeting DC-SIGN and Excluding Langerin Recognition</article-title>. <source>ACS Chem Biol</source> (<year>2018</year>) <volume>13</volume>:<page-range>600&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.1021/acschembio.7b00958</pub-id><pub-id pub-id-type="pmid">29272097</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oyarz&#250;n</surname><given-names>P</given-names></name><name name-style="western"><surname>Kobe</surname><given-names>B</given-names></name></person-group><article-title>Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production</article-title>. <source>Hum Vaccines Immunother</source> (<year>2016</year>) <volume>12</volume>:<page-range>763&#8211;7</page-range>. &#160;<pub-id pub-id-type="doi">10.1080/21645515.2015.1094595</pub-id><pub-id pub-id-type="pmcid">PMC4964635</pub-id><pub-id pub-id-type="pmid">26430814</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liljeroos</surname><given-names>L</given-names></name><name name-style="western"><surname>Malito</surname><given-names>E</given-names></name><name name-style="western"><surname>Ferlenghi</surname><given-names>I</given-names></name><name name-style="western"><surname>Bottomley</surname><given-names>MJ</given-names></name></person-group><article-title>Structural and Computational Biology in the Design of ImmunogenicVaccine Antigens</article-title>. <source>J Immunol Res</source> (<year>2015</year>) <volume>2015</volume>:<elocation-id>156241</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1155/2015/156241</pub-id><pub-id pub-id-type="pmid">26526043</pub-id><pub-id pub-id-type="pmcid">PMC4615220</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhivaki</surname><given-names>D</given-names></name><name name-style="western"><surname>Lo-Man</surname><given-names>R</given-names></name></person-group><article-title>Unique aspects of the perinatal immune system</article-title>. <source>Nat Rev Immunol</source> (<year>2017</year>) <volume>17</volume>:<fpage>495</fpage>&#8211;<lpage>507</lpage>. &#160;<pub-id pub-id-type="doi">10.1038/nri.2017.54</pub-id><pub-id pub-id-type="pmid">28627520</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kollmann</surname><given-names>TR</given-names></name><name name-style="western"><surname>Levy</surname><given-names>O</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>RR</given-names></name><name name-style="western"><surname>Goriely</surname><given-names>S</given-names></name></person-group><article-title>Innate Immune Function by Toll-like Receptors: Distinct Responses in Newborns and the Elderly</article-title>. <source>Immunity</source> (<year>2012</year>) <volume>37</volume>:<page-range>771&#8211;83</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2012.10.014</pub-id><pub-id pub-id-type="pmcid">PMC3538030</pub-id><pub-id pub-id-type="pmid">23159225</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aiello</surname><given-names>A</given-names></name><name name-style="western"><surname>Farzaneh</surname><given-names>F</given-names></name><name name-style="western"><surname>Candore</surname><given-names>G</given-names></name><name name-style="western"><surname>Caruso</surname><given-names>C</given-names></name><name name-style="western"><surname>Davinelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Gambino</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Immunosenescence and its hallmarks: How to oppose aging strategically? A review of potential options for therapeutic intervention</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>2247</elocation-id>:<elocation-id>2247</elocation-id>. &#160;<pub-id pub-id-type="doi">10.3389/fimmu.2019.02247</pub-id><pub-id pub-id-type="pmid">31608061</pub-id><pub-id pub-id-type="pmcid">PMC6773825</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hazeldine</surname><given-names>J</given-names></name><name name-style="western"><surname>Lord</surname><given-names>JM</given-names></name></person-group><article-title>Innate immunesenescence: underlying mechanisms and clinical relevance</article-title>. <source>Biogerontology</source> (<year>2015</year>) <volume>16</volume>:<fpage>187</fpage>&#8211;<lpage>201</lpage>. &#160;<pub-id pub-id-type="doi">10.1007/s10522-014-9514-3</pub-id><pub-id pub-id-type="pmid">25009085</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montgomery</surname><given-names>RR</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>AC</given-names></name></person-group><article-title>Paradoxical changes in innate immunity in aging: recent progress and new directions</article-title>. <source>J Leukoc Biol</source> (<year>2015</year>) <volume>98</volume>:<page-range>937&#8211;43</page-range>. &#160;<pub-id pub-id-type="doi">10.1189/jlb.5mr0315-104r</pub-id><pub-id pub-id-type="pmcid">PMC4661037</pub-id><pub-id pub-id-type="pmid">26188078</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chinn</surname><given-names>IK</given-names></name><name name-style="western"><surname>Blackburn</surname><given-names>CC</given-names></name><name name-style="western"><surname>Manley</surname><given-names>NR</given-names></name><name name-style="western"><surname>Sempowski</surname><given-names>GD</given-names></name></person-group><article-title>Changes in primary lymphoid organs with aging</article-title>. <source>Semin Immunol</source> (<year>2012</year>) <volume>24</volume>:<page-range>309&#8211;20</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.smim.2012.04.005</pub-id><pub-id pub-id-type="pmcid">PMC3415579</pub-id><pub-id pub-id-type="pmid">22559987</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kline</surname><given-names>GH</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>TA</given-names></name><name name-style="western"><surname>Klinman</surname><given-names>NR</given-names></name></person-group><article-title>B cell maintenance in aged mice reflects both increased B cell longevity and decreased B cell generation</article-title>. <source>J Immunol</source> (<year>1999</year>) <volume>162</volume>:<page-range>3342&#8211;9</page-range>.<pub-id pub-id-type="pmid">10092788</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stephan</surname><given-names>RP</given-names></name><name name-style="western"><surname>Lill-Elghanian</surname><given-names>DA</given-names></name><name name-style="western"><surname>Witte</surname><given-names>PL</given-names></name></person-group><article-title>Development of B cells in aged mice: decline in the ability of pro-Bcells to respond to IL-7 but not to other growth factors</article-title>. <source>J Immunol</source> (<year>1997</year>) <volume>158</volume>:<page-range>1598&#8211;609</page-range>.<pub-id pub-id-type="pmid">9029095</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becklund</surname><given-names>BR</given-names></name><name name-style="western"><surname>Purton</surname><given-names>JF</given-names></name><name name-style="western"><surname>Ramsey</surname><given-names>C</given-names></name><name name-style="western"><surname>Favre</surname><given-names>S</given-names></name><name name-style="western"><surname>Vogt</surname><given-names>TK</given-names></name><name name-style="western"><surname>Martin</surname><given-names>CE</given-names></name><etal/></person-group><article-title>The aged lymphoid tissue environment fails to support naive T cellhomeostasis</article-title>. <source>Sci Rep</source> (<year>2016</year>) <volume>6</volume>:<elocation-id>30842</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1038/srep30842</pub-id><pub-id pub-id-type="pmid">27480406</pub-id><pub-id pub-id-type="pmcid">PMC4969611</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrucci</surname><given-names>L</given-names></name><name name-style="western"><surname>Corsi</surname><given-names>A</given-names></name><name name-style="western"><surname>Lauretani</surname><given-names>F</given-names></name><name name-style="western"><surname>Bandinelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Bartali</surname><given-names>B</given-names></name><name name-style="western"><surname>Taub</surname><given-names>DD</given-names></name><etal/></person-group><article-title>The origins of age-related proinflammatory state</article-title>. <source>Blood</source> (<year>2005</year>) <volume>105</volume>:<page-range>2294&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1182/blood-2004-07-2599</pub-id><pub-id pub-id-type="pmcid">PMC9828256</pub-id><pub-id pub-id-type="pmid">15572589</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Martinis</surname><given-names>M</given-names></name><name name-style="western"><surname>Franceschi</surname><given-names>C</given-names></name><name name-style="western"><surname>Monti</surname><given-names>D</given-names></name><name name-style="western"><surname>Ginaldi</surname><given-names>L</given-names></name></person-group><article-title>Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity</article-title>. <source>FEBS Lett</source> (<year>2005</year>) <volume>579</volume>:<page-range>2035&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.febslet.2005.02.055</pub-id><pub-id pub-id-type="pmid">15811314</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cumberbatch</surname><given-names>M</given-names></name><name name-style="western"><surname>Dearman</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Kimber</surname><given-names>I</given-names></name></person-group><article-title>Influence of ageing on Langerhans cell migration in mice: Identification of a putative deficiency of epidermal interleukin-1&#945;</article-title>. <source>Immunology</source> (<year>2002</year>) <volume>105</volume>:<page-range>466&#8211;77</page-range>. &#160;<pub-id pub-id-type="doi">10.1046/j.1365-2567.2002.01381.x</pub-id><pub-id pub-id-type="pmcid">PMC1782675</pub-id><pub-id pub-id-type="pmid">11985667</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desai</surname><given-names>A</given-names></name><name name-style="western"><surname>Grolleau-Julius</surname><given-names>A</given-names></name><name name-style="western"><surname>Yung</surname><given-names>R</given-names></name></person-group><article-title>Leukocyte function in the aging immune system</article-title>. <source>J Leukoc Biol</source> (<year>2010</year>) <volume>87</volume>:<page-range>1001&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1189/jlb.0809542</pub-id><pub-id pub-id-type="pmcid">PMC4057658</pub-id><pub-id pub-id-type="pmid">20200405</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aprahamian</surname><given-names>T</given-names></name><name name-style="western"><surname>Takemura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Goukassian</surname><given-names>D</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>K</given-names></name></person-group><article-title>Ageing is associated with diminished apoptotic cell clearance in vivo</article-title>. <source>Clin Exp Immunol</source> (<year>2008</year>) <volume>152</volume>:<page-range>448&#8211;55</page-range>. &#160;<pub-id pub-id-type="doi">10.1111/j.1365-2249.2008.03658.x</pub-id><pub-id pub-id-type="pmcid">PMC2453212</pub-id><pub-id pub-id-type="pmid">18422728</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cambier</surname><given-names>J</given-names></name></person-group><article-title>Immunosenescence: a problem of lymphopoiesis, homeostasis, microenvironment, and signaling. John Cambier</article-title>. <source>Immunol Rev</source> (<year>2005</year>) <volume>205</volume>:<fpage>5</fpage>&#8211;<lpage>6</lpage>. &#160;<pub-id pub-id-type="doi">10.1111/j.0105-2896.2005.00276.x</pub-id><pub-id pub-id-type="pmid">15882340</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wertheimer</surname><given-names>AM</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>MS</given-names></name><name name-style="western"><surname>Park</surname><given-names>B</given-names></name><name name-style="western"><surname>Uhrlaub</surname><given-names>JL</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>C</given-names></name><name name-style="western"><surname>Pulko</surname><given-names>V</given-names></name><etal/></person-group><article-title>Aging and Cytomegalovirus Infection Differentially and Jointly Affect Distinct Circulating T Cell Subsets in Humans</article-title>. <source>J Immunol</source> (<year>2014</year>) <volume>192</volume>:<page-range>2143&#8211;55</page-range>. &#160;<pub-id pub-id-type="doi">10.4049/jimmunol.1301721</pub-id><pub-id pub-id-type="pmcid">PMC3989163</pub-id><pub-id pub-id-type="pmid">24501199</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kogut</surname><given-names>I</given-names></name><name name-style="western"><surname>Scholz</surname><given-names>JL</given-names></name><name name-style="western"><surname>Cancro</surname><given-names>MP</given-names></name><name name-style="western"><surname>Cambier</surname><given-names>JC</given-names></name></person-group><article-title>B cell maintenance and function in aging</article-title>. <source>Semin Immunol</source> (<year>2012</year>) <volume>24</volume>:<page-range>342&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.smim.2012.04.004</pub-id><pub-id pub-id-type="pmid">22560930</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coutinho</surname><given-names>AE</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>KE</given-names></name></person-group><article-title>The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights</article-title>. <source>Mol Cell Endocrinol</source> (<year>2011</year>) <volume>335</volume>:<fpage>2</fpage>&#8211;<lpage>13</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.mce.2010.04.005</pub-id><pub-id pub-id-type="pmid">20398732</pub-id><pub-id pub-id-type="pmcid">PMC3047790</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rea</surname><given-names>D</given-names></name><name name-style="western"><surname>Van Kooten</surname><given-names>C</given-names></name><name name-style="western"><surname>Van Meijgaarden</surname><given-names>KE</given-names></name><name name-style="western"><surname>Ottenhoff</surname><given-names>THM</given-names></name><name name-style="western"><surname>Melief</surname><given-names>CJM</given-names></name><name name-style="western"><surname>Offringa</surname><given-names>R</given-names></name></person-group><article-title>Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10</article-title>. <source>Blood</source> (<year>2000</year>) <volume>95</volume>:<page-range>3162&#8211;7</page-range>. &#160;<pub-id pub-id-type="doi">10.1182/blood.v95.10.3162</pub-id><pub-id pub-id-type="pmid">10807783</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rutella</surname><given-names>S</given-names></name><name name-style="western"><surname>Lemoli</surname><given-names>RM</given-names></name></person-group><article-title>Regulatory T cells and tolerogenic dendritic cells: From basic biology to clinical applications</article-title>. <source>Immunol Lett</source> (<year>2004</year>) <volume>94</volume>:<fpage>11</fpage>&#8211;<lpage>26</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.imlet.2004.04.015</pub-id><pub-id pub-id-type="pmid">15234530</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luther</surname><given-names>C</given-names></name><name name-style="western"><surname>Adamopoulou</surname><given-names>E</given-names></name><name name-style="western"><surname>Stoeckle</surname><given-names>C</given-names></name><name name-style="western"><surname>Brucklacher-Waldert</surname><given-names>V</given-names></name><name name-style="western"><surname>Rosenkranz</surname><given-names>D</given-names></name><name name-style="western"><surname>Stoltze</surname><given-names>L</given-names></name><etal/></person-group><article-title>Prednisolone Treatment Induces Tolerogenic Dendritic Cells and a Regulatory Milieu in Myasthenia Gravis Patients</article-title>. <source>J Immunol</source> (<year>2009</year>) <volume>183</volume>:<page-range>841&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.4049/jimmunol.0802046</pub-id><pub-id pub-id-type="pmid">19542375</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chamorro</surname><given-names>S</given-names></name><name name-style="western"><surname>Garc&#237;a-Vallejo</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Unger</surname><given-names>WWJ</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Bruijns</surname><given-names>SCM</given-names></name><name name-style="western"><surname>Laban</surname><given-names>S</given-names></name><etal/></person-group><article-title>TLR Triggering on Tolerogenic Dendritic Cells Results in TLR2 Up-Regulation and a Reduced Proinflammatory Immune Program</article-title>. <source>J Immunol</source> (<year>2009</year>) <volume>183</volume>:<page-range>2984&#8211;94</page-range>. &#160;<pub-id pub-id-type="doi">10.4049/jimmunol.0801155</pub-id><pub-id pub-id-type="pmid">19648269</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasquale</surname><given-names>A</given-names></name><name name-style="western"><surname>Preiss</surname><given-names>S</given-names></name><name name-style="western"><surname>Silva</surname><given-names>F</given-names></name><name name-style="western"><surname>Gar&#231;on</surname><given-names>N</given-names></name></person-group><article-title>Vaccine Adjuvants: from 1920 to 2015 and Beyond</article-title>.<source>Vaccines</source> (<year>2015</year>) <volume>3</volume>:<page-range>320&#8211;43</page-range>. &#160;<pub-id pub-id-type="doi">10.3390/vaccines3020320</pub-id><pub-id pub-id-type="pmcid">PMC4494348</pub-id><pub-id pub-id-type="pmid">26343190</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moyer</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Zmolek</surname><given-names>AC</given-names></name><name name-style="western"><surname>Irvine</surname><given-names>DJ</given-names></name></person-group><article-title>Beyond antigens and adjuvants: Formulating futurevaccines</article-title>. <source>J Clin Invest</source> (<year>2016</year>) <volume>126</volume>:<fpage>799</fpage>&#8211;<lpage>808</lpage>. &#160;<pub-id pub-id-type="doi">10.1172/JCI81083</pub-id><pub-id pub-id-type="pmid">26928033</pub-id><pub-id pub-id-type="pmcid">PMC4767337</pub-id></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grogan</surname><given-names>JL</given-names></name><name name-style="western"><surname>Mohrs</surname><given-names>M</given-names></name><name name-style="western"><surname>Harmon</surname><given-names>B</given-names></name><name name-style="western"><surname>Lacy</surname><given-names>DA</given-names></name><name name-style="western"><surname>Sedat</surname><given-names>JW</given-names></name><name name-style="western"><surname>Locksley</surname><given-names>RM</given-names></name></person-group><article-title>Early transcription and silencing of cytokine genes underlie polarization of T helper cell subsets</article-title>. <source>Immunity</source> (<year>2001</year>) <volume>14</volume>:<page-range>205&#8211;15</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/S1074-7613(01)00103-0</pub-id><pub-id pub-id-type="pmid">11290331</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Didierlaurent</surname><given-names>AM</given-names></name><name name-style="western"><surname>Morel</surname><given-names>S</given-names></name><name name-style="western"><surname>Lockman</surname><given-names>L</given-names></name><name name-style="western"><surname>Giannini</surname><given-names>SL</given-names></name><name name-style="western"><surname>Bisteau</surname><given-names>M</given-names></name><name name-style="western"><surname>Carlsen</surname><given-names>H</given-names></name><etal/></person-group><article-title>AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity</article-title>. <source>J Immunol</source> (<year>2009</year>) <volume>183</volume>:<page-range>6186&#8211;97</page-range>. &#160;<pub-id pub-id-type="doi">10.4049/jimmunol.0901474</pub-id><pub-id pub-id-type="pmid">19864596</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kundi</surname><given-names>M</given-names></name></person-group><article-title>New hepatitis B vaccine formulated with an improved adjuvant system</article-title>. <source>Expert Rev Vaccines</source> (<year>2007</year>) <volume>6</volume>:<page-range>133&#8211;40</page-range>. &#160;<pub-id pub-id-type="doi">10.1586/14760584.6.2.133</pub-id><pub-id pub-id-type="pmid">17408363</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olafsdottir</surname><given-names>TA</given-names></name><name name-style="western"><surname>Lingnau</surname><given-names>K</given-names></name><name name-style="western"><surname>Nagy</surname><given-names>E</given-names></name><name name-style="western"><surname>Jonsdottir</surname><given-names>I</given-names></name></person-group><article-title>IC31 <sup>&#174;</sup> , a Two-Component Novel Adjuvant Mixed with a Conjugate Vaccine Enhances Protective Immunity against Pneumococcal Disease in Neonatal Mice</article-title>. <source>Scand J Immunol</source> (<year>2009</year>) <volume>69</volume>:<fpage>194</fpage>&#8211;<lpage>202</lpage>. &#160;<pub-id pub-id-type="doi">10.1111/j.1365-3083.2008.02225.x</pub-id><pub-id pub-id-type="pmid">19281531</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knudsen</surname><given-names>NPH</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>A</given-names></name><name name-style="western"><surname>Buonsanti</surname><given-names>C</given-names></name><name name-style="western"><surname>Follmann</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Coler</surname><given-names>RN</given-names></name><etal/></person-group><article-title>Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens</article-title>. <source>Sci Rep</source> (<year>2016</year>) <volume>6</volume>:<fpage>1</fpage>&#8211;<lpage>13</lpage>. &#160;<pub-id pub-id-type="doi">10.1038/srep19570</pub-id><pub-id pub-id-type="pmid">26791076</pub-id><pub-id pub-id-type="pmcid">PMC4726129</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behzad</surname><given-names>H</given-names></name><name name-style="western"><surname>Huckriede</surname><given-names>ALW</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>L</given-names></name><name name-style="western"><surname>Gentleman</surname><given-names>B</given-names></name><name name-style="western"><surname>Coyle</surname><given-names>K</given-names></name><name name-style="western"><surname>Wilschut</surname><given-names>JC</given-names></name><etal/></person-group><article-title>GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults</article-title>. <source>J Infect Dis</source> (<year>2012</year>) <volume>205</volume>:<page-range>466&#8211;73</page-range>. &#160;<pub-id pub-id-type="doi">10.1093/infdis/jir769</pub-id><pub-id pub-id-type="pmcid">PMC3256953</pub-id><pub-id pub-id-type="pmid">22147791</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agger</surname><given-names>EM</given-names></name><name name-style="western"><surname>Rosenkrands</surname><given-names>I</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>J</given-names></name><name name-style="western"><surname>Brahimi</surname><given-names>K</given-names></name><name name-style="western"><surname>Vandahl</surname><given-names>BS</given-names></name><name name-style="western"><surname>Aagaard</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements</article-title>. <source>PloS One</source> (<year>2008</year>) <volume>3</volume>:<fpage>e3116</fpage>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0003116</pub-id><pub-id pub-id-type="pmid">18776936</pub-id><pub-id pub-id-type="pmcid">PMC2525815</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elliott</surname><given-names>STC</given-names></name><name name-style="western"><surname>Kallewaard</surname><given-names>NL</given-names></name><name name-style="western"><surname>Benjamin</surname><given-names>E</given-names></name><name name-style="western"><surname>Wachter-Rosati</surname><given-names>L</given-names></name><name name-style="western"><surname>McAuliffe</surname><given-names>JM</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A</given-names></name><etal/></person-group><article-title>DMAb inoculation of synthetic cross reactive antibodies protectsagainst lethal influenza A and B infections</article-title>. <source>NPJ Vaccines</source> (<year>2017</year>) <volume>2</volume>(<issue>18</issue>):<fpage>1</fpage>&#8211;<lpage>18</lpage>. &#160;<pub-id pub-id-type="doi">10.1038/s41541-017-0020-x</pub-id><pub-id pub-id-type="pmid">29263874</pub-id><pub-id pub-id-type="pmcid">PMC5627301</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uccellini</surname><given-names>MB</given-names></name><name name-style="western"><surname>Busto</surname><given-names>P</given-names></name><name name-style="western"><surname>Debatis</surname><given-names>M</given-names></name><name name-style="western"><surname>Marshak-Rothstein</surname><given-names>A</given-names></name><name name-style="western"><surname>Viglianti</surname><given-names>GA</given-names></name></person-group><article-title>Selective binding of anti-DNA antibodies to native dsDNA fragmentsof differing sequence</article-title>. <source>Immunol Lett</source> (<year>2012</year>) <volume>143</volume>:<fpage>85</fpage>&#8211;<lpage>91</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.imlet.2012.01.003</pub-id><pub-id pub-id-type="pmid">22285306</pub-id><pub-id pub-id-type="pmcid">PMC3655556</pub-id></mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vallin</surname><given-names>H</given-names></name><name name-style="western"><surname>Perers</surname><given-names>A</given-names></name><name name-style="western"><surname>Alm</surname><given-names>GV</given-names></name><name name-style="western"><surname>Ronnblom</surname><given-names>L</given-names></name></person-group><article-title>Anti-Double-Stranded DNA Antibodies and Immunostimulatory Plasmid DNA in Combination Mimic the Endogenous IFN-&#945; Inducer in Systemic Lupus Erythematosus</article-title>. <source>J Immunol</source> (<year>1999</year>) <volume>163</volume>:<page-range>6306&#8211;13</page-range>.<pub-id pub-id-type="pmid">10570325</pub-id></mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wellmann</surname><given-names>U</given-names></name><name name-style="western"><surname>Letz</surname><given-names>M</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Angermuller</surname><given-names>S</given-names></name><name name-style="western"><surname>Kalden</surname><given-names>JR</given-names></name><name name-style="western"><surname>Winkler</surname><given-names>TH</given-names></name></person-group><article-title>The evolution of human anti-double-stranded DNAautoantibodies</article-title>. <source>Proc Natl Acad Sci</source> (<year>2005</year>) <volume>102</volume>:<page-range>9258&#8211;63</page-range>. &#160;<pub-id pub-id-type="doi">10.1073/pnas.0500132102</pub-id><pub-id pub-id-type="pmcid">PMC1166593</pub-id><pub-id pub-id-type="pmid">15968001</pub-id></mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morel</surname><given-names>S</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>A</given-names></name><name name-style="western"><surname>Bourguignon</surname><given-names>P</given-names></name><name name-style="western"><surname>Delhaye</surname><given-names>S</given-names></name><name name-style="western"><surname>Baras</surname><given-names>B</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>V</given-names></name><etal/></person-group><article-title>Adjuvant System AS03 containing &#945;-tocopherol modulates innate immune response and leads to improved adaptive immunity</article-title>. <source>Vaccine</source> (<year>2011</year>) <volume>29</volume>:<page-range>2461&#8211;73</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.01.011</pub-id><pub-id pub-id-type="pmid">21256188</pub-id></mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henriksen-Lacey</surname><given-names>M</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>D</given-names></name><name name-style="western"><surname>Bramwell</surname><given-names>VW</given-names></name><name name-style="western"><surname>Lindenstr&#248;m</surname><given-names>T</given-names></name><name name-style="western"><surname>Agger</surname><given-names>EM</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>P</given-names></name><etal/></person-group><article-title>Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response</article-title>. <source>J Control Release</source> (<year>2010</year>) <volume>145</volume>:<page-range>102&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.jconrel.2010.03.027</pub-id><pub-id pub-id-type="pmid">20381556</pub-id></mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Dissel</surname><given-names>JT</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>SA</given-names></name><name name-style="western"><surname>Hoff</surname><given-names>ST</given-names></name><name name-style="western"><surname>Soonawala</surname><given-names>D</given-names></name><name name-style="western"><surname>Prins</surname><given-names>C</given-names></name><name name-style="western"><surname>Hokey</surname><given-names>DA</given-names></name><etal/></person-group><article-title>A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human</article-title>. <source>Vaccine</source> (<year>2014</year>) <volume>32</volume>:<page-range>7098&#8211;107</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.10.036</pub-id><pub-id pub-id-type="pmid">25454872</pub-id></mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gar&#231;on</surname><given-names>N</given-names></name><name name-style="western"><surname>Chomez</surname><given-names>P</given-names></name><name name-style="western"><surname>Van Mechelen</surname><given-names>M</given-names></name></person-group><article-title>GlaxoSmithKline Adjuvant Systems in vaccines: Concepts, achievements and perspectives</article-title>. <source>Expert Rev Vaccines</source> (<year>2007</year>) <volume>6</volume>:<page-range>723&#8211;39</page-range>. &#160;<pub-id pub-id-type="doi">10.1586/14760584.6.5.723</pub-id><pub-id pub-id-type="pmid">17931153</pub-id></mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bejon</surname><given-names>P</given-names></name><name name-style="western"><surname>Lusingu</surname><given-names>J</given-names></name><name name-style="western"><surname>Olotu</surname><given-names>A</given-names></name><name name-style="western"><surname>Leach</surname><given-names>A</given-names></name><name name-style="western"><surname>Lievens</surname><given-names>M</given-names></name><name name-style="western"><surname>Vekemans</surname><given-names>J</given-names></name><etal/></person-group><article-title>Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age</article-title>. <source>N Engl J Med</source> (<year>2008</year>) <volume>359</volume>:<page-range>2521&#8211;32</page-range>. &#160;<pub-id pub-id-type="doi">10.1056/NEJMoa0807381</pub-id><pub-id pub-id-type="pmcid">PMC2655100</pub-id><pub-id pub-id-type="pmid">19064627</pub-id></mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olotu</surname><given-names>A</given-names></name><name name-style="western"><surname>Lusingu</surname><given-names>J</given-names></name><name name-style="western"><surname>Leach</surname><given-names>A</given-names></name><name name-style="western"><surname>Lievens</surname><given-names>M</given-names></name><name name-style="western"><surname>Vekemans</surname><given-names>J</given-names></name><name name-style="western"><surname>Msham</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: A randomised controlled trial</article-title>. <source>Lancet Infect Dis</source> (<year>2011</year>) <volume>11</volume>:<page-range>102&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/S1473-3099(10)70262-0</pub-id><pub-id pub-id-type="pmcid">PMC3341451</pub-id><pub-id pub-id-type="pmid">21237715</pub-id></mixed-citation></ref><ref id="B138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanberry</surname><given-names>L</given-names></name><name name-style="western"><surname>Strugnell</surname><given-names>R</given-names></name></person-group><article-title>Vaccines of the future</article-title>. <source>Perspect Vaccinol</source> (<year>2011</year>) <volume>1</volume>:<page-range>151&#8211;99</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.pervac.2011.05.006</pub-id></mixed-citation></ref><ref id="B139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duthie</surname><given-names>MS</given-names></name><name name-style="western"><surname>Windish</surname><given-names>HP</given-names></name><name name-style="western"><surname>Fox</surname><given-names>CB</given-names></name><name name-style="western"><surname>Reed</surname><given-names>SG</given-names></name></person-group><article-title>Use of defined TLR ligands as adjuvants within humanvaccines</article-title>. <source>Immunol Rev</source> (<year>2011</year>) <volume>239</volume>:<page-range>178&#8211;96</page-range>. &#160;<pub-id pub-id-type="doi">10.1111/j.1600-065X.2010.00978.x</pub-id><pub-id pub-id-type="pmcid">PMC5872835</pub-id><pub-id pub-id-type="pmid">21198672</pub-id></mixed-citation></ref><ref id="B140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gnjatic</surname><given-names>S</given-names></name><name name-style="western"><surname>Sawhney</surname><given-names>NB</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>N</given-names></name></person-group><article-title>Toll-like receptor agonists are they good adjuvants</article-title>? <source>Cancer J</source> (<year>2010</year>) <volume>16</volume>:<page-range>382&#8211;91</page-range>. &#160;<pub-id pub-id-type="doi">10.1097/PPO.0b013e3181eaca65</pub-id><pub-id pub-id-type="pmcid">PMC2922045</pub-id><pub-id pub-id-type="pmid">20693851</pub-id></mixed-citation></ref><ref id="B141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>SC</given-names></name><name name-style="western"><surname>Brahmakshatriya</surname><given-names>V</given-names></name><name name-style="western"><surname>Huston</surname><given-names>G</given-names></name><name name-style="western"><surname>Dibble</surname><given-names>J</given-names></name><name name-style="western"><surname>Swain</surname><given-names>SL</given-names></name></person-group><article-title>TLR-Activated Dendritic Cells Enhance the Response of Aged Naive CD4 T Cells via an IL-6&#8211;Dependent Mechanism</article-title>. <source>J Immunol</source> (<year>2010</year>) <volume>185</volume>:<page-range>6783&#8211;94</page-range>. &#160;<pub-id pub-id-type="doi">10.4049/jimmunol.0901296</pub-id><pub-id pub-id-type="pmcid">PMC3375592</pub-id><pub-id pub-id-type="pmid">20980632</pub-id></mixed-citation></ref><ref id="B142"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gill</surname><given-names>MA</given-names></name><name name-style="western"><surname>Palucka</surname><given-names>AK</given-names></name><name name-style="western"><surname>Barton</surname><given-names>T</given-names></name><name name-style="western"><surname>Ghaffar</surname><given-names>F</given-names></name><name name-style="western"><surname>Jafri</surname><given-names>H</given-names></name><name name-style="western"><surname>Banchereau</surname><given-names>J</given-names></name><etal/></person-group><article-title>Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytial virus and other viral respiratory infections</article-title>. <source>J Infect Dis</source> (<year>2005</year>) <volume>191</volume>:<page-range>1105&#8211;15</page-range>. &#160;<pub-id pub-id-type="doi">10.1086/428589</pub-id><pub-id pub-id-type="pmid">15747246</pub-id></mixed-citation></ref><ref id="B143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dimmock</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Easton</surname><given-names>AJ</given-names></name></person-group><article-title>Defective Interfering Influenza Virus RNAs: Time To Reevaluate Their Clinical Potential as Broad-Spectrum Antivirals</article-title>? <source>J Virol</source> (<year>2014</year>) <volume>88</volume>:<page-range>5217&#8211;27</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/JVI.03193-13</pub-id><pub-id pub-id-type="pmcid">PMC4019098</pub-id><pub-id pub-id-type="pmid">24574404</pub-id></mixed-citation></ref><ref id="B144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dimmock</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Rainsford</surname><given-names>EW</given-names></name><name name-style="western"><surname>Scott</surname><given-names>PD</given-names></name><name name-style="western"><surname>Marriott</surname><given-names>AC</given-names></name></person-group><article-title>Influenza Virus Protecting RNA: an Effective Prophylactic and Therapeutic Antiviral</article-title>. <source>J Virol</source> (<year>2008</year>) <volume>82</volume>:<page-range>8570&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.1128/jvi.00743-08</pub-id><pub-id pub-id-type="pmcid">PMC2519629</pub-id><pub-id pub-id-type="pmid">18579602</pub-id></mixed-citation></ref><ref id="B145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duhaut</surname><given-names>SD</given-names></name><name name-style="western"><surname>Dimmock</surname><given-names>NJ</given-names></name></person-group><article-title>Defective influenza A virus generated entirely from plasmids: Its RNA is expressed in infected mouse lung and modulates disease</article-title>. <source>J Virol Methods</source> (<year>2003</year>) <volume>108</volume>:<fpage>75</fpage>&#8211;<lpage>82</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/S0166-0934(02)00260-4</pub-id><pub-id pub-id-type="pmid">12565156</pub-id></mixed-citation></ref><ref id="B146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>PD</given-names></name><name name-style="western"><surname>Meng</surname><given-names>B</given-names></name><name name-style="western"><surname>Marriott</surname><given-names>AC</given-names></name><name name-style="western"><surname>Easton</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Dimmock</surname><given-names>NJ</given-names></name></person-group><article-title>Defective interfering virus protects elderly mice from influenza</article-title>. <source>Virol J</source> (<year>2011</year>) <volume>8</volume>:<elocation-id>212</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1186/1743-422X-8-212</pub-id><pub-id pub-id-type="pmid">21549019</pub-id><pub-id pub-id-type="pmcid">PMC3117841</pub-id></mixed-citation></ref><ref id="B147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dimmock</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Dove</surname><given-names>BK</given-names></name><name name-style="western"><surname>Scott</surname><given-names>PD</given-names></name><name name-style="western"><surname>Meng</surname><given-names>B</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>I</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>L</given-names></name><etal/></person-group><article-title>Cloned Defective Interfering Influenza Virus Protects Ferrets from Pandemic 2009 Influenza A Virus and Allows Protective Immunity to Be Established</article-title>. <source>PloS One</source> (<year>2012</year>) <volume>7</volume>:<elocation-id>49394</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0049394</pub-id><pub-id pub-id-type="pmcid">PMC3521014</pub-id><pub-id pub-id-type="pmid">23251341</pub-id></mixed-citation></ref><ref id="B148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dimmock</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Dove</surname><given-names>BK</given-names></name><name name-style="western"><surname>Meng</surname><given-names>B</given-names></name><name name-style="western"><surname>Scott</surname><given-names>PD</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>I</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>L</given-names></name><etal/></person-group><article-title>Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir</article-title>. <source>Antiviral Res</source> (<year>2012</year>) <volume>96</volume>:<page-range>376&#8211;85</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.antiviral.2012.09.017</pub-id><pub-id pub-id-type="pmcid">PMC3526778</pub-id><pub-id pub-id-type="pmid">23041142</pub-id></mixed-citation></ref><ref id="B149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>PD</given-names></name><name name-style="western"><surname>Meng</surname><given-names>B</given-names></name><name name-style="western"><surname>Marriott</surname><given-names>AC</given-names></name><name name-style="western"><surname>Easton</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Dimmock</surname><given-names>NJ</given-names></name></person-group><article-title>Defective interfering influenza virus confers only short-lived protection against influenza virus disease: Evidence for a role for adaptive immunity in DI virus-mediated protection in vivo</article-title>. <source>Vaccine</source> (<year>2011</year>) <volume>29</volume>:<page-range>6584&#8211;91</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.06.114</pub-id><pub-id pub-id-type="pmcid">PMC3163266</pub-id><pub-id pub-id-type="pmid">21762748</pub-id></mixed-citation></ref><ref id="B150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>PD</given-names></name><name name-style="western"><surname>Meng</surname><given-names>B</given-names></name><name name-style="western"><surname>Marriott</surname><given-names>AC</given-names></name><name name-style="western"><surname>Easton</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Dimmock</surname><given-names>NJ</given-names></name></person-group><article-title>Defective interfering influenza A virus protects in vivo against disease caused by a heterologous influenza B virus</article-title>. <source>J Gen Virol</source> (<year>2011</year>) <volume>92</volume>:<page-range>2122&#8211;32</page-range>. &#160;<pub-id pub-id-type="doi">10.1099/vir.0.034132-0</pub-id><pub-id pub-id-type="pmid">21632569</pub-id></mixed-citation></ref><ref id="B151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Easton</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Scott</surname><given-names>PD</given-names></name><name name-style="western"><surname>Edworthy</surname><given-names>NL</given-names></name><name name-style="western"><surname>Meng</surname><given-names>B</given-names></name><name name-style="western"><surname>Marriott</surname><given-names>AC</given-names></name><name name-style="western"><surname>Dimmock</surname><given-names>NJ</given-names></name></person-group><article-title>A novel broad-spectrum treatment for respiratory virus infections: Influenza-based defective interfering virus provides protection against pneumovirus infection in vivo</article-title>. <source>Vaccine</source> (<year>2011</year>) <volume>29</volume>:<page-range>2777&#8211;84</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.01.102</pub-id><pub-id pub-id-type="pmid">21320545</pub-id></mixed-citation></ref><ref id="B152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lyu</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>R</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Ye</surname><given-names>K</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Q</given-names></name><etal/></person-group><article-title>The antiviral and antitumor effects of defective interfering particles/genomes and their mechanisms</article-title>. <source>Front Microbiol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>1852</elocation-id>:<elocation-id>1852</elocation-id>. &#160;<pub-id pub-id-type="doi">10.3389/fmicb.2019.01852</pub-id><pub-id pub-id-type="pmid">31447826</pub-id><pub-id pub-id-type="pmcid">PMC6696905</pub-id></mixed-citation></ref><ref id="B153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pravetoni</surname><given-names>M</given-names></name></person-group><article-title>Biologics to treat substance use disorders: Current status and new directions</article-title>. <source>Hum Vaccines Immunother</source> (<year>2016</year>) <volume>12</volume>:<page-range>3005&#8211;19</page-range>. &#160;<pub-id pub-id-type="doi">10.1080/21645515.2016.1212785</pub-id><pub-id pub-id-type="pmcid">PMC5215474</pub-id><pub-id pub-id-type="pmid">27441896</pub-id></mixed-citation></ref><ref id="B154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carrera</surname><given-names>MRA</given-names></name><name name-style="western"><surname>Ashley</surname><given-names>JA</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>LH</given-names></name><name name-style="western"><surname>Wirsching</surname><given-names>P</given-names></name><name name-style="western"><surname>Koob</surname><given-names>GF</given-names></name><name name-style="western"><surname>Janda</surname><given-names>KD</given-names></name></person-group><article-title>Suppression of psychoactive effects of cocaine by active immunization</article-title>. <source>Nature</source> (<year>1995</year>) <volume>378</volume>:<page-range>727&#8211;30</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/378727a0</pub-id><pub-id pub-id-type="pmid">7501020</pub-id></mixed-citation></ref><ref id="B155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jalah</surname><given-names>R</given-names></name><name name-style="western"><surname>Torres</surname><given-names>OB</given-names></name><name name-style="western"><surname>Mayorov</surname><given-names>AV</given-names></name><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Antoline</surname><given-names>JFG</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Efficacy, but Not Antibody Titer or Affinity, of a Heroin Hapten Conjugate Vaccine Correlates with Increasing Hapten Densities on Tetanus Toxoid, but Not on CRM197 Carriers</article-title>. <source>Bioconjug Chem</source> (<year>2015</year>) <volume>26</volume>:<page-range>1041&#8211;53</page-range>. &#160;<pub-id pub-id-type="doi">10.1021/acs.bioconjchem.5b00085</pub-id><pub-id pub-id-type="pmcid">PMC4472500</pub-id><pub-id pub-id-type="pmid">25970207</pub-id></mixed-citation></ref><ref id="B156"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCluskie</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Thorn</surname><given-names>J</given-names></name><name name-style="western"><surname>Mehelic</surname><given-names>PR</given-names></name><name name-style="western"><surname>Kolhe</surname><given-names>P</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>K</given-names></name><name name-style="western"><surname>Finneman</surname><given-names>JI</given-names></name><etal/></person-group><article-title>Molecular attributes of conjugate antigen influence function of antibodies induced by anti-nicotine vaccine in mice and non-human primates</article-title>. <source>Int Immunopharmacol</source> (<year>2015</year>) <volume>25</volume>:<page-range>518&#8211;27</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.intimp.2015.02.030</pub-id><pub-id pub-id-type="pmid">25737198</pub-id></mixed-citation></ref><ref id="B157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimishima</surname><given-names>A</given-names></name><name name-style="western"><surname>Wenthur</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>B</given-names></name><name name-style="western"><surname>Janda</surname><given-names>KD</given-names></name></person-group><article-title>An advance in prescription opioid vaccines: Overdose mortality reduction and extraordinary alteration of drug half-life</article-title>. <source>ACS Chem Biol</source> (<year>2017</year>) <volume>12</volume>:<fpage>36</fpage>&#8211;<lpage>40</lpage>. &#160;<pub-id pub-id-type="doi">10.1021/acschembio.6b00977</pub-id><pub-id pub-id-type="pmid">28103678</pub-id><pub-id pub-id-type="pmcid">PMC6434689</pub-id></mixed-citation></ref><ref id="B158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bremer</surname><given-names>PT</given-names></name><name name-style="western"><surname>Kimishima</surname><given-names>A</given-names></name><name name-style="western"><surname>Schlosburg</surname><given-names>JE</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>B</given-names></name><name name-style="western"><surname>Collins</surname><given-names>KC</given-names></name><name name-style="western"><surname>Janda</surname><given-names>KD</given-names></name></person-group><article-title>Combatting Synthetic Designer Opioids: A Conjugate Vaccine Ablates Lethal Doses of Fentanyl Class Drugs</article-title>. <source>Angew Chemie Int Ed</source> (<year>2016</year>) <volume>55</volume>:<page-range>3772&#8211;5</page-range>. &#160;<pub-id pub-id-type="doi">10.1002/anie.201511654</pub-id><pub-id pub-id-type="pmcid">PMC4860013</pub-id><pub-id pub-id-type="pmid">26879590</pub-id></mixed-citation></ref><ref id="B159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>KC</given-names></name><name name-style="western"><surname>Schlosburg</surname><given-names>JE</given-names></name><name name-style="western"><surname>Bremer</surname><given-names>PT</given-names></name><name name-style="western"><surname>Janda</surname><given-names>KD</given-names></name></person-group><article-title>Methamphetamine Vaccines: Improvement through Hapten Design</article-title>. <source>J Med Chem</source> (<year>2016</year>) <volume>59</volume>:<page-range>3878&#8211;85</page-range>. &#160;<pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b00084</pub-id><pub-id pub-id-type="pmcid">PMC5895457</pub-id><pub-id pub-id-type="pmid">27054372</pub-id></mixed-citation></ref><ref id="B160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bremer</surname><given-names>PT</given-names></name><name name-style="western"><surname>Janda</surname><given-names>KD</given-names></name></person-group><article-title>Conjugate Vaccine Immunotherapy for Substance Use Disorder</article-title>. <source>Pharmacol Rev</source> (<year>2017</year>) <volume>69</volume>:<fpage>298</fpage>&#8211;<lpage>315</lpage>. <pub-id pub-id-type="doi">10.1124/pr.117.013904</pub-id><pub-id pub-id-type="pmid">28634286</pub-id><pub-id pub-id-type="pmcid">PMC5482184</pub-id></mixed-citation></ref><ref id="B161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sulima</surname><given-names>A</given-names></name><name name-style="western"><surname>Jalah</surname><given-names>R</given-names></name><name name-style="western"><surname>Antoline</surname><given-names>JFG</given-names></name><name name-style="western"><surname>Torres</surname><given-names>OB</given-names></name><name name-style="western"><surname>Imler</surname><given-names>GH</given-names></name><name name-style="western"><surname>Deschamps</surname><given-names>JR</given-names></name><etal/></person-group><article-title>A Stable Heroin Analogue That Can Serve as a Vaccine Hapten to Induce Antibodies That Block the Effects of Heroin and Its Metabolites in Rodents and That Cross-React Immunologically with Related Drugs of Abuse</article-title>. <source>J Med Chem</source> (<year>2018</year>) <volume>61</volume>:<page-range>329&#8211;43</page-range>. &#160;<pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b01427</pub-id><pub-id pub-id-type="pmcid">PMC5767880</pub-id><pub-id pub-id-type="pmid">29236495</pub-id></mixed-citation></ref><ref id="B162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>JD</given-names></name><name name-style="western"><surname>Bremer</surname><given-names>PT</given-names></name><name name-style="western"><surname>Ducime</surname><given-names>A</given-names></name><name name-style="western"><surname>Creehan</surname><given-names>KM</given-names></name><name name-style="western"><surname>Kisby</surname><given-names>BR</given-names></name><name name-style="western"><surname>Taffe</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Active vaccination attenuates the psychostimulant effects of &#945;-PVP and MDPV in rats</article-title>. <source>Neuropharmacology</source> (<year>2017</year>) <volume>116</volume>:<fpage>1</fpage>&#8211;<lpage>8</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.neuropharm.2016.12.005</pub-id><pub-id pub-id-type="pmid">27956054</pub-id><pub-id pub-id-type="pmcid">PMC5385148</pub-id></mixed-citation></ref><ref id="B163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isomura</surname><given-names>S</given-names></name><name name-style="western"><surname>Wirsching</surname><given-names>P</given-names></name><name name-style="western"><surname>Janda</surname><given-names>KD</given-names></name></person-group><article-title>An immunotherapeutic program for the treatment of nicotine addiction: Hapten design and synthesis</article-title>. <source>J Org Chem</source> (<year>2001</year>) <volume>66</volume>:<page-range>4115&#8211;21</page-range>. &#160;<pub-id pub-id-type="doi">10.1021/jo001442w</pub-id><pub-id pub-id-type="pmid">11397142</pub-id></mixed-citation></ref><ref id="B164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peterson</surname><given-names>EC</given-names></name><name name-style="western"><surname>Gunnell</surname><given-names>M</given-names></name><name name-style="western"><surname>Che</surname><given-names>Y</given-names></name><name name-style="western"><surname>Goforth</surname><given-names>RL</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>FI</given-names></name><name name-style="western"><surname>Henry</surname><given-names>R</given-names></name><etal/></person-group><article-title>Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse</article-title>. <source>J Pharmacol Exp Ther</source> (<year>2007</year>) <volume>322</volume>:<page-range>30&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1124/jpet.106.117150</pub-id><pub-id pub-id-type="pmid">17452421</pub-id></mixed-citation></ref><ref id="B165"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreno</surname><given-names>AY</given-names></name><name name-style="western"><surname>Mayorov</surname><given-names>AV</given-names></name><name name-style="western"><surname>Janda</surname><given-names>KD</given-names></name></person-group><article-title>Impact of distinct chemical structures for the development of a methamphetamine vaccine</article-title>. <source>J Am Chem Soc</source> (<year>2011</year>) <volume>133</volume>:<page-range>6587&#8211;95</page-range>. &#160;<pub-id pub-id-type="doi">10.1021/ja108807j</pub-id><pub-id pub-id-type="pmcid">PMC3090292</pub-id><pub-id pub-id-type="pmid">21473576</pub-id></mixed-citation></ref><ref id="B166"><label>166</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stowe</surname><given-names>GN</given-names></name><name name-style="western"><surname>Vendruscolo</surname><given-names>LF</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>S</given-names></name><name name-style="western"><surname>Schlosburg</surname><given-names>JE</given-names></name><name name-style="western"><surname>Misra</surname><given-names>KK</given-names></name><name name-style="western"><surname>Schulteis</surname><given-names>G</given-names></name><etal/></person-group><article-title>A vaccine strategy that induces protective immunity against heroin</article-title>. <source>J Med Chem</source> (<year>2011</year>) <volume>54</volume>:<page-range>5195&#8211;204</page-range>. &#160;<pub-id pub-id-type="doi">10.1021/jm200461m</pub-id><pub-id pub-id-type="pmcid">PMC3142939</pub-id><pub-id pub-id-type="pmid">21692508</pub-id></mixed-citation></ref><ref id="B167"><label>167</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pravetoni</surname><given-names>M</given-names></name><name name-style="western"><surname>Le Naour</surname><given-names>M</given-names></name><name name-style="western"><surname>Harmon</surname><given-names>TM</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>AM</given-names></name><name name-style="western"><surname>Portoghese</surname><given-names>PS</given-names></name><name name-style="western"><surname>Pentel</surname><given-names>PR</given-names></name></person-group><article-title>An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia</article-title>. <source>J Pharmacol Exp Ther</source> (<year>2012</year>) <volume>341</volume>:<page-range>225&#8211;32</page-range>. &#160;<pub-id pub-id-type="doi">10.1124/jpet.111.189506</pub-id><pub-id pub-id-type="pmcid">PMC3310692</pub-id><pub-id pub-id-type="pmid">22262924</pub-id></mixed-citation></ref><ref id="B168"><label>168</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pryde</surname><given-names>DC</given-names></name><name name-style="western"><surname>Jones</surname><given-names>LH</given-names></name><name name-style="western"><surname>Gervais</surname><given-names>DP</given-names></name><name name-style="western"><surname>Stead</surname><given-names>DR</given-names></name><name name-style="western"><surname>Blakemore</surname><given-names>DC</given-names></name><name name-style="western"><surname>Selby</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Selection of a Novel Anti-Nicotine Vaccine: Influence of Antigen Design on Antibody Function in Mice</article-title>. <source>PloS One</source> (<year>2013</year>) <volume>8</volume>:<fpage>e76557</fpage>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0076557</pub-id><pub-id pub-id-type="pmid">24098532</pub-id><pub-id pub-id-type="pmcid">PMC3788104</pub-id></mixed-citation></ref><ref id="B169"><label>169</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pravetoni</surname><given-names>M</given-names></name><name name-style="western"><surname>Le Naour</surname><given-names>M</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>AM</given-names></name><name name-style="western"><surname>Harmon</surname><given-names>TM</given-names></name><name name-style="western"><surname>Hawley</surname><given-names>TM</given-names></name><name name-style="western"><surname>Portoghese</surname><given-names>PS</given-names></name><etal/></person-group><article-title>Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens</article-title>. <source>J Med Chem</source> (<year>2013</year>) <volume>56</volume>:<page-range>915&#8211;23</page-range>. &#160;<pub-id pub-id-type="doi">10.1021/jm3013745</pub-id><pub-id pub-id-type="pmcid">PMC3791856</pub-id><pub-id pub-id-type="pmid">23249238</pub-id></mixed-citation></ref><ref id="B170"><label>170</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>KC</given-names></name><name name-style="western"><surname>Janda</surname><given-names>KD</given-names></name></person-group><article-title>Investigating hapten clustering as a strategy to enhance vaccines against drugs of abuse</article-title>. <source>Bioconjug Chem</source> (<year>2014</year>) <volume>25</volume>:<fpage>593</fpage>&#8211;<lpage>600</lpage>. &#160;<pub-id pub-id-type="doi">10.1021/bc500016k</pub-id><pub-id pub-id-type="pmid">24521489</pub-id><pub-id pub-id-type="pmcid">PMC3983143</pub-id></mixed-citation></ref><ref id="B171"><label>171</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stevens</surname><given-names>MW</given-names></name><name name-style="western"><surname>Gunnell</surname><given-names>MG</given-names></name><name name-style="western"><surname>Tawney</surname><given-names>R</given-names></name><name name-style="western"><surname>Owens</surname><given-names>SM</given-names></name></person-group><article-title>Optimization of a methamphetamine conjugate vaccine for antibody production in mice</article-title>. <source>Int Immunopharmacol</source> (<year>2016</year>) <volume>35</volume>:<page-range>137&#8211;41</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.intimp.2016.03.028</pub-id><pub-id pub-id-type="pmcid">PMC4851881</pub-id><pub-id pub-id-type="pmid">27039212</pub-id></mixed-citation></ref><ref id="B172"><label>172</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bremer</surname><given-names>PT</given-names></name><name name-style="western"><surname>Schlosburg</surname><given-names>JE</given-names></name><name name-style="western"><surname>Banks</surname><given-names>ML</given-names></name><name name-style="western"><surname>Steele</surname><given-names>FF</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>B</given-names></name><name name-style="western"><surname>Poklis</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Development of a Clinically Viable Heroin Vaccine</article-title>. <source>J Am Chem Soc</source> (<year>2017</year>) <volume>139</volume>:<page-range>8601&#8211;11</page-range>. &#160;<pub-id pub-id-type="doi">10.1021/jacs.7b03334</pub-id><pub-id pub-id-type="pmcid">PMC5612493</pub-id><pub-id pub-id-type="pmid">28574716</pub-id></mixed-citation></ref><ref id="B173"><label>173</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pravetoni</surname><given-names>M</given-names></name><name name-style="western"><surname>Pentel</surname><given-names>PR</given-names></name><name name-style="western"><surname>Potter</surname><given-names>DN</given-names></name><name name-style="western"><surname>Chartoff</surname><given-names>EH</given-names></name><name name-style="western"><surname>Tally</surname><given-names>L</given-names></name><name name-style="western"><surname>LeSage</surname><given-names>MG</given-names></name></person-group><article-title>Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats</article-title>. <source>PloS One</source> (<year>2014</year>) <volume>9</volume>:<elocation-id>101807</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0101807</pub-id><pub-id pub-id-type="pmcid">PMC4099132</pub-id><pub-id pub-id-type="pmid">25025380</pub-id></mixed-citation></ref><ref id="B174"><label>174</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kosten</surname><given-names>TR</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>M</given-names></name><name name-style="western"><surname>Bond</surname><given-names>J</given-names></name><name name-style="western"><surname>Settles</surname><given-names>M</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>JSC</given-names></name><name name-style="western"><surname>Shields</surname><given-names>J</given-names></name><etal/></person-group><article-title>Human therapeutic cocaine vaccine: Safety and immunogenicity</article-title>. <source>Vaccine</source> (<year>2002</year>) <volume>20</volume>:<page-range>1196&#8211;204</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/S0264-410X(01)00425-X</pub-id><pub-id pub-id-type="pmid">11803082</pub-id></mixed-citation></ref><ref id="B175"><label>175</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martell</surname><given-names>BA</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>E</given-names></name><name name-style="western"><surname>Poling</surname><given-names>J</given-names></name><name name-style="western"><surname>Gonsai</surname><given-names>K</given-names></name><name name-style="western"><surname>Kosten</surname><given-names>TR</given-names></name></person-group><article-title>Vaccine pharmacotherapy for the treatment of cocaine dependence</article-title>. <source>Biol Psychiatry</source> (<year>2005</year>) <volume>58</volume>:<page-range>158&#8211;64</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.biopsych.2005.04.032</pub-id><pub-id pub-id-type="pmid">16038686</pub-id></mixed-citation></ref><ref id="B176"><label>176</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreno</surname><given-names>AY</given-names></name><name name-style="western"><surname>Azar</surname><given-names>MR</given-names></name><name name-style="western"><surname>Warren</surname><given-names>NA</given-names></name><name name-style="western"><surname>Dickerson</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Koob</surname><given-names>GF</given-names></name><name name-style="western"><surname>Janda</surname><given-names>KD</given-names></name></person-group><article-title>A critical evaluation of a nicotine vaccine within a self-administration behavioral model</article-title>. <source>Mol Pharm</source> (<year>2010</year>) <volume>7</volume>:<page-range>431&#8211;41</page-range>. &#160;<pub-id pub-id-type="doi">10.1021/mp900213u</pub-id><pub-id pub-id-type="pmid">20104903</pub-id></mixed-citation></ref><ref id="B177"><label>177</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>R&#252;edi-Bettschen</surname><given-names>D</given-names></name><name name-style="western"><surname>Wood</surname><given-names>SL</given-names></name><name name-style="western"><surname>Gunnell</surname><given-names>MG</given-names></name><name name-style="western"><surname>West</surname><given-names>CM</given-names></name><name name-style="western"><surname>Pidaparthi</surname><given-names>RR</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>FI</given-names></name><etal/></person-group><article-title>Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food</article-title>. <source>Vaccine</source> (<year>2013</year>) <volume>31</volume>:<page-range>4596&#8211;602</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2013.07.038</pub-id><pub-id pub-id-type="pmcid">PMC3835592</pub-id><pub-id pub-id-type="pmid">23906885</pub-id></mixed-citation></ref><ref id="B178"><label>178</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cornish</surname><given-names>KE</given-names></name><name name-style="western"><surname>De Villiers</surname><given-names>SHL</given-names></name><name name-style="western"><surname>Pravetoni</surname><given-names>M</given-names></name><name name-style="western"><surname>Pentel</surname><given-names>PR</given-names></name></person-group><article-title>Immunogenicity of individual vaccine components in a bivalent nicotine vaccine differ according to vaccine formulation and administration conditions</article-title>. <source>PloS One</source> (<year>2013</year>) <volume>8</volume>:<elocation-id>82557</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0082557</pub-id><pub-id pub-id-type="pmcid">PMC3846984</pub-id><pub-id pub-id-type="pmid">24312662</pub-id></mixed-citation></ref><ref id="B179"><label>179</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kosten</surname><given-names>TR</given-names></name><name name-style="western"><surname>Domingo</surname><given-names>CB</given-names></name><name name-style="western"><surname>Shorter</surname><given-names>D</given-names></name><name name-style="western"><surname>Orson</surname><given-names>F</given-names></name><name name-style="western"><surname>Green</surname><given-names>C</given-names></name><name name-style="western"><surname>Somoza</surname><given-names>E</given-names></name><etal/></person-group><article-title>Vaccine for cocaine dependence: A randomized double-blind placebo-controlled efficacy trial</article-title>. <source>Drug Alcohol Depend</source> (<year>2014</year>) <volume>140</volume>:<page-range>42&#8211;7</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2014.04.003</pub-id><pub-id pub-id-type="pmcid">PMC4073297</pub-id><pub-id pub-id-type="pmid">24793366</pub-id></mixed-citation></ref><ref id="B180"><label>180</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pravetoni</surname><given-names>M</given-names></name><name name-style="western"><surname>Vervacke</surname><given-names>JS</given-names></name><name name-style="western"><surname>Distefano</surname><given-names>MD</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>AM</given-names></name><name name-style="western"><surname>Laudenbach</surname><given-names>M</given-names></name><name name-style="western"><surname>Pentel</surname><given-names>PR</given-names></name></person-group><article-title>Effect of Currently Approved Carriers and Adjuvants on the Pre-Clinical Efficacy of a Conjugate Vaccine against Oxycodone in Mice and Rats</article-title>. <source>PloS One</source> (<year>2014</year>) <volume>9</volume>:<fpage>e96547</fpage>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0096547</pub-id><pub-id pub-id-type="pmid">24797666</pub-id><pub-id pub-id-type="pmcid">PMC4010527</pub-id></mixed-citation></ref><ref id="B181"><label>181</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCluskie</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Thorn</surname><given-names>J</given-names></name><name name-style="western"><surname>Gervais</surname><given-names>DP</given-names></name><name name-style="western"><surname>Stead</surname><given-names>DR</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name><name name-style="western"><surname>Benoit</surname><given-names>M</given-names></name><etal/></person-group><article-title>Anti-nicotine vaccines: Comparison of adjuvanted CRM197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates</article-title>. <source>Int Immunopharmacol</source> (<year>2015</year>) <volume>29</volume>:<page-range>663&#8211;71</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.intimp.2015.09.012</pub-id><pub-id pub-id-type="pmid">26404190</pub-id></mixed-citation></ref><ref id="B182"><label>182</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlosburg</surname><given-names>JE</given-names></name><name name-style="western"><surname>Vendruscolo</surname><given-names>LF</given-names></name><name name-style="western"><surname>Bremer</surname><given-names>PT</given-names></name><name name-style="western"><surname>Lockner</surname><given-names>JW</given-names></name><name name-style="western"><surname>Wade</surname><given-names>CL</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>AAK</given-names></name><etal/></person-group><article-title>Dynamic vaccine blocks relapse to compulsive intake of heroin</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2013</year>) <volume>110</volume>:<page-range>9036&#8211;41</page-range>. &#160;<pub-id pub-id-type="doi">10.1073/pnas.1219159110</pub-id><pub-id pub-id-type="pmcid">PMC3670323</pub-id><pub-id pub-id-type="pmid">23650354</pub-id></mixed-citation></ref><ref id="B183"><label>183</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cornuz</surname><given-names>J</given-names></name><name name-style="western"><surname>Zwahlen</surname><given-names>S</given-names></name><name name-style="western"><surname>Jungi</surname><given-names>WF</given-names></name><name name-style="western"><surname>Osterwalder</surname><given-names>J</given-names></name><name name-style="western"><surname>Klingler</surname><given-names>K</given-names></name><name name-style="western"><surname>van Melle</surname><given-names>G</given-names></name><etal/></person-group><article-title>A vaccine against nicotine for smoking cessation: A randomizedcontrolled trial</article-title>. <source>PloS One</source> (<year>2008</year>) <volume>3</volume>(<issue>6</issue>):<elocation-id>e2547</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0002547</pub-id><pub-id pub-id-type="pmid">18575629</pub-id><pub-id pub-id-type="pmcid">PMC2432028</pub-id></mixed-citation></ref><ref id="B184"><label>184</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatsukami</surname><given-names>DK</given-names></name><name name-style="western"><surname>Jorenby</surname><given-names>DE</given-names></name><name name-style="western"><surname>Gonzales</surname><given-names>D</given-names></name><name name-style="western"><surname>Rigotti</surname><given-names>NA</given-names></name><name name-style="western"><surname>Glover</surname><given-names>ED</given-names></name><name name-style="western"><surname>Oncken</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic</article-title>. <source>Clin Pharmacol Ther</source> (<year>2011</year>) <volume>89</volume>:<page-range>392&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/clpt.2010.317</pub-id><pub-id pub-id-type="pmcid">PMC4106715</pub-id><pub-id pub-id-type="pmid">21270788</pub-id></mixed-citation></ref><ref id="B185"><label>185</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fahim</surname><given-names>RE</given-names></name><name name-style="western"><surname>Kessler</surname><given-names>PD</given-names></name><name name-style="western"><surname>Kalnik</surname><given-names>MW</given-names></name></person-group><article-title>Therapeutic vaccines against tobacco addiction</article-title>. <source>Expert Rev Vaccines</source> (<year>2013</year>) <volume>12</volume>:<page-range>333&#8211;42</page-range>. &#160;<pub-id pub-id-type="doi">10.1586/erv.13.13</pub-id><pub-id pub-id-type="pmid">23496672</pub-id></mixed-citation></ref><ref id="B186"><label>186</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martell</surname><given-names>BA</given-names></name><name name-style="western"><surname>Orson</surname><given-names>FM</given-names></name><name name-style="western"><surname>Poling</surname><given-names>J</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>E</given-names></name><name name-style="western"><surname>Rossen</surname><given-names>RD</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>T</given-names></name><etal/></person-group><article-title>Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: A randomized, double-blind, placebo-controlled efficacy trial</article-title>. <source>Arch Gen Psychiatry</source> (<year>2009</year>) <volume>66</volume>:<page-range>1116&#8211;23</page-range>. &#160;<pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2009.128</pub-id><pub-id pub-id-type="pmcid">PMC2878137</pub-id><pub-id pub-id-type="pmid">19805702</pub-id></mixed-citation></ref><ref id="B187"><label>187</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Townsend</surname><given-names>EA</given-names></name><name name-style="western"><surname>Banks</surname><given-names>ML</given-names></name></person-group><article-title>Preclinical Evaluation of Vaccines to Treat Opioid Use Disorders: How Close are We to a Clinically Viable Therapeutic</article-title>? <source>CNS Drugs</source> (<year>2020</year>) <volume>34</volume>:<page-range>449&#8211;61</page-range>. &#160;<pub-id pub-id-type="doi">10.1007/s40263-020-00722-8</pub-id><pub-id pub-id-type="pmcid">PMC7223115</pub-id><pub-id pub-id-type="pmid">32248427</pub-id></mixed-citation></ref><ref id="B188"><label>188</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raya</surname><given-names>BA</given-names></name><name name-style="western"><surname>Edward</surname><given-names>KM</given-names></name><name name-style="western"><surname>Scheifele</surname><given-names>DW</given-names></name><name name-style="western"><surname>Halperin</surname><given-names>SA</given-names></name></person-group><article-title>Pertussis and influenza immunisation during pregnancy: a landscape review</article-title>. <source>Lancet Infect Dis</source> (<year>2017</year>) <volume>17</volume>:<page-range>209&#8211;22</page-range>. <pub-id pub-id-type="doi">10.1016/S1473-3099(17)30190-1</pub-id><pub-id pub-id-type="pmid">28433704</pub-id></mixed-citation></ref><ref id="B189"><label>189</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hozbor</surname><given-names>D</given-names></name></person-group><article-title>New Pertussis Vaccines: A Need and aChallenge</article-title>. <source>Pertussis Infection and Vaccines (book), New Pertussis Vaccines: A Need and a Challenge (book section)</source> (<year>2019</year>). pp. <page-range>115&#8211;26</page-range>. &#160;<pub-id pub-id-type="doi">10.1007/5584_2019_407</pub-id><pub-id pub-id-type="pmid">31432399</pub-id></mixed-citation></ref><ref id="B190"><label>190</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitchin</surname><given-names>NRE</given-names></name></person-group><article-title>Review of diphtheria, tetanus and pertussis vaccines in clinical development</article-title>. <source>Expert Rev Vaccines</source> (<year>2011</year>) <volume>10</volume>:<page-range>605&#8211;15</page-range>. &#160;<pub-id pub-id-type="doi">10.1586/erv.11.60</pub-id><pub-id pub-id-type="pmid">21604982</pub-id></mixed-citation></ref><ref id="B191"><label>191</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angsantikul</surname><given-names>P</given-names></name><name name-style="western"><surname>Fang</surname><given-names>RH</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Toxoid Vaccination against Bacterial Infection Using Cell Membrane-Coated Nanoparticles</article-title>. <source>Bioconjug Chem</source> (<year>2018</year>) <volume>29</volume>:<page-range>604&#8211;12</page-range>. &#160;<pub-id pub-id-type="doi">10.1021/acs.bioconjchem.7b00692</pub-id><pub-id pub-id-type="pmcid">PMC5893865</pub-id><pub-id pub-id-type="pmid">29241006</pub-id></mixed-citation></ref><ref id="B192"><label>192</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Goedegebuure</surname><given-names>SP</given-names></name><name name-style="western"><surname>Gillanders</surname><given-names>WE</given-names></name></person-group><article-title>Preclinical and clinical development of neoantigen vaccines</article-title>. <source>Ann Oncol</source> (<year>2017</year>) <volume>28</volume>:<page-range>xii11&#8211;7</page-range>. &#160;<pub-id pub-id-type="doi">10.1093/annonc/mdx681</pub-id><pub-id pub-id-type="pmcid">PMC5834106</pub-id><pub-id pub-id-type="pmid">29253113</pub-id></mixed-citation></ref><ref id="B193"><label>193</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aurisicchio</surname><given-names>L</given-names></name><name name-style="western"><surname>Pallocca</surname><given-names>M</given-names></name><name name-style="western"><surname>Ciliberto</surname><given-names>G</given-names></name><name name-style="western"><surname>Palombo</surname><given-names>F</given-names></name></person-group><article-title>The perfect personalized cancer therapy: Cancer vaccines against neoantigens</article-title>. <source>J Exp Clin Cancer Res</source> (<year>2018</year>) <volume>37</volume>:<elocation-id>86</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1186/s13046-018-0751-1</pub-id><pub-id pub-id-type="pmid">29678194</pub-id><pub-id pub-id-type="pmcid">PMC5910567</pub-id></mixed-citation></ref><ref id="B194"><label>194</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maeng</surname><given-names>HM</given-names></name><name name-style="western"><surname>Berzofsky</surname><given-names>JA</given-names></name></person-group><article-title>Strategies for developing and optimizing cancervaccines</article-title>. <source>F1000Research</source> (<year>2019</year>) <volume>8</volume>:<fpage>654</fpage>. &#160;<pub-id pub-id-type="doi">10.12688/f1000research.18693.1</pub-id><pub-id pub-id-type="pmcid">PMC6518434</pub-id><pub-id pub-id-type="pmid">31131086</pub-id></mixed-citation></ref><ref id="B195"><label>195</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tagliamonte</surname><given-names>M</given-names></name><name name-style="western"><surname>Petrizzo</surname><given-names>A</given-names></name><name name-style="western"><surname>Tornesello</surname><given-names>ML</given-names></name><name name-style="western"><surname>Buonaguro</surname><given-names>FM</given-names></name><name name-style="western"><surname>Buonaguro</surname><given-names>L</given-names></name></person-group><article-title>Antigen-specific vaccines for cancer treatment</article-title>. <source>Hum Vaccines Immunother</source> (<year>2014</year>) <volume>10</volume>:<page-range>3332&#8211;46</page-range>. &#160;<pub-id pub-id-type="doi">10.4161/21645515.2014.973317</pub-id><pub-id pub-id-type="pmcid">PMC4514024</pub-id><pub-id pub-id-type="pmid">25483639</pub-id></mixed-citation></ref><ref id="B196"><label>196</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U</given-names></name><name name-style="western"><surname>T&#252;reci</surname><given-names>&#214;</given-names></name></person-group><article-title>Personalized vaccines for cancer immunotherapy</article-title>. <source>Sci (80)</source> (<year>2018</year>) <volume>359</volume>:<page-range>1355&#8211;60</page-range>. &#160;<pub-id pub-id-type="doi">10.1126/science.aar7112</pub-id><pub-id pub-id-type="pmid">29567706</pub-id></mixed-citation></ref><ref id="B197"><label>197</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopes</surname><given-names>A</given-names></name><name name-style="western"><surname>Vandermeulen</surname><given-names>G</given-names></name><name name-style="western"><surname>Pr&#233;at</surname><given-names>V</given-names></name></person-group><article-title>Cancer DNA vaccines: current preclinical and clinical developmentsand future perspectives</article-title>. <source>J Exp Clin Cancer Res</source> (<year>2019</year>) <volume>38</volume>:<fpage>146</fpage>. &#160;<pub-id pub-id-type="doi">10.1186/s13046-019-1154-7</pub-id><pub-id pub-id-type="pmid">30953535</pub-id><pub-id pub-id-type="pmcid">PMC6449928</pub-id></mixed-citation></ref><ref id="B198"><label>198</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sayour</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Mendez-Gomez</surname><given-names>HR</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>DA</given-names></name></person-group><article-title>Cancer vaccine immunotherapy with RNA-loadedliposomes</article-title>. <source>Int J Mol Sci</source> (<year>2018</year>) <volume>19</volume>:<fpage>2890</fpage>. &#160;<pub-id pub-id-type="doi">10.3390/ijms19102890</pub-id><pub-id pub-id-type="pmcid">PMC6213933</pub-id><pub-id pub-id-type="pmid">30249040</pub-id></mixed-citation></ref><ref id="B199"><label>199</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Granstein</surname><given-names>RD</given-names></name><name name-style="western"><surname>Ding</surname><given-names>W</given-names></name><name name-style="western"><surname>Ozawa</surname><given-names>H</given-names></name></person-group><article-title>Induction of anti-tumor immunity with epidermal cells pulsed with tumor- derived RNA or intradermal administration of RNA</article-title>. <source>J Invest Dermatol</source> (<year>2000</year>) <volume>114</volume>:<page-range>632&#8211;6</page-range>. &#160;<pub-id pub-id-type="doi">10.1046/j.1523-1747.2000.00929.x</pub-id><pub-id pub-id-type="pmid">10733665</pub-id></mixed-citation></ref><ref id="B200"><label>200</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheel</surname><given-names>B</given-names></name><name name-style="western"><surname>Aulwurm</surname><given-names>S</given-names></name><name name-style="western"><surname>Probst</surname><given-names>J</given-names></name><name name-style="western"><surname>Stitz</surname><given-names>L</given-names></name><name name-style="western"><surname>Hoerr</surname><given-names>I</given-names></name><name name-style="western"><surname>Rammensee</surname><given-names>H-G</given-names></name><etal/></person-group><article-title>Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA</article-title>. <source>Eur J Immunol</source> (<year>2006</year>) <volume>36</volume>:<page-range>2807&#8211;16</page-range>. &#160;<pub-id pub-id-type="doi">10.1002/eji.200635910</pub-id><pub-id pub-id-type="pmid">17013976</pub-id></mixed-citation></ref><ref id="B201"><label>201</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Lint</surname><given-names>S</given-names></name><name name-style="western"><surname>Goyvaerts</surname><given-names>C</given-names></name><name name-style="western"><surname>Maenhout</surname><given-names>S</given-names></name><name name-style="western"><surname>Goethals</surname><given-names>L</given-names></name><name name-style="western"><surname>Disy</surname><given-names>A</given-names></name><name name-style="western"><surname>Benteyn</surname><given-names>D</given-names></name><etal/></person-group><article-title>Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy</article-title>. <source>Cancer Res</source> (<year>2012</year>) <volume>72</volume>:<page-range>1661&#8211;71</page-range>. &#160;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-2957</pub-id><pub-id pub-id-type="pmid">22337996</pub-id></mixed-citation></ref><ref id="B202"><label>202</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bialkowski</surname><given-names>L</given-names></name><name name-style="western"><surname>Van Weijnen</surname><given-names>A</given-names></name><name name-style="western"><surname>Van Der Jeught</surname><given-names>K</given-names></name><name name-style="western"><surname>Renmans</surname><given-names>D</given-names></name><name name-style="western"><surname>Daszkiewicz</surname><given-names>L</given-names></name><name name-style="western"><surname>Heirman</surname><given-names>C</given-names></name><etal/></person-group><article-title>Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours</article-title>. <source>Sci Rep</source> (<year>2016</year>) <volume>6</volume>:<fpage>1</fpage>&#8211;<lpage>15</lpage>. &#160;<pub-id pub-id-type="doi">10.1038/srep22509</pub-id><pub-id pub-id-type="pmid">26931556</pub-id><pub-id pub-id-type="pmcid">PMC4773884</pub-id></mixed-citation></ref><ref id="B203"><label>203</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>K&#252;bler</surname><given-names>H</given-names></name><name name-style="western"><surname>Scheel</surname><given-names>B</given-names></name><name name-style="western"><surname>Gnad-Vogt</surname><given-names>U</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K</given-names></name><name name-style="western"><surname>Schultze-Seemann</surname><given-names>W</given-names></name><name name-style="western"><surname>vom Dorp</surname><given-names>F</given-names></name><etal/></person-group><article-title>Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study</article-title>. <source>J Immunother Cancer</source> (<year>2015</year>) <volume>3</volume>:<fpage>26</fpage>. &#160;<pub-id pub-id-type="doi">10.1186/s40425-015-0068-y</pub-id><pub-id pub-id-type="pmid">26082837</pub-id><pub-id pub-id-type="pmcid">PMC4468959</pub-id></mixed-citation></ref><ref id="B204"><label>204</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Audouy</surname><given-names>SAL</given-names></name><name name-style="western"><surname>De Leij</surname><given-names>LFMH</given-names></name><name name-style="western"><surname>Hoekstra</surname><given-names>D</given-names></name><name name-style="western"><surname>Molema</surname><given-names>G</given-names></name></person-group><article-title>In vivo characteristics of cationic liposomes as delivery vectors for gene therapy</article-title>. <source>Pharm Res</source> (<year>2002</year>) <volume>19</volume>:<page-range>1599&#8211;605</page-range>. &#160;<pub-id pub-id-type="doi">10.1023/A:1020989709019</pub-id><pub-id pub-id-type="pmid">12458664</pub-id></mixed-citation></ref><ref id="B205"><label>205</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lorenzer</surname><given-names>C</given-names></name><name name-style="western"><surname>Dirin</surname><given-names>M</given-names></name><name name-style="western"><surname>Winkler</surname><given-names>AM</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>V</given-names></name><name name-style="western"><surname>Winkler</surname><given-names>J</given-names></name></person-group><article-title>Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics</article-title>. <source>J Control Release</source> (<year>2015</year>) <volume>203</volume>:<fpage>1</fpage>&#8211;<lpage>15</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.jconrel.2015.02.003</pub-id><pub-id pub-id-type="pmid">25660205</pub-id></mixed-citation></ref><ref id="B206"><label>206</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hess</surname><given-names>PR</given-names></name><name name-style="western"><surname>Boczkowski</surname><given-names>D</given-names></name><name name-style="western"><surname>Nair</surname><given-names>SK</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>D</given-names></name><name name-style="western"><surname>Gilboa</surname><given-names>E</given-names></name></person-group><article-title>Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen</article-title>. <source>Cancer Immunol Immunother</source> (<year>2006</year>) <volume>55</volume>:<page-range>672&#8211;83</page-range>. &#160;<pub-id pub-id-type="doi">10.1007/s00262-005-0064-z</pub-id><pub-id pub-id-type="pmcid">PMC11030883</pub-id><pub-id pub-id-type="pmid">16133108</pub-id></mixed-citation></ref><ref id="B207"><label>207</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phua</surname><given-names>KKL</given-names></name><name name-style="western"><surname>Staats</surname><given-names>HF</given-names></name><name name-style="western"><surname>Leong</surname><given-names>KW</given-names></name><name name-style="western"><surname>Nair</surname><given-names>SK</given-names></name></person-group><article-title>Intranasal mRNA nanoparticle vaccination induces prophylactic andtherapeutic anti-tumor immunity</article-title>. <source>Sci Rep</source> (<year>2014</year>) <volume>4</volume>:<fpage>5128</fpage>. &#160;<pub-id pub-id-type="doi">10.1038/srep05128</pub-id><pub-id pub-id-type="pmid">24894817</pub-id><pub-id pub-id-type="pmcid">PMC4044635</pub-id></mixed-citation></ref><ref id="B208"><label>208</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oberli</surname><given-names>MA</given-names></name><name name-style="western"><surname>Reichmuth</surname><given-names>AM</given-names></name><name name-style="western"><surname>Dorkin</surname><given-names>JR</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Fenton</surname><given-names>OS</given-names></name><name name-style="western"><surname>Jaklenec</surname><given-names>A</given-names></name><etal/></person-group><article-title>Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy</article-title>. <source>Nano Lett</source> (<year>2017</year>) <volume>17</volume>:<page-range>1326&#8211;35</page-range>. &#160;<pub-id pub-id-type="doi">10.1021/acs.nanolett.6b03329</pub-id><pub-id pub-id-type="pmcid">PMC5523404</pub-id><pub-id pub-id-type="pmid">28273716</pub-id></mixed-citation></ref><ref id="B209"><label>209</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>C</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Ji</surname><given-names>L</given-names></name><name name-style="western"><surname>Ramesh</surname><given-names>R</given-names></name><name name-style="western"><surname>Jayachandran</surname><given-names>G</given-names></name><etal/></person-group><article-title>Phase I clinical trial of systemically administeredTUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans</article-title>. <source>PloS One</source> (<year>2012</year>) <volume>7</volume>(<issue>4</issue>):<elocation-id>e34833</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0034833</pub-id><pub-id pub-id-type="pmid">22558101</pub-id><pub-id pub-id-type="pmcid">PMC3338819</pub-id></mixed-citation></ref><ref id="B210"><label>210</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>EA</given-names></name><name name-style="western"><surname>Moloney</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name><name name-style="western"><surname>Au-Yeung</surname><given-names>A</given-names></name><name name-style="western"><surname>China</surname><given-names>C</given-names></name><name name-style="western"><surname>Scolyer</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: A phase 1 first-in-human trial (DISCOVER)</article-title>. <source>Lancet</source> (<year>2013</year>) <volume>381</volume>:<page-range>1835&#8211;43</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(12)62166-7</pub-id><pub-id pub-id-type="pmcid">PMC3951714</pub-id><pub-id pub-id-type="pmid">23660123</pub-id></mixed-citation></ref><ref id="B211"><label>211</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>R</given-names></name><name name-style="western"><surname>Mcarthur</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Baze</surname><given-names>W</given-names></name><name name-style="western"><surname>Barnhart</surname><given-names>K</given-names></name><name name-style="western"><surname>Wu</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Preclinical mammalian safety studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)</article-title>. <source>Mol Cancer Ther</source> (<year>2017</year>) <volume>16</volume>:<page-range>1114&#8211;23</page-range>. &#160;<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-16-0541</pub-id><pub-id pub-id-type="pmcid">PMC5457703</pub-id><pub-id pub-id-type="pmid">28265009</pub-id></mixed-citation></ref><ref id="B212"><label>212</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porter</surname><given-names>DL</given-names></name><name name-style="western"><surname>Levine</surname><given-names>BL</given-names></name><name name-style="western"><surname>Kalos</surname><given-names>M</given-names></name><name name-style="western"><surname>Bagg</surname><given-names>A</given-names></name><name name-style="western"><surname>June</surname><given-names>CH</given-names></name></person-group><article-title>Chimeric Antigen Receptor&#8211;Modified T Cells in Chronic Lymphoid Leukemia</article-title>. <source>N Engl J Med</source> (<year>2011</year>) <volume>365</volume>:<page-range>725&#8211;33</page-range>. &#160;<pub-id pub-id-type="doi">10.1056/NEJMoa1103849</pub-id><pub-id pub-id-type="pmcid">PMC3387277</pub-id><pub-id pub-id-type="pmid">21830940</pub-id></mixed-citation></ref><ref id="B213"><label>213</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stadler</surname><given-names>CR</given-names></name><name name-style="western"><surname>B&#228;hr-Mahmud</surname><given-names>H</given-names></name><name name-style="western"><surname>Celik</surname><given-names>L</given-names></name><name name-style="western"><surname>Hebich</surname><given-names>B</given-names></name><name name-style="western"><surname>Roth</surname><given-names>AS</given-names></name><name name-style="western"><surname>Roth</surname><given-names>RP</given-names></name><etal/></person-group><article-title>Elimination of large tumors in mice by mRNA-encoded bispecific antibodies</article-title>. <source>Nat Med</source> (<year>2017</year>) <volume>23</volume>:<page-range>815&#8211;7</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/nm.4356</pub-id><pub-id pub-id-type="pmid">28604701</pub-id></mixed-citation></ref><ref id="B214"><label>214</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilgenhof</surname><given-names>S</given-names></name><name name-style="western"><surname>Van Nuffel</surname><given-names>AMT</given-names></name><name name-style="western"><surname>Benteyn</surname><given-names>D</given-names></name><name name-style="western"><surname>Corthals</surname><given-names>J</given-names></name><name name-style="western"><surname>Aerts</surname><given-names>C</given-names></name><name name-style="western"><surname>Heirman</surname><given-names>C</given-names></name><etal/></person-group><article-title>A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients</article-title>. <source>Ann Oncol</source> (<year>2013</year>) <volume>24</volume>:<page-range>2686&#8211;93</page-range>. &#160;<pub-id pub-id-type="doi">10.1093/annonc/mdt245</pub-id><pub-id pub-id-type="pmid">23904461</pub-id></mixed-citation></ref><ref id="B215"><label>215</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kranz</surname><given-names>LM</given-names></name><name name-style="western"><surname>Diken</surname><given-names>M</given-names></name><name name-style="western"><surname>Haas</surname><given-names>H</given-names></name><name name-style="western"><surname>Kreiter</surname><given-names>S</given-names></name><name name-style="western"><surname>Loquai</surname><given-names>C</given-names></name><name name-style="western"><surname>Reuter</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy</article-title>. <source>Nature</source> (<year>2016</year>) <volume>534</volume>:<fpage>396</fpage>&#8211;<lpage>401</lpage>. &#160;<pub-id pub-id-type="doi">10.1038/nature18300</pub-id><pub-id pub-id-type="pmid">27281205</pub-id></mixed-citation></ref><ref id="B216"><label>216</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNamara</surname><given-names>MA</given-names></name><name name-style="western"><surname>Nair</surname><given-names>SK</given-names></name><name name-style="western"><surname>Holl</surname><given-names>EK</given-names></name></person-group><article-title>RNA-Based Vaccines in Cancer Immunotherapy</article-title>. <source>J Immunol Res</source> (<year>2015</year>) <volume>2015</volume>:<elocation-id>794528</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1155/2015/794528</pub-id><pub-id pub-id-type="pmid">26665011</pub-id><pub-id pub-id-type="pmcid">PMC4668311</pub-id></mixed-citation></ref><ref id="B217"><label>217</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sayour</surname><given-names>EJ</given-names></name><name name-style="western"><surname>De Leon</surname><given-names>G</given-names></name><name name-style="western"><surname>Pham</surname><given-names>C</given-names></name><name name-style="western"><surname>Grippin</surname><given-names>A</given-names></name><name name-style="western"><surname>Kemeny</surname><given-names>H</given-names></name><name name-style="western"><surname>Chua</surname><given-names>J</given-names></name><etal/></person-group><article-title>Systemic activation of antigen-presenting cells via RNA-Loadednanoparticles</article-title>. <source>Oncoimmunology</source> (<year>2017</year>) <volume>6</volume>(<issue>1</issue>):<elocation-id>e1256527</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1080/2162402X.2016.1256527</pub-id><pub-id pub-id-type="pmid">28197373</pub-id><pub-id pub-id-type="pmcid">PMC5283636</pub-id></mixed-citation></ref><ref id="B218"><label>218</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilgenhof</surname><given-names>S</given-names></name><name name-style="western"><surname>Corthals</surname><given-names>J</given-names></name><name name-style="western"><surname>Heirman</surname><given-names>C</given-names></name><name name-style="western"><surname>Van Baren</surname><given-names>N</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>S</given-names></name><name name-style="western"><surname>Kvistborg</surname><given-names>P</given-names></name><etal/></person-group><article-title>Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patientswith pretreated advanced melanoma</article-title>. <source>J Clin Oncol</source> (<year>2016</year>) <volume>34</volume>:<page-range>1330&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.1200/JCO.2015.63.4121</pub-id><pub-id pub-id-type="pmid">26926680</pub-id></mixed-citation></ref><ref id="B219"><label>219</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Miao</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name></person-group><article-title>mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma</article-title>. <source>Mol Ther</source> (<year>2018</year>) <volume>26</volume>:<page-range>420&#8211;34</page-range>. <pub-id pub-id-type="doi">10.1016/j.ymthe.2017.11.009</pub-id><pub-id pub-id-type="pmcid">PMC5835019</pub-id><pub-id pub-id-type="pmid">29249397</pub-id></mixed-citation></ref><ref id="B220"><label>220</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>YS</given-names></name><name name-style="western"><surname>Sansanaphongpricha</surname><given-names>K</given-names></name><name name-style="western"><surname>Prince</surname><given-names>MEP</given-names></name><name name-style="western"><surname>Sun</surname><given-names>D</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>GT</given-names></name><name name-style="western"><surname>Lei</surname><given-names>YL</given-names></name></person-group><article-title>Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer</article-title>. <source>J Dent Res</source> (<year>2018</year>) <volume>97</volume>:<page-range>627&#8211;34</page-range>. &#160;<pub-id pub-id-type="doi">10.1177/0022034518764416</pub-id><pub-id pub-id-type="pmcid">PMC5960883</pub-id><pub-id pub-id-type="pmid">29533731</pub-id></mixed-citation></ref><ref id="B221"><label>221</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mastelic-Gavillet</surname><given-names>B</given-names></name><name name-style="western"><surname>Balint</surname><given-names>K</given-names></name><name name-style="western"><surname>Boudousquie</surname><given-names>C</given-names></name><name name-style="western"><surname>Gannon</surname><given-names>PO</given-names></name><name name-style="western"><surname>Kandalaft</surname><given-names>LE</given-names></name></person-group><article-title>Personalized dendritic cell vaccines-recent breakthroughs andencouraging clinical results</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>766</elocation-id>. &#160;<pub-id pub-id-type="doi">10.3389/fimmu.2019.00766</pub-id><pub-id pub-id-type="pmid">31031762</pub-id><pub-id pub-id-type="pmcid">PMC6470191</pub-id></mixed-citation></ref><ref id="B222"><label>222</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollard</surname><given-names>C</given-names></name><name name-style="western"><surname>De Koker</surname><given-names>S</given-names></name><name name-style="western"><surname>Saelens</surname><given-names>X</given-names></name><name name-style="western"><surname>Vanham</surname><given-names>G</given-names></name><name name-style="western"><surname>Grooten</surname><given-names>J</given-names></name></person-group><article-title>Challenges and advances towards the rational design of mRNA vaccines</article-title>. <source>Trends Mol Med</source> (<year>2013</year>) <volume>19</volume>:<page-range>705&#8211;13</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.molmed.2013.09.002</pub-id><pub-id pub-id-type="pmid">24138818</pub-id></mixed-citation></ref><ref id="B223"><label>223</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becker</surname><given-names>PD</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>CA</given-names></name></person-group><article-title>Rational design of vaccination strategies to promote antigen entryinto the MHC class I-restricted presentation pathway</article-title>. <source>Transfus MedHemother</source> (<year>2017</year>) <volume>77</volume>:<fpage>398</fpage>&#8211;<lpage>411</lpage>. &#160;<pub-id pub-id-type="doi">10.1159/000082484</pub-id></mixed-citation></ref><ref id="B224"><label>224</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatti-Mays</surname><given-names>ME</given-names></name><name name-style="western"><surname>Redman</surname><given-names>JM</given-names></name><name name-style="western"><surname>Collins</surname><given-names>JM</given-names></name><name name-style="western"><surname>Bilusic</surname><given-names>M</given-names></name></person-group><article-title>Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations</article-title>. <source>Hum Vaccines Immunother</source> (<year>2017</year>) <volume>13</volume>:<page-range>2561&#8211;74</page-range>. &#160;<pub-id pub-id-type="doi">10.1080/21645515.2017.1364322</pub-id><pub-id pub-id-type="pmcid">PMC5703410</pub-id><pub-id pub-id-type="pmid">28857666</pub-id></mixed-citation></ref><ref id="B225"><label>225</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vermaelen</surname><given-names>K</given-names></name></person-group><article-title>Vaccine strategies to improve anticancer cellular immuneresponses</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>8</elocation-id>. &#160;<pub-id pub-id-type="doi">10.3389/fimmu.2019.00008</pub-id><pub-id pub-id-type="pmid">30723469</pub-id><pub-id pub-id-type="pmcid">PMC6349827</pub-id></mixed-citation></ref><ref id="B226"><label>226</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez</surname><given-names>CR</given-names></name><name name-style="western"><surname>De Palma</surname><given-names>M</given-names></name></person-group><article-title>Engineering dendritic cell vaccines to improve cancerimmunotherapy</article-title>. <source>Nat Commun</source> (<year>2019</year>) <volume>10</volume>:<fpage>5408</fpage>. &#160;<pub-id pub-id-type="doi">10.1038/s41467-019-13368-y</pub-id><pub-id pub-id-type="pmid">31776331</pub-id><pub-id pub-id-type="pmcid">PMC6881351</pub-id></mixed-citation></ref><ref id="B227"><label>227</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sander</surname><given-names>AF</given-names></name><name name-style="western"><surname>Lollini</surname><given-names>P-L</given-names></name></person-group><article-title>Virus-like antigen display for cancer vaccine development, what is the potential</article-title>? <source>Expert Rev Vaccines</source> (<year>2018</year>) <volume>17</volume>:<page-range>285&#8211;8</page-range>. &#160;<pub-id pub-id-type="doi">10.1080/14760584.2018.1455505</pub-id><pub-id pub-id-type="pmid">29560746</pub-id></mixed-citation></ref><ref id="B228"><label>228</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>R</given-names></name><name name-style="western"><surname>Umeano</surname><given-names>AC</given-names></name><name name-style="western"><surname>Kou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Farooqi</surname><given-names>AA</given-names></name></person-group><article-title>Nanoparticle systems for cancer vaccine</article-title>. <source>Nanomedicine</source> (<year>2019</year>) <volume>8</volume>:<page-range>627&#8211;48</page-range>. &#160;<pub-id pub-id-type="doi">10.2217/nnm-2018-0147</pub-id><pub-id pub-id-type="pmcid">PMC6439506</pub-id><pub-id pub-id-type="pmid">30806568</pub-id></mixed-citation></ref><ref id="B229"><label>229</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butts</surname><given-names>C</given-names></name><name name-style="western"><surname>Socinski</surname><given-names>MA</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>PL</given-names></name><name name-style="western"><surname>Thatcher</surname><given-names>N</given-names></name><name name-style="western"><surname>Havel</surname><given-names>L</given-names></name><name name-style="western"><surname>Krzakowski</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial</article-title>. <source>Lancet Oncol</source> (<year>2014</year>) <volume>15</volume>:<fpage>59</fpage>&#8211;<lpage>68</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/S1470-2045(13)70510-2</pub-id><pub-id pub-id-type="pmid">24331154</pub-id></mixed-citation></ref><ref id="B230"><label>230</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosalia</surname><given-names>RA</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>LJ</given-names></name><name name-style="western"><surname>van Duikeren</surname><given-names>S</given-names></name><name name-style="western"><surname>Tromp</surname><given-names>AT</given-names></name><name name-style="western"><surname>Silva</surname><given-names>AL</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W</given-names></name><etal/></person-group><article-title>CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses</article-title>. <source>Biomaterials</source> (<year>2015</year>) <volume>40</volume>:<fpage>88</fpage>&#8211;<lpage>97</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.10.053</pub-id><pub-id pub-id-type="pmid">25465442</pub-id></mixed-citation></ref><ref id="B231"><label>231</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schuster</surname><given-names>J</given-names></name><name name-style="western"><surname>Lai</surname><given-names>RK</given-names></name><name name-style="western"><surname>Recht</surname><given-names>LD</given-names></name><name name-style="western"><surname>Reardon</surname><given-names>DA</given-names></name><name name-style="western"><surname>Paleologos</surname><given-names>NA</given-names></name><name name-style="western"><surname>Groves</surname><given-names>MD</given-names></name><etal/></person-group><article-title>multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: The ACT III study</article-title>. <source>Neuro Oncol</source> (<year>2015</year>) <volume>17</volume>:<page-range>854&#8211;61</page-range>. &#160;<pub-id pub-id-type="doi">10.1093/neuonc/nou348</pub-id><pub-id pub-id-type="pmcid">PMC4483122</pub-id><pub-id pub-id-type="pmid">25586468</pub-id></mixed-citation></ref><ref id="B232"><label>232</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riabov</surname><given-names>V</given-names></name><name name-style="western"><surname>Tretyakova</surname><given-names>I</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>RB</given-names></name><name name-style="western"><surname>Pushko</surname><given-names>P</given-names></name><name name-style="western"><surname>Klyushnenkova</surname><given-names>EN</given-names></name></person-group><article-title>Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer</article-title>. <source>Vaccine</source> (<year>2015</year>) <volume>33</volume>:<page-range>5386&#8211;95</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.08.062</pub-id><pub-id pub-id-type="pmcid">PMC4581984</pub-id><pub-id pub-id-type="pmid">26319744</pub-id></mixed-citation></ref><ref id="B233"><label>233</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singer</surname><given-names>C</given-names></name><name name-style="western"><surname>Pfeiler</surname><given-names>G</given-names></name><name name-style="western"><surname>Hubalek</surname><given-names>M</given-names></name><name name-style="western"><surname>Bartsch</surname><given-names>R</given-names></name><name name-style="western"><surname>Stoeger</surname><given-names>H</given-names></name><name name-style="western"><surname>Pichler</surname><given-names>A</given-names></name><etal/></person-group><article-title>Efficacy and safety of the therapeutic cancervaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized,neoadjuvant phase-II study (ABCSG-34)</article-title>. <source>Eur J Cancer</source> (<year>2020</year>) <volume>132</volume>:<fpage>43</fpage>&#8211;<lpage>52</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.ejca.2020.03.018</pub-id><pub-id pub-id-type="pmid">32325419</pub-id></mixed-citation></ref><ref id="B234"><label>234</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varypataki</surname><given-names>EM</given-names></name><name name-style="western"><surname>Benne</surname><given-names>N</given-names></name><name name-style="western"><surname>Bouwstra</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W</given-names></name><name name-style="western"><surname>Ossendorp</surname><given-names>F</given-names></name></person-group><article-title>Efficient eradication of established tumors in mice with cationic liposome-based synthetic long-peptide vaccines</article-title>. <source>Cancer Immunol Res</source> (<year>2017</year>) <volume>5</volume>:<page-range>222&#8211;33</page-range>. &#160;<pub-id pub-id-type="doi">10.1158/2326-6066.CIR-16-0283</pub-id><pub-id pub-id-type="pmid">28143806</pub-id></mixed-citation></ref><ref id="B235"><label>235</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zupan&#269;i&#269;</surname><given-names>E</given-names></name><name name-style="western"><surname>Curato</surname><given-names>C</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JS</given-names></name><name name-style="western"><surname>Yeini</surname><given-names>E</given-names></name><name name-style="western"><surname>Porat</surname><given-names>Z</given-names></name><name name-style="western"><surname>Viana</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer</article-title>. <source>Nanomed Nanotechnol Biol Med</source> (<year>2018</year>) <volume>14</volume>:<page-range>835&#8211;47</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.nano.2017.12.011</pub-id><pub-id pub-id-type="pmid">29306001</pub-id></mixed-citation></ref><ref id="B236"><label>236</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanley</surname><given-names>M</given-names></name></person-group><article-title>Tumour virus vaccines: Hepatitis B virus and humanpapillomavirus</article-title>. <source>Philos Trans R Soc B Biol Sci</source> (<year>2017</year>) <volume>372</volume>:<elocation-id>20160268</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1098/rstb.2016.0268</pub-id><pub-id pub-id-type="pmcid">PMC5597735</pub-id><pub-id pub-id-type="pmid">28893935</pub-id></mixed-citation></ref><ref id="B237"><label>237</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tegerstedt</surname><given-names>K</given-names></name><name name-style="western"><surname>Lindencrona</surname><given-names>JA</given-names></name><name name-style="western"><surname>Curcio</surname><given-names>C</given-names></name><name name-style="western"><surname>Andreasson</surname><given-names>K</given-names></name><name name-style="western"><surname>Tullus</surname><given-names>C</given-names></name><name name-style="western"><surname>Forni</surname><given-names>G</given-names></name><etal/></person-group><article-title>A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors</article-title>. <source>Cancer Res</source> (<year>2005</year>) <volume>65</volume>:<page-range>5953&#8211;7</page-range>. &#160;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-0335</pub-id><pub-id pub-id-type="pmid">15994974</pub-id></mixed-citation></ref><ref id="B238"><label>238</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tegerstedt</surname><given-names>K</given-names></name><name name-style="western"><surname>Franz&#233;n</surname><given-names>A</given-names></name><name name-style="western"><surname>Ramqvist</surname><given-names>T</given-names></name><name name-style="western"><surname>Dalianis</surname><given-names>T</given-names></name></person-group><article-title>Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2/neu expressing tumor</article-title>. <source>Cancer Immunol Immunother</source> (<year>2007</year>) <volume>56</volume>:<page-range>1335&#8211;44</page-range>. &#160;<pub-id pub-id-type="doi">10.1007/s00262-007-0281-8</pub-id><pub-id pub-id-type="pmcid">PMC11031012</pub-id><pub-id pub-id-type="pmid">17268793</pub-id></mixed-citation></ref><ref id="B239"><label>239</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andreasson</surname><given-names>K</given-names></name><name name-style="western"><surname>Tegerstedt</surname><given-names>K</given-names></name><name name-style="western"><surname>Eriksson</surname><given-names>M</given-names></name><name name-style="western"><surname>Curcio</surname><given-names>C</given-names></name><name name-style="western"><surname>Cavallo</surname><given-names>F</given-names></name><name name-style="western"><surname>Forni</surname><given-names>G</given-names></name><etal/></person-group><article-title>Murine pneumotropic virus chimeric Her2/ <italic toggle="yes">neu</italic> virus-like particles as prophylactic and therapeutic vaccines against Her2/ <italic toggle="yes">neu</italic> expressing tumors</article-title>. <source>Int J Cancer</source> (<year>2009</year>) <volume>124</volume>:<page-range>150&#8211;6</page-range>. &#160;<pub-id pub-id-type="doi">10.1002/ijc.23920</pub-id><pub-id pub-id-type="pmid">18839427</pub-id></mixed-citation></ref><ref id="B240"><label>240</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jalali</surname><given-names>SA</given-names></name><name name-style="western"><surname>Sankian</surname><given-names>M</given-names></name><name name-style="western"><surname>Tavakkol-Afshari</surname><given-names>J</given-names></name><name name-style="western"><surname>Jaafari</surname><given-names>MR</given-names></name></person-group><article-title>Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles</article-title>. <source>Nanomed Nanotechnol Biol Med</source> (<year>2012</year>) <volume>8</volume>:<fpage>692</fpage>&#8211;<lpage>701</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.nano.2011.09.010</pub-id><pub-id pub-id-type="pmid">22024191</pub-id></mixed-citation></ref><ref id="B241"><label>241</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singer</surname><given-names>J</given-names></name><name name-style="western"><surname>Manzano-Szalai</surname><given-names>K</given-names></name><name name-style="western"><surname>Fazekas</surname><given-names>J</given-names></name><name name-style="western"><surname>Thell</surname><given-names>K</given-names></name><name name-style="western"><surname>Bentley-Lukschal</surname><given-names>A</given-names></name><name name-style="western"><surname>Stremnitzer</surname><given-names>C</given-names></name><etal/></person-group><article-title>Proof of concept study with an HER-2 mimotope anticancer vaccinededuced from a novel AAV-mimotope library platform</article-title>. <source>Oncoimmunology</source> (<year>2016</year>) <volume>5</volume>(<issue>7</issue>):<elocation-id>e1171446</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1080/2162402X.2016.1171446</pub-id><pub-id pub-id-type="pmid">27622022</pub-id><pub-id pub-id-type="pmcid">PMC5006910</pub-id></mixed-citation></ref><ref id="B242"><label>242</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shukla</surname><given-names>S</given-names></name><name name-style="western"><surname>Myers</surname><given-names>JT</given-names></name><name name-style="western"><surname>Woods</surname><given-names>SE</given-names></name><name name-style="western"><surname>Gong</surname><given-names>X</given-names></name><name name-style="western"><surname>Czapar</surname><given-names>AE</given-names></name><name name-style="western"><surname>Commandeur</surname><given-names>U</given-names></name><etal/></person-group><article-title>Plant viral nanoparticles-based HER2 vaccine: Immune response influenced by differential transport, localization and cellular interactions of particulate carriers</article-title>. <source>Biomaterials</source> (<year>2017</year>) <volume>121</volume>:<fpage>15</fpage>&#8211;<lpage>27</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.biomaterials.2016.12.030</pub-id><pub-id pub-id-type="pmid">28063980</pub-id></mixed-citation></ref><ref id="B243"><label>243</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arab</surname><given-names>A</given-names></name><name name-style="western"><surname>Nicastro</surname><given-names>J</given-names></name><name name-style="western"><surname>Slavcev</surname><given-names>R</given-names></name><name name-style="western"><surname>Razazan</surname><given-names>A</given-names></name><name name-style="western"><surname>Barati</surname><given-names>N</given-names></name><name name-style="western"><surname>Nikpoor</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8+ T response</article-title>. <source>Immunol Res</source> (<year>2018</year>) <volume>66</volume>:<page-range>200&#8211;6</page-range>. &#160;<pub-id pub-id-type="doi">10.1007/s12026-017-8969-0</pub-id><pub-id pub-id-type="pmid">29143917</pub-id></mixed-citation></ref><ref id="B244"><label>244</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palladini</surname><given-names>A</given-names></name><name name-style="western"><surname>Thrane</surname><given-names>S</given-names></name><name name-style="western"><surname>Janitzek</surname><given-names>CM</given-names></name><name name-style="western"><surname>Pihl</surname><given-names>J</given-names></name><name name-style="western"><surname>Clemmensen</surname><given-names>SB</given-names></name><name name-style="western"><surname>de Jongh</surname><given-names>WA</given-names></name><etal/></person-group><article-title>Virus-like particle display of HER2 induces potent anti-cancerresponses</article-title>. <source>Oncoimmunology</source> (<year>2018</year>) <volume>7</volume>(<issue>3</issue>):<elocation-id>e1408749</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1080/2162402X.2017.1408749</pub-id><pub-id pub-id-type="pmid">29399414</pub-id><pub-id pub-id-type="pmcid">PMC5790387</pub-id></mixed-citation></ref><ref id="B245"><label>245</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiedermann</surname><given-names>U</given-names></name><name name-style="western"><surname>Wiltschke</surname><given-names>C</given-names></name><name name-style="western"><surname>Jasinska</surname><given-names>J</given-names></name><name name-style="western"><surname>Kundi</surname><given-names>M</given-names></name><name name-style="western"><surname>Zurbriggen</surname><given-names>R</given-names></name><name name-style="western"><surname>Garner-Spitzer</surname><given-names>E</given-names></name><etal/></person-group><article-title>A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: A phase i study</article-title>. <source>Breast Cancer Res Treat</source> (<year>2010</year>) <volume>119</volume>:<page-range>673&#8211;83</page-range>. &#160;<pub-id pub-id-type="doi">10.1007/s10549-009-0666-9</pub-id><pub-id pub-id-type="pmid">20092022</pub-id></mixed-citation></ref><ref id="B246"><label>246</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mason</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Gnanandarajah</surname><given-names>JS</given-names></name><name name-style="western"><surname>Engiles</surname><given-names>JB</given-names></name><name name-style="western"><surname>Gray</surname><given-names>F</given-names></name><name name-style="western"><surname>Laughlin</surname><given-names>D</given-names></name><name name-style="western"><surname>Gaurnier-Hausser</surname><given-names>A</given-names></name><etal/></person-group><article-title>Immunotherapy with a HER2-Targeting listeria induces HER2-Specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma</article-title>. <source>Clin Cancer Res</source> (<year>2016</year>) <volume>22</volume>:<page-range>4380&#8211;90</page-range>. &#160;<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-0088</pub-id><pub-id pub-id-type="pmid">26994144</pub-id></mixed-citation></ref><ref id="B247"><label>247</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lizotte</surname><given-names>PH</given-names></name><name name-style="western"><surname>Wen</surname><given-names>AM</given-names></name><name name-style="western"><surname>Sheen</surname><given-names>MR</given-names></name><name name-style="western"><surname>Fields</surname><given-names>J</given-names></name><name name-style="western"><surname>Rojanasopondist</surname><given-names>P</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>NF</given-names></name><etal/></person-group><article-title>In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer</article-title>. <source>Nat Nanotechnol</source> (<year>2016</year>) <volume>11</volume>:<fpage>295</fpage>&#8211;<lpage>303</lpage>. &#160;<pub-id pub-id-type="doi">10.1038/nnano.2015.292</pub-id><pub-id pub-id-type="pmid">26689376</pub-id><pub-id pub-id-type="pmcid">PMC4777632</pub-id></mixed-citation></ref><ref id="B248"><label>248</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neek</surname><given-names>M</given-names></name><name name-style="western"><surname>Il</surname><given-names>KT</given-names></name><name name-style="western"><surname>Wang</surname><given-names>SW</given-names></name></person-group><article-title>Protein-based nanoparticles in cancer vaccine development</article-title>. <source>Nanomed Nanotechnol Biol Med</source> (<year>2019</year>) <volume>15</volume>:<page-range>164&#8211;74</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.nano.2018.09.004</pub-id><pub-id pub-id-type="pmcid">PMC6289732</pub-id><pub-id pub-id-type="pmid">30291897</pub-id></mixed-citation></ref><ref id="B249"><label>249</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>List of Blueprint priority diseases</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.emro.who.int/pandemic-epidemic-diseases/news/list-of-blueprint-priority-diseases.html">http://www.emro.who.int/pandemic-epidemic-diseases/news/list-of-blueprint-priority-diseases.html</uri> (<year>2018</year>).</mixed-citation></ref><ref id="B250"><label>250</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isanaka</surname><given-names>S</given-names></name><name name-style="western"><surname>Guindo</surname><given-names>O</given-names></name><name name-style="western"><surname>Langendorf</surname><given-names>C</given-names></name><name name-style="western"><surname>Matar Seck</surname><given-names>A</given-names></name><name name-style="western"><surname>Plikaytis</surname><given-names>BD</given-names></name><name name-style="western"><surname>Sayinzoga-Makombe</surname><given-names>N</given-names></name><etal/></person-group><article-title>Efficacy of a Low-Cost, Heat-Stable Oral Rotavirus Vaccine in Niger</article-title>. <source>N Engl J Med</source> (<year>2017</year>) <volume>376</volume>:<page-range>1121&#8211;30</page-range>. &#160;<pub-id pub-id-type="doi">10.1056/NEJMoa1609462</pub-id><pub-id pub-id-type="pmid">28328346</pub-id></mixed-citation></ref><ref id="B251"><label>251</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Fda, Cber</collab></person-group> . Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/133748/download">https://www.fda.gov/media/133748/download</uri> (Accessed <date-in-citation>September 1, 2020</date-in-citation>).</mixed-citation></ref><ref id="B252"><label>252</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kis</surname><given-names>Z</given-names></name><name name-style="western"><surname>Shattock</surname><given-names>R</given-names></name><name name-style="western"><surname>Shah</surname><given-names>N</given-names></name><name name-style="western"><surname>Kontoravdi</surname><given-names>C</given-names></name></person-group><article-title>Emerging Technologies for Low-Cost, Rapid VaccineManufacture</article-title>. <source>Biotechnol J</source> (<year>2019</year>) <volume>14</volume>:<fpage>1</fpage>&#8211;<lpage>14</lpage>. &#160;<pub-id pub-id-type="doi">10.1002/biot.201800376</pub-id><pub-id pub-id-type="pmid">31286673</pub-id></mixed-citation></ref><ref id="B253"><label>253</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berlanda Scorza</surname><given-names>F</given-names></name><name name-style="western"><surname>Tsvetnitsky</surname><given-names>V</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>JJ</given-names></name></person-group><article-title>Universal influenza vaccines: Shifting to better vaccines</article-title>. <source>Vaccine</source> (<year>2016</year>) <volume>34</volume>:<page-range>2926&#8211;33</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/J.VACCINE.2016.03.085</pub-id><pub-id pub-id-type="pmcid">PMC4899887</pub-id><pub-id pub-id-type="pmid">27038130</pub-id></mixed-citation></ref><ref id="B254"><label>254</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilbert</surname><given-names>SC</given-names></name><name name-style="western"><surname>Warimwe</surname><given-names>GM</given-names></name></person-group><article-title>Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology</article-title>. <source>Vaccine</source> (<year>2017</year>) <volume>35</volume>:<page-range>4461&#8211;4</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/J.VACCINE.2017.04.085</pub-id><pub-id pub-id-type="pmcid">PMC5571606</pub-id><pub-id pub-id-type="pmid">28576573</pub-id></mixed-citation></ref><ref id="B255"><label>255</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Diazgranados</surname><given-names>C</given-names></name><name name-style="western"><surname>Janes</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>DeCamp</surname><given-names>AC</given-names></name><name name-style="western"><surname>Metch</surname><given-names>B</given-names></name><etal/></person-group><article-title>Selection of HIV vaccine candidates for concurrent testing in an efficacy trial</article-title>. <source>Curr Opin Virol</source> (<year>2016</year>) <volume>17</volume>:<fpage>57</fpage>&#8211;<lpage>65</lpage>. &#160;<pub-id pub-id-type="doi">10.1016/j.coviro.2016.01.007</pub-id><pub-id pub-id-type="pmid">26827165</pub-id><pub-id pub-id-type="pmcid">PMC4902743</pub-id></mixed-citation></ref><ref id="B256"><label>256</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warimwe</surname><given-names>GM</given-names></name><name name-style="western"><surname>Gesharisha</surname><given-names>J</given-names></name><name name-style="western"><surname>Carr</surname><given-names>BV</given-names></name><name name-style="western"><surname>Otieno</surname><given-names>S</given-names></name><name name-style="western"><surname>Otingah</surname><given-names>K</given-names></name><name name-style="western"><surname>Wright</surname><given-names>D</given-names></name><etal/></person-group><article-title>Chimpanzee adenovirus vaccine provides multispecies protectionagainst rift valley fever</article-title>. <source>Sci Rep</source> (<year>2016</year>) <volume>6</volume>:<elocation-id>20617</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1038/srep20617</pub-id><pub-id pub-id-type="pmid">26847478</pub-id><pub-id pub-id-type="pmcid">PMC4742904</pub-id></mixed-citation></ref><ref id="B257"><label>257</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plotkin</surname><given-names>SA</given-names></name></person-group><article-title>Vaccines for epidemic infections and the role of CEPI</article-title>. <source>Hum Vaccin Immunother</source> (<year>2017</year>) <volume>13</volume>:<page-range>2755&#8211;62</page-range>. &#160;<pub-id pub-id-type="doi">10.1080/21645515.2017.1306615</pub-id><pub-id pub-id-type="pmcid">PMC5718831</pub-id><pub-id pub-id-type="pmid">28375764</pub-id></mixed-citation></ref><ref id="B258"><label>258</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seib</surname><given-names>K</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>AJ</given-names></name><name name-style="western"><surname>de Wals</surname><given-names>P</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>RM</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>F</given-names></name><name name-style="western"><surname>Hatchett</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Policy making for vaccine use as a driver of vaccine innovation and development in the developed world</article-title>. <source>Vaccine</source> (<year>2017</year>) <volume>35</volume>:<page-range>1380&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/J.VACCINE.2016.10.080</pub-id><pub-id pub-id-type="pmid">28253995</pub-id></mixed-citation></ref><ref id="B259"><label>259</label><mixed-citation publication-type="webpage"><source>172 countries &amp; multiple candidate vaccines engaged in COVID-19 Vaccine Global Access Facility &#8211; CEPI</source> . Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cepi.net/news_cepi/172-countries-multiple-candidate-vaccines-engaged-in-covid-19-vaccine-global-access-facility/">https://cepi.net/news_cepi/172-countries-multiple-candidate-vaccines-engaged-in-covid-19-vaccine-global-access-facility/</uri> (Accessed <date-in-citation>September 1, 2020</date-in-citation>).</mixed-citation></ref><ref id="B260"><label>260</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>NC</given-names></name><name name-style="western"><surname>Lv</surname><given-names>H</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Paulson</surname><given-names>JC</given-names></name><name name-style="western"><surname>Mok</surname><given-names>CKP</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>IA</given-names></name></person-group><article-title>Preventing an Antigenically Disruptive Mutation in Egg-Based H3N2 Seasonal Influenza Vaccines by Mutational Incompatibility</article-title>. <source>Cell Host Microbe</source> (<year>2019</year>) <volume>25</volume>:<page-range>836&#8211;44</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.chom.2019.04.013</pub-id><pub-id pub-id-type="pmcid">PMC6579542</pub-id><pub-id pub-id-type="pmid">31151913</pub-id></mixed-citation></ref><ref id="B261"><label>261</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>BS</given-names></name><name name-style="western"><surname>Mascola</surname><given-names>JR</given-names></name><name name-style="western"><surname>Fauci</surname><given-names>AS</given-names></name></person-group><article-title>Novel vaccine technologies: Essential Components of an AdequateResponse to Emerging Viral Diseases</article-title>. <source>JAMA</source> (<year>2018</year>) <volume>319</volume>:<fpage>1431</fpage>. &#160;<pub-id pub-id-type="doi">10.1001/jama.2018.0345</pub-id><pub-id pub-id-type="pmid">29566112</pub-id></mixed-citation></ref><ref id="B262"><label>262</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lurie</surname><given-names>N</given-names></name><name name-style="western"><surname>Saville</surname><given-names>M</given-names></name><name name-style="western"><surname>Hatchett</surname><given-names>R</given-names></name><name name-style="western"><surname>Halton</surname><given-names>J</given-names></name></person-group><article-title>Developing Covid-19 Vaccines at Pandemic Speed</article-title>. <source>N Engl J Med</source> (<year>2020</year>) <volume>382</volume>:<page-range>1969&#8211;73</page-range>. &#160;<pub-id pub-id-type="doi">10.1056/NEJMp2005630</pub-id><pub-id pub-id-type="pmid">32227757</pub-id></mixed-citation></ref><ref id="B263"><label>263</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>WH</given-names></name><name name-style="western"><surname>Strych</surname><given-names>U</given-names></name><name name-style="western"><surname>Hotez</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Bottazzi</surname><given-names>ME</given-names></name></person-group><article-title>The SARS-CoV-2 Vaccine Pipeline: an Overview</article-title>. <source>Curr Trop Med Rep</source> (<year>2020</year>) <volume>7</volume>:<page-range>61&#8211;4</page-range>. &#160;<pub-id pub-id-type="doi">10.1007/s40475-020-00201-6</pub-id><pub-id pub-id-type="pmcid">PMC7094941</pub-id><pub-id pub-id-type="pmid">32219057</pub-id></mixed-citation></ref><ref id="B264"><label>264</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amanat</surname><given-names>F</given-names></name><name name-style="western"><surname>Krammer</surname><given-names>F</given-names></name></person-group><article-title>SARS-CoV-2 Vaccines: Status Report</article-title>. <source>Immunity</source> (<year>2020</year>) <volume>52</volume>:<page-range>583&#8211;9</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2020.03.007</pub-id><pub-id pub-id-type="pmcid">PMC7136867</pub-id><pub-id pub-id-type="pmid">32259480</pub-id></mixed-citation></ref><ref id="B265"><label>265</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name></person-group><article-title>Don&#8217;t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees</article-title>. <source>Nature</source> (<year>2020</year>) <volume>579</volume>:<fpage>321</fpage>. &#160;<pub-id pub-id-type="doi">10.1038/d41586-020-00751-9</pub-id><pub-id pub-id-type="pmid">32179860</pub-id></mixed-citation></ref><ref id="B266"><label>266</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>H</given-names></name><name name-style="western"><surname>Wu</surname><given-names>NC</given-names></name><name name-style="western"><surname>Mok</surname><given-names>CKP</given-names></name></person-group><article-title>COVID-19 vaccines: knowing the unknown</article-title>. <source>EurJ Immunol</source> (<year>2020</year>) <volume>50</volume>:<page-range>939&#8211;43</page-range>. &#160;<pub-id pub-id-type="doi">10.1002/eji.202048663</pub-id><pub-id pub-id-type="pmcid">PMC7280575</pub-id><pub-id pub-id-type="pmid">32437587</pub-id></mixed-citation></ref><ref id="B267"><label>267</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwasaki</surname><given-names>A</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name></person-group><article-title>The potential danger of suboptimal antibody responses in COVID-19</article-title>. <source>Nat Rev Immunol</source> (<year>2020</year>) <volume>20</volume>:<page-range>339&#8211;41</page-range>. &#160;<pub-id pub-id-type="doi">10.1038/s41577-020-0321-6</pub-id><pub-id pub-id-type="pmcid">PMC7187142</pub-id><pub-id pub-id-type="pmid">32317716</pub-id></mixed-citation></ref><ref id="B268"><label>268</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Usher</surname><given-names>AD</given-names></name></person-group><article-title>COVID-19 vaccines for all</article-title>? <source>Lancet</source> (<year>2020</year>) <volume>395</volume>:<page-range>1822&#8211;3</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/s0140-6736(20)31354-4</pub-id><pub-id pub-id-type="pmcid">PMC7289577</pub-id><pub-id pub-id-type="pmid">32534638</pub-id></mixed-citation></ref><ref id="B269"><label>269</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamey</surname><given-names>G</given-names></name><name name-style="western"><surname>Sch&#228;ferhoff</surname><given-names>M</given-names></name><name name-style="western"><surname>Hatchett</surname><given-names>R</given-names></name><name name-style="western"><surname>Pate</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F</given-names></name><name name-style="western"><surname>McDade</surname><given-names>KK</given-names></name></person-group><article-title>Ensuring global access to COVID-19 vaccines</article-title>. <source>Lancet</source> (<year>2020</year>) <volume>395</volume>:<page-range>1405&#8211;6</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(20)30763-7</pub-id><pub-id pub-id-type="pmcid">PMC7271264</pub-id><pub-id pub-id-type="pmid">32243778</pub-id></mixed-citation></ref><ref id="B270"><label>270</label><mixed-citation publication-type="webpage"><source>Survival of the Most: Why Multiple Vaccines May Be the Best Way to Stop the COVID-19 Pandemic</source> . Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.massgeneral.org/news/coronavirus/research/vaccines/multiple-vaccines-best-way-stop-covid-19-pandemic">https://www.massgeneral.org/news/coronavirus/research/vaccines/multiple-vaccines-best-way-stop-covid-19-pandemic</uri> (Accessed <date-in-citation>August 30, 2020</date-in-citation>).</mixed-citation></ref><ref id="B271"><label>271</label><mixed-citation publication-type="webpage"><source>Multiple vaccines could be needed to fully stop COVID-19 pandemic, UW vaccinologist says - GeekWire</source> . Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.geekwire.com/2020/multiple-vaccines-needed-fully-stop-covid-19-pandemic-uw-vaccinologist-says/">https://www.geekwire.com/2020/multiple-vaccines-needed-fully-stop-covid-19-pandemic-uw-vaccinologist-says/</uri> (Accessed <date-in-citation>August 30, 2020</date-in-citation>).</mixed-citation></ref><ref id="B272"><label>272</label><mixed-citation publication-type="webpage"><source>Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) - Full Text View - ClinicalTrials.gov</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04283461">https://clinicaltrials.gov/ct2/show/NCT04283461</uri> (Accessed <date-in-citation>July 4, 2020</date-in-citation>).</mixed-citation></ref><ref id="B273"><label>273</label><mixed-citation publication-type="webpage"><source>A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults - Full Text View - ClinicalTrials.gov</source> . Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04449276">https://www.clinicaltrials.gov/ct2/show/NCT04449276</uri> (Accessed <date-in-citation>July 4, 2020</date-in-citation>).</mixed-citation></ref><ref id="B274"><label>274</label><mixed-citation publication-type="webpage"><source>A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults - Full Text View - ClinicalTrials.gov</source> . Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04380701">https://clinicaltrials.gov/ct2/show/NCT04380701</uri> (Accessed <date-in-citation>July 4, 2020</date-in-citation>).</mixed-citation></ref><ref id="B275"><label>275</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mulligan</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Lyke</surname><given-names>KE</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>SP</given-names></name><etal/></person-group><article-title>Phase 1/2 Study to Describe the Safety and Immunogenicity of aCOVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report</article-title>. <source>medRxiv</source> (<year>2020</year>) . <pub-id pub-id-type="doi">10.1101/2020.06.30.20142570</pub-id></mixed-citation></ref><ref id="B276"><label>276</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>EE</given-names></name><name name-style="western"><surname>Frenck</surname><given-names>R</given-names></name><name name-style="western"><surname>Falsey</surname><given-names>AR</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name><etal/></person-group><article-title>RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study</article-title>. <source>medRxiv Prepr Serv Heal Sci</source> (<year>2020</year>). &#160;<pub-id pub-id-type="doi">10.1101/2020.08.17.20176651</pub-id>. 2020.08.17.20176651.</mixed-citation></ref><ref id="B277"><label>277</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mulligan</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Lyke</surname><given-names>KE</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name><etal/></person-group><article-title>Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults</article-title>. <source>Nature</source> (<year>2020</year>), <fpage>1</fpage>&#8211;<lpage>8</lpage>. &#160;<pub-id pub-id-type="doi">10.1038/s41586-020-2639-4</pub-id><pub-id pub-id-type="pmid">32785213</pub-id></mixed-citation></ref><ref id="B278"><label>278</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>ISRCTN</collab></person-group><source>ISRCTN17072692: Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women</source> . Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.isrctn.com/ISRCTN17072692">http://www.isrctn.com/ISRCTN17072692</uri> (Accessed <date-in-citation>July 4, 2020</date-in-citation>).</mixed-citation></ref><ref id="B279"><label>279</label><mixed-citation publication-type="webpage"><source>Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects - Full Text View - ClinicalTrials.gov</source> . Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04480957">https://clinicaltrials.gov/ct2/show/NCT04480957</uri> (Accessed <date-in-citation>September 6, 2020</date-in-citation>).</mixed-citation></ref><ref id="B280"><label>280</label><mixed-citation publication-type="webpage"><source>A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18-59 years and 60 years and above</source> . Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.chictr.org.cn/showprojen.aspx?proj=55524">http://www.chictr.org.cn/showprojen.aspx?proj=55524</uri> (Accessed <date-in-citation>September 6, 2020</date-in-citation>).</mixed-citation></ref><ref id="B281"><label>281</label><mixed-citation publication-type="webpage"><source>Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers - Full Text View - ClinicalTrials.gov</source> . Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04336410">https://clinicaltrials.gov/ct2/show/NCT04336410</uri> (Accessed <date-in-citation>July 4, 2020</date-in-citation>).</mixed-citation></ref><ref id="B282"><label>282</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>INOVIO</collab></person-group><source>Reports Positive Interim Phase I Data for COVID-19 DNA Vaccine, Joins &#8220;Warp Speed&#8221; Primate Study</source> . Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.genengnews.com/news/inovio-reports-positive-interim-phase-i-data-for-covid-19-dna-vaccine-joins-warp-speed-primate-study/?utm_medium=newsletter&amp;utm_source=GEN+Daily+News+Highlights&amp;utm_content=01&amp;utm_campaign=GEN+Daily+News+Highlights_20200701">https://www.genengnews.com/news/inovio-reports-positive-interim-phase-i-data-for-covid-19-dna-vaccine-joins-warp-speed-primate-study/?utm_medium=newsletter&amp;utm_source=GEN+Daily+News+Highlights&amp;utm_content=01&amp;utm_campaign=GEN+Daily+News+Highlights_20200701</uri> (Accessed <date-in-citation>July 4, 2020</date-in-citation>).</mixed-citation></ref><ref id="B283"><label>283</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>A</given-names></name><name name-style="western"><surname>Walters</surname><given-names>J</given-names></name><name name-style="western"><surname>Reuschel</surname><given-names>EL</given-names></name><name name-style="western"><surname>Schultheis</surname><given-names>K</given-names></name><name name-style="western"><surname>Parzych</surname><given-names>E</given-names></name><name name-style="western"><surname>Gary</surname><given-names>EN</given-names></name><etal/></person-group><article-title>Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model</article-title>. <source>bioRxiv</source> (<year>2020</year>). &#160;<pub-id pub-id-type="doi">10.1101/2020.07.28.225649</pub-id>. 2020.07.28.225649.</mixed-citation></ref><ref id="B284"><label>284</label><mixed-citation publication-type="webpage"><source>Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults - Full Text View - ClinicalTrials.gov</source> . Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04445389">https://clinicaltrials.gov/ct2/show/NCT04445389</uri> (Accessed <date-in-citation>July 4, 2020</date-in-citation>).</mixed-citation></ref><ref id="B285"><label>285</label><mixed-citation publication-type="webpage"><source>Study of COVID-19 DNA Vaccine (AG0301-COVID19) - Full Text View - ClinicalTrials.gov</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04463472">https://clinicaltrials.gov/ct2/show/NCT04463472</uri> (Accessed <date-in-citation>September 6, 2020</date-in-citation>).</mixed-citation></ref><ref id="B286"><label>286</label><mixed-citation publication-type="webpage"><source>Study of COVID-19 DNA Vaccine (AG0302-COVID19) - Full Text View - ClinicalTrials.gov</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04527081">https://clinicaltrials.gov/ct2/show/NCT04527081</uri> (Accessed <date-in-citation>September 6, 2020</date-in-citation>).</mixed-citation></ref><ref id="B287"><label>287</label><mixed-citation publication-type="book"><source>A prospective, randomized, adaptive, phase I/II clinical study to evaluate the safety andimmunogenicity of Novel Corona Virus -2019-nCov vaccine candidate of M/s Cadila Healthcare Limitedby intradermal route in healthy subjects</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45306&amp;EncHid=&amp;userName=Zydus">http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45306&amp;EncHid=&amp;userName=Zydus</uri>.</mixed-citation></ref><ref id="B288"><label>288</label><mixed-citation publication-type="webpage"><source>Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19 - Full Text View - ClinicalTrials.gov</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04334980">https://clinicaltrials.gov/ct2/show/NCT04334980</uri> (Accessed <date-in-citation>July 4, 2020</date-in-citation>).</mixed-citation></ref><ref id="B289"><label>289</label><mixed-citation publication-type="webpage"><source>Immunity and Safety of Covid-19 Synthetic Minigene Vaccine - Full Text View - ClinicalTrials.gov</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04276896">https://clinicaltrials.gov/ct2/show/NCT04276896</uri> (Accessed <date-in-citation>July 4, 2020</date-in-citation>).</mixed-citation></ref><ref id="B290"><label>290</label><mixed-citation publication-type="webpage"><source>Safety and Immunity of Covid-19 aAPC Vaccine - Full Text View - ClinicalTrials.gov</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04299724">https://clinicaltrials.gov/ct2/show/NCT04299724</uri> (Accessed <date-in-citation>July 4, 2020</date-in-citation>).</mixed-citation></ref><ref id="B291"><label>291</label><mixed-citation publication-type="webpage"><source>Phase Ib-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults - Full Text View - ClinicalTrials.gov</source> . Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04386252">https://clinicaltrials.gov/ct2/show/NCT04386252</uri> (Accessed <date-in-citation>July 4, 2020</date-in-citation>).</mixed-citation></ref><ref id="B292"><label>292</label><mixed-citation publication-type="webpage"><source>Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant - Full Text View - ClinicalTrials.gov</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04368988?term=novavax&amp;recrs=ab&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT04368988?term=novavax&amp;recrs=ab&amp;draw=2&amp;rank=1</uri> (Accessed <date-in-citation>July 4, 2020</date-in-citation>).</mixed-citation></ref><ref id="B293"><label>293</label><mixed-citation publication-type="webpage"><source>SCB-2019 as COVID-19 Vaccine - Full Text View - ClinicalTrials.gov</source> . Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04405908">https://clinicaltrials.gov/ct2/show/NCT04405908</uri> (Accessed <date-in-citation>July 4, 2020</date-in-citation>).</mixed-citation></ref><ref id="B294"><label>294</label><mixed-citation publication-type="webpage"><source>Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection - Full Text View - ClinicalTrials.gov</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04428073">https://clinicaltrials.gov/ct2/show/NCT04428073</uri> (Accessed <date-in-citation>July 4, 2020</date-in-citation>).</mixed-citation></ref><ref id="B295"><label>295</label><mixed-citation publication-type="webpage"><source>A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 - Full Text View - ClinicalTrials.gov</source> . Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04487210">https://clinicaltrials.gov/ct2/show/NCT04487210</uri> (Accessed <date-in-citation>September 6, 2020</date-in-citation>).</mixed-citation></ref><ref id="B296"><label>296</label><mixed-citation publication-type="webpage"><source>A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine - Full Text View - ClinicalTrials.gov</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04522089">https://clinicaltrials.gov/ct2/show/NCT04522089</uri> (Accessed <date-in-citation>September 6, 2020</date-in-citation>).</mixed-citation></ref><ref id="B297"><label>297</label><mixed-citation publication-type="webpage"><source>An interventional study to evaluate the safety and immune response of a vaccine against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2, the virus that causes COVID-19 infection) when given to healthy adult participants</source> . Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.australianclinicaltrials.gov.au/anzctr/trial/ACTRN12620000674932">https://www.australianclinicaltrials.gov.au/anzctr/trial/ACTRN12620000674932</uri> (Accessed <date-in-citation>September 6, 2020</date-in-citation>).</mixed-citation></ref><ref id="B298"><label>298</label><mixed-citation publication-type="webpage"><source>A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults - Full Text View - ClinicalTrials.gov</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04495933">https://clinicaltrials.gov/ct2/show/NCT04495933</uri> (Accessed <date-in-citation>September 6, 2020</date-in-citation>).</mixed-citation></ref><ref id="B299"><label>299</label><mixed-citation publication-type="webpage"><source>Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years. - Full Text View - ClinicalTrials.gov</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04450004">https://clinicaltrials.gov/ct2/show/NCT04450004</uri> (Accessed <date-in-citation>September 6, 2020</date-in-citation>).</mixed-citation></ref><ref id="B300"><label>300</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Aley</surname><given-names>PK</given-names></name><name name-style="western"><surname>Angus</surname><given-names>B</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S</given-names></name><name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial</article-title>. <source>Lancet</source> (<year>2020</year>) <volume>396</volume>:<page-range>467&#8211;78</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(20)31604-4</pub-id><pub-id pub-id-type="pmcid">PMC7445431</pub-id><pub-id pub-id-type="pmid">32702298</pub-id></mixed-citation></ref><ref id="B301"><label>301</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Doremalen</surname><given-names>N</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>A</given-names></name><name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name><name name-style="western"><surname>Purushotham</surname><given-names>JN</given-names></name><name name-style="western"><surname>Port</surname><given-names>JR</given-names></name><etal/></person-group><article-title>ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques</article-title>. <source>Nature</source> (<year>2020</year>) <fpage>1</fpage>&#8211;<lpage>8</lpage>. &#160;<pub-id pub-id-type="doi">10.1038/s41586-020-2608-y</pub-id><pub-id pub-id-type="pmcid">PMC8436420</pub-id><pub-id pub-id-type="pmid">32731258</pub-id></mixed-citation></ref><ref id="B302"><label>302</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>FC</given-names></name><name name-style="western"><surname>Li</surname><given-names>YH</given-names></name><name name-style="western"><surname>Guan</surname><given-names>XH</given-names></name><name name-style="western"><surname>Hou</surname><given-names>LH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>JX</given-names></name><etal/></person-group><article-title>Safety, tolerability, and immunogenicity of a recombinant adenovirustype-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-humantrial</article-title>. <source>Lancet</source> (<year>2020</year>) <volume>395</volume>:<page-range>1845&#8211;54</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(20)31208-3</pub-id><pub-id pub-id-type="pmcid">PMC7255193</pub-id><pub-id pub-id-type="pmid">32450106</pub-id></mixed-citation></ref><ref id="B303"><label>303</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>FC</given-names></name><name name-style="western"><surname>Guan</surname><given-names>XH</given-names></name><name name-style="western"><surname>Li</surname><given-names>YH</given-names></name><name name-style="western"><surname>Huang</surname><given-names>JY</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T</given-names></name><name name-style="western"><surname>Hou</surname><given-names>LH</given-names></name><etal/></person-group><article-title>Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial</article-title>. <source>Lancet</source> (<year>2020</year>) <volume>396</volume>:<page-range>479&#8211;88</page-range>. &#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(20)31605-6</pub-id><pub-id pub-id-type="pmcid">PMC7836858</pub-id><pub-id pub-id-type="pmid">32702299</pub-id></mixed-citation></ref><ref id="B304"><label>304</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahase</surname><given-names>E</given-names></name></person-group><article-title>Covid-19: Where are we on immunity and vaccines</article-title>? <source>BMJ</source> (<year>2020</year>) <volume>370</volume>:<elocation-id>m3096</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1136/bmj.m3096</pub-id><pub-id pub-id-type="pmid">32759299</pub-id></mixed-citation></ref><ref id="B305"><label>305</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mercado</surname><given-names>NB</given-names></name><name name-style="western"><surname>Zahn</surname><given-names>R</given-names></name><name name-style="western"><surname>Wegmann</surname><given-names>F</given-names></name><name name-style="western"><surname>Loos</surname><given-names>C</given-names></name><name name-style="western"><surname>Chandrashekar</surname><given-names>A</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques</article-title>. <source>Nature</source> (<year>2020</year>), <fpage>1</fpage>&#8211;<lpage>11</lpage>. &#160;<pub-id pub-id-type="doi">10.1038/s41586-020-2607-z</pub-id><pub-id pub-id-type="pmcid">PMC7581548</pub-id><pub-id pub-id-type="pmid">32731257</pub-id></mixed-citation></ref><ref id="B306"><label>306</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahase</surname><given-names>E</given-names></name></person-group><article-title>Covid-19: Russia approves vaccine without large scale testing or published results</article-title>. <source>BMJ</source> (<year>2020</year>) <volume>370</volume>:<elocation-id>m3205</elocation-id>. &#160;<pub-id pub-id-type="doi">10.1136/bmj.m3205</pub-id><pub-id pub-id-type="pmid">32816758</pub-id></mixed-citation></ref><ref id="B307"><label>307</label><mixed-citation publication-type="webpage"><source>Clinical Trial to Evaluate the Safety and Immunogenicitiy of the COVID-19 Vaccine - Full Text View - ClinicalTrials.gov</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04497298">https://clinicaltrials.gov/ct2/show/NCT04497298</uri> (Accessed <date-in-citation>September 6, 2020</date-in-citation>).</mixed-citation></ref><ref id="B308"><label>308</label><mixed-citation publication-type="webpage"><source>A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001) - Full Text View - ClinicalTrials.gov</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04498247">https://www.clinicaltrials.gov/ct2/show/NCT04498247</uri> (Accessed <date-in-citation>[Accessed September 6, 2020]</date-in-citation>).</mixed-citation></ref></ref-list></back></article></pmc-articleset>